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LC (liquid chromatography) 
ESI (electrospray ionization) 
MS (mass spectrometry) 
MS/MS (tandem mass spectrometry) 
LC-ESI-MS/MS (liquid chromatography-electrospray ionization-tandem mass 
 spectrometry) 
m/z (mass-to-charge ratio) 
MRM (multiple reaction monitoring) 
Q1;Q2;Q3 [quadrupole 1; quadrupole 2 (collision cell); quadrupole 3) 
[M + H]+ (singly protonated precursor ion) 
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XIC (extracted ion chromatogram) 
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LOD (limit of detection) 
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Et (analyte enrichment at time = t) 
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 Fatty acyl-Coenzyme As (Figure 1) are metabolites of lipid anabolism (1) and 
catabolism (2).  A method was developed for their quantitation in extracts of cultured 
mammalian cells (3) using liquid chromatography-electrospray ionization-tandem mass 
spectrometry (LC-ESI-MS/MS). Palmitoyl-CoA (C16:0-CoA) is utilized for de novo 
sphingolipid biosynthesis catalyzed by serine palmitoyltransferase (SPT) (4-6), which 
condenses palmitoyl-CoA and serine to form 3-ketosphinganine. After reduction to form 
sphinganine (Sa), dihydroceramide synthase (CerS) can N-acylate the Sa using a 
second fatty acyl-CoA molecule, forming dihydroceramide (DHCer) (7-9). The CerS 
enzyme family utilizes different acyl chain lengths of fatty acyl-CoAs in an isoform-
specific manner (7), resulting in DHCer with N-acyl chains ranging from C16 to C26 [and 
even longer (10)] in mammalian tissues. DHCer is trans-4,5-desaturated to yield 
ceramide (11, 12), which is further metabolized by the addition of moieties at the 1-O-
position, forming sphingomyelin (SM) (13) and ceramide monohexose (CMH). 
 The rates of fatty acyl-CoA and sphingolipid biosynthesis were determined using 
stable isotope-labeling and LC-ESI-MS/MS analysis of the analyte isotopologues and 
isotopomers. Isotopic labeling of palmitoyl-CoA with [U-13C]-palmitate in HEK293 and 
RAW264.7 cells was robust and rapid (~ 60% labeling of the metabolite pool in 3 hr). 
Isotopic labeling of sphingolipids indicated utilization of [M + 16]-palmitoyl-CoA by SPT 
and CerS isoforms in both cell types. Metabolic flux modeling was applied to the data for 
[U-13C]-palmitate activation to [M + 16]-palmitoyl-CoA and its subsequent utilization in de 
novo sphingolipid biosynthesis, and this analysis indicated rapid turn-over rates for 
palmitoyl-CoA and ceramide in both cell types. 
 Palmitate treatment of cultured cells alters their metabolic status and gene 
expression, therefore labeling of palmitoyl-CoA by treatment with [1-13C]-acetate was 
 xiii 
employed. A distribution of mass-shifted palmitoyl-CoA species (isotopologues) is 
observed based on the number of incorporations of [1-13C]-acetate during de novo 
biosynthesis, requiring computational analysis to derive two parameters: the isotopic 
enrichment of the precursor pool, and the fraction of palmitoyl-CoA that was 
biosynthesized during the experiment. Previous reports by others describe mass 
isotopomer distribution analysis (MIDA) (14) and isotopomer spectral analysis (ISA) (15) 
for this purpose, and both approaches indicated concurrent results. 
 In summary, the quantitation of fatty acyl-CoAs and their isotopic enrichment 
during stable isotope-labeling studies of lipid metabolism can provide data that 
significantly change the interpretation of analyte quantitation in these experiments, as 





1.1 Fatty acyl-CoAs and their metabolism 
 Fatty acyl-CoAs such as palmitoyl-CoA (Figure 1, top panel) are thioesters of 
fatty acids and Coenzyme A. They are intermediates in a wide array of metabolic 
processes, including the anabolism of more complex lipids, such as acylglycerols (16), 
glycerophospholipids (17), cholesteryl esters (18), and sphingolipids (19). The utilization 
of fatty acyl-CoAs during the de novo biosynthesis of sphingolipids is the central focus of 
this dissertation, however, a brief overview of fatty acyl-CoA metabolism (Figure 2) is 
warranted before proceeding to their participation in sphingolipid metabolism. 
 Fatty acyl-CoAs have been described as “activated” fatty acids in the sense that 
many of the cellular processes that consume acyl chains either for energy (e.g. carnitine 
palmitoyltransferase in mitochondria (20)) or for lipid biosynthesis (e.g. serine 
palmitoyltransferase in the endoplasmic reticulum (4, 21, 22)) require fatty acyl-CoAs as 
substrates and show little or no activity with free fatty acids as substrates. Thus, the 
generation and degradation of fatty acyl-CoAs are potential control points in lipid 
metabolism (23) that determine the availability of these substrates. A number of cellular 
processes are involved in determining the amounts of different fatty acyl-CoAs under a 
given set of conditions; these include the availability (24) and uptake (25, 26) of 
extracellular fatty acids, the synthesis of fatty acyl-CoAs (16, 27-36), their intracellular 
transport by carrier proteins (37, 38), their utilization by enzymes of lipid biosynthesis, 
their metabolism by elongases (39-45) and desaturases (46-48), their degradation by 
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Figure 1. Palmitoyl-Coenzyme A with complete Coenzyme A structure (upper 
panel), and fatty acyl-CoAs utilized during de novo sphingolipid biosynthesis 
with abbreviated Coenzyme A structures (lower panel). In both panels, the Cx:y 
abbreviation denotes an acyl chain with x carbon atoms and y double bonds. The 
double bond nomenclature shown for nervonoyl- and ximenoyl-CoA specifies the first 
atom of the methylene bond counting from the omega (methyl) end of the acyl chain. 
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Figure 2. Fatty acyl-CoA acyl chain diversity generated by elongation, 
desaturation, and β-oxidation. The abbreviation Cx:y denotes an acyl chain with x 
carbon atoms and y double bonds. The common names in red font denote the fatty 
acid; fatty acyl-CoAs have the suffix –oyl rather than –ic. One example of a 
systematic name (docosapentaenoic) is also shown. The ΔN desaturase 
nomenclature indicates that the first carbon atom of the double bond is the Nth atom 
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Adapted from Figure 6, Chapter 7 of Biochemistry of Lipids, Lipoproteins and Membranes 






















 The wide variety of extracellular (dietary) and intracellular fatty acids together 
with the activities of synthetases, thioesterases, elongases and desaturases results in 
fatty acyl-CoAs with different chain lengths and numbers of double bonds (Figure 2). 
Despite this large number of fatty acyl-CoA molecular species, they appear to be 
selectively channeled into the biosynthesis of particular lipid classes (36) by 
mechanisms including enzyme specificity for a relatively narrow range of substrate fatty 
acyl-CoAs (54). For example, the sn-2 acyl moiety of glycerophospholipids is frequently 
an acyl chain with 18 to 20 carbon atoms and 2 to 4 double bonds, based on the fatty 
acyl-CoA substrate specificity of 1-acyl-glycerol-3-phosphate O-acyltransferase 
(AGPAT) (55). The theme of lipid biosynthetic enzymes having relatively narrow 
substrate specificities for fatty acyl-CoAs will continue during the following overview of 
sphingolipid metabolism. 
 
1.2 Sphingolipid metabolism 
Sphingolipids are 1,3-hydroxy-2-amino alkanes or alkenes with substantial 
structural diversity.  Sphingolipids are structural components of cellular membranes in all 
eukaryotes, and their variety of signal transduction roles is also established (56, 57).  
Selected sphingolipids and a portion of their de novo biosynthetic and turnover pathways 
are shown in Figure 3, from which it is clear that some molecular species are free 
sphingoid bases (non-acylated), other species are N-acylated sphingoid bases, and still 
other species are more complex N-acylated sphingoid bases with a polar moiety at the 
1-position.  Sphingoid bases shown in Figure 3 include sphinganine (Sa) and 
sphingosine (So), N-acyl species include dihydroceramide (DHCer) and ceramide (Cer), 
and 1-O-modified sphingolipids include ceramide-1-phosphate, glucosylceramide 
(GlcCer), and sphingomyelin (SM). 
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Although increasing molecular diversity results from a series of biosynthetic 
enzymatic reactions, it should not be overlooked that reversal of these reactions 
(catabolism or turnover) is a commonly encountered aspect of sphingolipid metabolism.  
Cells exert fine-tuned control over biosynthesis and catabolism, and opposing outcomes 
in cellular state may hang in the balance: So and sphingosine-1-phosphate (So-1-P) are 
interconverted by kinases and phosphatases (58); the non-phosphorylated sphingoid 
base is pro-apoptotic (59) but the phosphorylated sphingoid base is anti-apoptotic (60).  
Studies of sphingolipid biology require a high degree of specificity during the quantitation 
of multiple molecular species in a single sample because of the structural similarity and 
interconversion of sphingolipid species.  Thus, the ability to analytically distinguish 
(resolve) these species is critical for the accurate determination of cellular sphingolipid 
quantities. 
 It is also important to emphasize that Figure 3 shows only a portion of 
sphingolipid metabolism, and numerous structural variations of sphingoid bases (61) and 
N-acyl sphingolipids have been described (61). The elaboration of carbohydrate-based 
1-O-moieties, in particular, increases the number of sphingolipid structures into the 
thousands (www.sphingomap.org), indicating considerable room for further discoveries 
about sphingolipid structure, metabolism, and bioactivity. 
 
1.3 Sphingolipid quantitation 
Currently, among the numerous methodologies for the quantitation of multiple 
sphingolipids in small biological samples (which have been reviewed recently in (62) by 
this author) liquid chromatography-electrospray ionization tandem mass spectrometry 
(LC-ESI-MS/MS) analysis of cell extracts to which internal standards have been added is 





































































































































Figure 3. A portion of sphingolipid metabolism including de novo biosynthesis. The methylene 
subscript –(CH2)x- is often 11 yielding a 1, 3-dihydroxy, 18 carbon alkyl chain with no sites of 
unsaturation (d18:0), but can range from 7 (d14:0) to greater than 15 (d22:0).  The – (CH2)y-  of the fatty 
acyl chain typically ranges from 11 (16 carbons total) to greater than 25 (30 carbons total). Enzymes are 
serine palmitoyltransferase – 1, 3-ketosphinganine reductase – 2, (dihydro)ceramide synthase – 3, Δ4-
dihydroceramide desaturase – 4, glucosylceramide synthase – 5, sphingomyelin synthase – 6, 
sphingosine/sphinganine kinase – 7, sphingosine-1-phosphate phosphatase – 8, sphingomyelinase – 9, 
ß-glucoceramidase – 10, and ceramidase – 11. 
 7 
A typical experiment begins by culturing cells and treating them with, for 
example, stable isotope-labeled palmitate (63). Cells are collected after rinsing with 
phosphate-buffered saline (PBS) to remove medium and the lipids present in fetal calf 
serum (FCS), a common medium component. After the addition of appropriate internal 
standards ((64, 65), and see Experimental Procedures in Chapters 2-5) to the cell 
sample, organic solvents are added [typically 2:1 methanol / chloroform (v/v)] and 
sonication is used to disrupt cells and solubilize lipids.  Further handling of the extract to 
purify sphingoid bases and N-acyl species has been reviewed recently (65).  
The sample (see below) is injected onto a liquid chromatography (LC) column, 
and molecular species of sphingolipids are resolved (66) based on their relative affinities 
for the column’s packing material (the stationary phase) and the solvents flowing through 
the column (the mobile phase) (67, 68). In addition to the resolution of analytes provided 
by LC, a second advantage is the washing away (non-retention on the column) of many 
cellular compounds that are not of interest and can have deleterious effects upon the 
detection of analytes. 
The effluent from the LC column is connected to the electrospray ionization (ESI) 
source of a triple quadrupole tandem mass spectrometer (69). This ion source’s central 
component is a hollow metal needle, which is held at a high positive or negative potential 
(70).  At the exit tip of the needle, nebulizing gas produces highly charged solvent 
droplets containing analytes that are subsequently drawn towards the orifice of the mass 
spectrometer via both potential and atmospheric pressure differences. In the ESI source, 
these droplets become smaller by a combination of solvent evaporation (aided by the 
passage of high-temperature nitrogen through the electrospray stream) and the mutual 
repulsion of similar charges within and between droplets (acquired via passage through 
the high-potential electrospray needle). During the transition from atmospheric pressure 
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(in the ESI source) to vacuum (in the interface) the solvent is pumped away and the 
analytes are ionized in the gas phase (71). 
Multiple reaction monitoring (MRM) is an MS/MS method used for quantitation (3, 
65, 68, 72-77). MRM selects an ion with a particular mass-to-charge ratio (m/z) value (a 
precursor ion) using Q1, followed by collision-induced dissociation (78) of the precursor 
ion in Q2, and selection of a structure-specific m/z value (a fragment ion or product ion) 
with Q3. In practice, the instrument repeatedly monitors several precursor ion-product 
ion pairs, dwelling on each pair for 10 to 50 milliseconds. The entire list of MRM pairs 
can be monitored in less than 1 sec, allowing near-continuous monitoring for several 
analytes during LC elution time. Thus, as an analyte elutes from the LC column and is 
ionized in the ESI source, precursor ions selected with Q1 and product ions selected 
with Q3 via MRM result in a signal, or peak, on the extracted ion chromatogram (XIC). 
The integrated area of this peak is the basis for analyte quantitation.  
LC-ESI-MS/MS of sphingolipids is sensitive and specific; analytes are identified 
by three criteria: LC elution time, precursor ion m/z, and structure-specific product ion 
m/z. In order to correct for sample-to-sample variability when quantitating an analyte by 
LC-ESI-MS/MS, a useful approach is the use of at least one internal standard molecular 
species. A stable isotope-labeled version of the analyte is desirable (see below), but in 
the absence of such a standard, analogs of the species of interest may be used, such as 
a sphingoid base with an odd number of carbon atoms (i.e., C17) or a ceramide with an 
N-acyl chain length not observed in biological samples (i.e., C12). A known quantity of 
this standard is added to the biological sample, the sample is extracted and analyzed, 
and the peak corresponding to the (internal) standard is used as a benchmark to 
determine the quantities represented by the peaks of the analytes. In this way, extraction 
inefficiency and sample-to-sample variation are corrected by the internal standard, 
assuming that its physical and chemical behavior in the extraction protocol is nearly 
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identical to that of the analyte. This is one reason that a stable-isotope labeled standard 
is desirable, another reason is that even small differences in molecular structure 
between the standard and the analyte can result in different ionization and / or 
fragmentation efficiencies between the standard and the analyte (3). These differences 
must be measured and, if they are significant, incorporated into the calculations that 
determine analyte quantity based on the standard’s peak area. In both of the examples 
above, sphingoid bases and N-acyl sphingolipids, no such correction is necessary when 
using appropriate internal standards (65). 
 
1.4 Stable isotope labeling of cultured mammalian cells 
Because the catabolism (turnover) of sphingolipids has been shown to have a 
quantitatively significant contribution to the amounts of sphingolipids such as So (79) 
and Cer (80, 81), it is not always possible to distinguish the contributions of de novo 
biosynthesis and catabolism to the measured quantity of a particular sphingolipid. An 
important experimental approach for answering this question has been the treatment of 
cultured cells with radio-labeled precursors of sphingolipid metabolism, such as 3H- or 
14C-labeled serine or palmitate (82, 83). An assumption of this technique is that these 
precursors are assimilated by the cells and metabolized in a manner identical to their 
unlabeled counterparts (an absence of “isotope effects”). In a well-implemented radio-
labeling experiment the radioactivity of a purified metabolite and its quantity are 
measured, the specific activity of the metabolite (radioactivity per unit mass) is 
calculated, and this measurement provides direct information about the contribution of 
the labeled precursor to the biosynthesis of that metabolite during the time of the 
experiment. 
A variation of this approach is to use stable isotope-labeled precursor (84) 
treatment of cultured cells, followed by quantitation of mass-shifted (and non-shifted) 
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metabolites using a (tandem) mass spectrometer (85-87). These mass-shifted molecules 
are isotopologues of the non-shifted (monoisotopic) molecules. By analogy to a radio-
labeling experiment, the tracer-tracee ratio (TTR) or isotopic enrichment of an analyte 
can be calculated (shown in detail in Chapter 3 and (88)). Some advantages of using 
stable isotopes include avoiding the risk and regulations of radioisotope work, the ethical 
acceptance of stable isotope labeling during human experiments (89-91), and 
importantly, the availability of new dimensions of data (92). Specifically, MRM allows the 
molecular moieties labeled by the incorporation of stable isotope into analyte molecules 
to be determined, providing new details concerning their biosynthetic mechanisms, as 
demonstrated by the stable isotope labeling of palmitoyl-CoA and sphingolipids 
(Chapters 3-5). 
 
1.5 Stable isotope labeling of fatty acyl-coenzyme A species and sphingolipids 
Labeling with [U-13C]-palmitate 
The moiety common to fatty acyl-CoAs and sphingolipids is the acyl chain, 
therefore, treatment with a stable isotope-labeled fatty acid will label both types of lipids 
(93, 94), as well as other types of lipids (95, 96). The MS/MS analysis is greatly 
simplified if labeled molecules have mass shifts of more than 3 Da compared to 
unlabeled molecules (97), and [U-13C]-palmitate, a C16 fatty acid in which every carbon 
atom is 13C, was selected as the tracer during the first experiments (Figure 4). This 
































[M + 0], [M + 16], 
and [M + 32] 
Cultured mammalian cells 
Figure 4. Labeling de novo biosynthesized sphingolipids with [U-13C]-
palmitate. Uptake of the stable isotope-labeled tracer by cultured cells and its 
incorporation into sphingolipids was quantitated by extracting lipids from samples of 
cells after different treatment times, and quantitating labeled and unlabeled lipids via 
LC-ESI-MS/MS as described in Chapters 2, 3, 4, and 5. Chemically identical 
molecular species of lipids were present as unlabeled [M + 0], singly-labeled [M + 
16], and in certain cases, doubly-labeled [M + 32] isotopologues. 
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unlabeled palmitate (256 Da), and so labeled metabolites such as fatty acyl-CoAs and 
sphingolipids will have mass increases of 16 Da, or 32 Da if two labeled fatty acyl-CoA 
molecules were used to biosynthesize one sphingolipid molecule.  
[U-13C]-palmitate was added to the medium of HEK293 cells, and both labeled 
and unlabeled fatty acyl-CoAs and sphingolipids were quantitated by LC-ESI-MS/MS. 
The results of this analysis were compared with results for HEK293 cells stably over-
expressing SPT (hereafter referred to as SPT1/2 cells), which have increased rates of 
de novo sphingolipid biosynthesis (Wei, et al., in preparation). The results indicated that 
SPT1/2 cells had significantly higher amounts of sphingolipids before [U-13C]-palmitate 
treatment, and that the addition of the labeled palmitate caused a robust increase in [M + 
16] and [M + 32] sphingolipids, which was several fold greater in SPT1/2 cells as 
detailed in Chapter 4. 
The [U-13C]-palmitate labeling experiments encompassed quantitation of 
palmitoyl-CoA, Sa, sphinganine-1-phosphate (Sa-1-P), So, and So-1-P using MRM pairs 
for the unlabeled [M + 0] and labeled [M + 16] isotopologues of each analyte. In addition, 
N-acyl sphingolipids were quantitated, including DHCer, Cer, dihydrosphingomyelin 
(DHSM), SM, ceramide monohexose (CMH), and dihydroceramide monohexose 
(DHCMH). These N-acyl sphingolipids have two acyl chains derived from fatty acyl-
CoAs, and were therefore present as [M + 0] isotopologues (designated 12C), [M + 32] 
isotopologues (designated dual labeled), and [M + 16] isotopologues. The latter were 
two isotopomers that could be discriminated by MS/MS fragmentation as being labeled 
on either the sphingoid base moiety (designated base labeled) or the N-acyl moiety 
(designated fatty acid labeled), with the exception of SM since positive ion mode MS/MS 
analysis of SM does not distinguish acyl chain labeling. However, the enzymatic 
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conversion of SM to ceramide-1-phosphate (Cer-1-P) by phospholipase D, followed by 
LC-ESI-MS/MS analysis of the Cer-1-P did distinguish fatty acid and base labeled 
isotopomers (Chapter 3). 
 
Interpretation of dynamic [U-13C]-palmitate labeling data to calculate the rate of 
appearance of unlabeled analytes 
 The dynamic collection of quantitative data from 0 to 6 hr for both labeled 
analytes (tracers) and unlabeled analytes (tracees) allowed the application of 
mathematical modeling (Figure 5) for the estimation of the rates of fatty acyl-CoA and 
sphingolipid biosynthesis. This previously described approach (88) uses quantitation of 
tracer and tracee to calculate the analyte isotopic enrichment (defined here as tracer / 
tracer + tracee), which is plotted vs. time in order to graphically visualize labeling of the 
analyte. Depending upon the analyte, the choice of tracer, the kinetics of the metabolic 
system under investigation, and the duration of the labeling experiment, a steady-state in 
the isotopic enrichment of a particular analyte may or may not be achieved.  If so, the 
steady state is interpreted to be a condition where the rate of appearance (Ra) of tracer 
is equal to the rate of disappearance (Rd) of tracer from the metabolite pool, and 
knowledge of the pool size and its plateau isotopic enrichment can be used to back-
calculate the Ra of tracee (unlabeled analyte). 
Specifically, the labeling kinetics (of a single-pool metabolite with constant 
concentration during the experiment) are described by the following equation (88):
 
Eq. 1 
Et = analyte isotopic enrichment at time = t (in h) ! 















HEK293 0.548 ± 0.005 1.15 ± 0.05 0.999 
SPT1/2 0.441 ± 0.01 0.87 ± 0.08 0.992 
HEK293 
SPT1/2 
Figure 5. The isotopic enrichment of d18:1/C16:0 ceramide in HEK293 and SPT1/2 
cells during 6 hr of treatment with 0.1 mM [U-13C]-palmitate. Isotopic enrichment and 
curve-fitting were calculated as described in Experimental Procedures, Chapter 4. The 
plateau isotopic enrichment (Ep) and fractional turn-over rate per hr (k) estimated by the 
data, as well as goodness-of-fit (R2) for each cell type is shown. Results are based on 
the mean of four Petri dishes for each cell type, and both k and Ep were significantly 
different (p < 0.05) by Student’s t-test. The physiological interpretation of Ep for the 
analyte is the fraction of newly biosynthesized polymer (55% vs 44%), and of k is the 
turn-over rate per unit time (1.2 times per hr vs. 0.9 times per hr). 
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Ep = plateau isotopic enrichment of the analyte at steady-state 
k = fractional turn-over rate of the analyte pool per unit time 
By software-based curve-fitting of the observed isotopic enrichment data to Eq. 1 
with concurrent estimation of Ep and k, the LC-ESI-MS/MS quantitation of the metabolite 
pool size (Q) allows the calculation of the Ra of (tracer + tracee). Finally, by calculating 
the Ra of tracer alone using Ep, this value can be subtracted from the Ra of (tracer + 
tracee), and the Ra of tracee determined. This value represents the rate of appearance 
of unlabeled analyte during the experiment, and in the work described here it is 
interpreted to represent the rate of de novo biosynthesis of the analyte. 
The results of this analysis of fatty acyl-CoA and sphingolipid isotopic labeling 
are consistent with a high turn-over rate for palmitoyl-CoA, which is also supported by 
the coarse observation that it is rapidly (~ 3 h) and robustly (~ 60%) labeled in HEK293 
cells using [U-13C]-palmitate as the tracer. The fractional turn-over rate per unit time (k) 
of the palmitoyl-CoA pool in HEK293 and SPT1/2 cells was calculated to be 
approximately 0.7, or 70% turn-over of the palmitoyl-CoA pool in 1 h. In contrast to 
C16:0 Cer, there was not a significant difference in palmitoyl-CoA isotopic enrichment, k, 
or Ra when comparing HEK293 and SPT1/2 cells, supporting the hypothesis that 
increased sphingolipid de novo biosynthesis, rather than differences in the sphingolipid 
biosynthetic precursor palmitoyl-CoA, were the cause of increased quantities of labeled 
sphingolipids in SPT1/2 cells. 
 
Labeling RAW264.7 cells with [1-13C]-acetate: an alternative to the [U-13C]-palmitate 
tracer 
A second approach to the stable isotope-labeling of fatty acyl-CoAs and 
sphingolipids utilized [1-13C]-acetate. The motivations for taking this approach were 
previously reported changes in lipid metabolism (98) and gene transcription (99) that 
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accompany treatment of cells with palmitate at concentrations similar to the one used in 
these experiments, and so an alternative metabolic route to the isotopic labeling of fatty 
acyl-CoAs and sphingolipids was desirable. One such route is de novo fatty acid 
biosynthesis (Figure 6), which can be probed by the treatment of cells with stable 
isotope-labeled acetate, such as [1-13C]-acetate. 
 After uptake by cells, a metabolic fate of [1-13C]-acetate is activation to acetyl-
CoA, followed by conversion to malonyl-CoA via acetyl-CoA carboxylase (100-103), and 
finally incorporation into de novo biosynthesized palmitate via fatty acid synthase 
(FAS(103-106)). Since eight C2 molecules are converted by FAS into a single C16 
molecule, de novo palmitate (and therefore de novo palmitoyl-CoA) can be labeled with 
0 to 8 13C atoms, depending upon the isotopic enrichment of the malonyl-CoA precursor 
pool. This biosynthetic action will change the abundances of palmitoyl-CoA 
isotopologues, and by using the multinomial distribution to describe the observed 
pattern, the isotopic enrichment of the malonyl-CoA precursor pool can be calculated. In 
addition, the fraction of the palmitoyl-CoA that was newly synthesized (and displays an 
altered mass isotopomer distribution) can be determined. Two approaches were taken 
for data analysis after the [1-13C]-acetate treatment experiments: mass isotopomer 
distribution analysis (MIDA) as described by Hellerstein and Neese (14), and isotopomer 
spectral analysis (ISA) as described by Kelleher and Masterson (15). Both analyses 
calculated similar estimates of the isotopic enrichment of the precursor pool (~ 5-10%) 







































Figure 6. Labeling de novo biosynthesized sphingolipids with [1-13C]-acetate. 
Enzyme abbreviations are acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), 
acyl-CoA synthetase (ACSL), serine palmitoyltransferase (SPT), 3-ketosphinganine 
reductase (3KSR), and (dihydro)ceramide synthase (DHCS). 
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1.6 Summary 
 The development of a method for quantitation of fatty acyl-CoAs by LC-ESI-
MS/MS in small samples of biological material [Chapter 2 and (3)] supplements studies 
of the metabolism of complex lipids, such as sphingolipids. For example, a cultured cell 
paradigm in which increased quantities of sphingolipids were observed has been 
confirmed to be the results of increased de novo sphingolipid biosynthesis, rather than 
increased catabolism of pre-existing sphingolipids. 
 Specifically, the over-expression of serine palmitoyltransferase, the first enzyme 
of de novo sphingolipid biosynthesis, in HEK293 cells resulted in increased quantities of 
sphingolipids, and a greater accumulation of [M + 16] and [M + 32] sphingolipids after 
treatment with [U-13C]-palmitate (Chapter 4). The ability to quantitate [M + 0] and [M + 
16] palmitoyl-CoA showed that the isotopic enrichment of palmitoyl-CoA was not the 
source of observed differences in isotopically labeled sphingolipids. 
 Furthermore, the quantitation of the isotopic enrichment of palmitoyl-CoA allowed 
the total quantity of de novo biosynthesized sphingolipids to be estimated, if one 
assumes that a single, well-mixed pool of palmitoyl-CoA is available for SPT and CerS. 
Comparison of the observed quantity of unlabeled ceramide to the quantity that was 
calculated to have been de novo biosynthesized implied that ~ 50% of the observed 
unlabeled quantity could be accounted for by de novo biosynthesis in HEK293 and 
SPT1/2 cells (Chapters 3 and 4). Therefore, quantitation of the isotopic enrichment of 
palmitoyl-CoA provided data that significantly changed the interpretation of sphingolipid 
quantitation in these experiments. 
 The availability of data about isotopic labeling of sphingolipids (Chapter 3) 
suggested the application of previously described approaches for the analysis of 
metabolic labeling; one such approach (88) led to calculating enrichment for fatty acyl-
CoAs and sphingolipids and the observation that some species clearly reached isotopic 
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equilibrium. Modeling this isotopic enrichment and measurement of metabolite quantities 
with LC-ESI-MS/MS allowed the estimation of the rate of appearance of unlabeled 
metabolite, which quantitated the increase in de novo sphingolipids (2 to 5-fold) caused 
by over-expression of SPT in HEK293 cells (Chapter 4). 
 Although metabolic labeling of de novo sphingolipid biosynthesis with [U-13C]-
palmitate was informative, an alternative to [U-13C]-palmitate was also used: labeling of 
de novo biosynthesized palmitate via treatment of cultured cells with [1-13C]-acetate 
(Chapter 5). Two previously described approaches based on multinomial distribution (14, 
15) were taken for the analysis of the [1-13C]-acetate labeling data; both approaches 
reached similar conclusions about the isotopic enrichment of the biosynthetic precursor 
acetate (6 to 10%) and the fraction of newly biosynthesized palmitoyl-CoA (~ 60%) after 
6 hr of treating RAW264.7 cells with 1.0 mM [1-13C]-acetate. 
 In summary, the quantitation of fatty acyl-CoAs, and particularly quantitation of 
their isotopic enrichment during stable isotope-labeling studies of lipid metabolism, can 
provide data that significantly change the interpretation of analyte quantitation in these 





QUANTITATION OF FATTY ACYL-COENZYME A SPECIES IN MAMMALIAN CELL 
EXTRACTS BY LIQUID CHROMATOGRAPHY-ELECTROSPRAY IONIZATION-
TANDEM MASS SPECTROMETRY (LC-ESI-MS/MS)1 
 
2.1 Introduction 
Fatty acyl-CoAs participate in energy metabolism, the biosynthesis and recycling 
of complex lipids, post-translational modification of proteins, regulation of gene 
expression, and other cellular processes (107).  They are derived from de novo fatty acid 
biosynthesis and the recycling of preexisting fatty acids (73), and serve as intermediates 
of most fatty acid modification reactions, such as oxidation (108), elongation and 
desaturation (109).  Hence, for both metabolic and regulatory studies, it would be useful 
to have an analytical method to quantitate a wide variety of these compounds. 
Mass spectrometry (MS) and tandem mass spectrometry (MS/MS) have been 
shown to be particularly useful for analysis of fatty acyl-CoAs because they provide high 
levels of structural specificity and sensitivity (93, 110-115), especially when combined 
with liquid chromatography (LC) and electrospray ionization (ESI) (93, 110-113).  
Previously published methods have used negative ion mode MS (93) and MS/MS (111, 
112), as well as positive ion mode MS/MS utilizing a precursor ion scan (110), but they 
have not been applied to a wide spectrum of fatty acyl-CoA molecular species, 
especially the very-long-chain fatty acyl-CoAs with alkyl chain lengths greater than 20 
carbons. 
                                                
1 This chapter has been published; the authors are Haynes, C., Allegood, J., Sims, K., Wang, E., 
Sullards, M., and Merrill, A. 
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This chapter describes an LC-ESI-MS/MS protocol (3) that builds on some of the 
features of these methods for analysis of a wider profile of fatty acyl-CoAs than has 
heretofore been reported, i.e., with alkyl chain lengths varying from C14 (myristoyl-CoA) 
to C26 (cerotoyl-CoA), and is potentially applicable to species as short as C2 (acetyl-
CoA) and free CoA-SH. Analysis of extracts from RAW264.7 cells (a mouse 
macrophage-like line) and MCF7 cells (a human breast carcinoma line) demonstrated 
the method’s utility for profiling and quantitating multiple molecular species of fatty acyl-
CoAs in relatively small samples, and revealed interesting differences in the fatty acyl-
CoA profiles for these cell lines. The availability of this fairly simple and robust method 
should facilitate inclusion of this family of compounds in a wide range of studies, 
including more comprehensive analyses such as “lipidomics” and “metabolomics.” 
 
2.2  Experimental procedures 
Reagents 
Fatty acyl-CoAs (C14 to C26 and the odd chain-length internal standards C15:0-, 
C17:0-, C23:0-, and C25:0-CoA) were obtained as tri-ammonium salts from Avanti Polar 
Lipids (Alabaster, AL) and according to the manufacturer, analysis of the fatty acyl-CoAs 
by TLC, HPLC, mass spectrometry, NMR and other tests such as the Bartlett assay for 
phosphorus were consistent with the purity being >99%. CoASH (lithium salt 
monohydrate), acetyl- (C2:0-) (sodium salt), octanoyl- (C8:0-) (sodium salt) and lauroyl- 
(C12:0)-CoA (sodium salt) were from Sigma-Aldrich (St. Louis, MO) and were 95-99% 
pure. HPLC-grade CH3OH (catalog number MX0475-1), CH3CN (AX0145-1) and CHCl3 
(CX1058-1) were from EMD (Darmstadt, Germany). Triethylammonium acetate (TEAA) 
was from Fluka (Buchs, Switzerland), and triethylamine (TEA) was from Sigma-Aldrich 
(St. Louis, MO). The water (> 18 MΩ / cm) was purified by a Barnstead Diamond 




MCF7 cells (HTB-22) and RAW264.7 cells (TIB-71) were obtained from the 
ATCC (Manassas, VA). RAW264.7 cells were grown in DMEM (Cellgro catalog number 
10-013, that contains 4 mM L-glutamine, and 4.5 g/l glucose, Mediatech, Manassas, 
VA), and 10% heat-inactivated fetal calf serum (HyClone catalog number SH30071.03, 
Logan, UT). MCF7 cells were grown in MEM supplemented with 10% FBS (HyClone 
catalog number SV30071.03, Logan, UT), 2 mM L-glutamine, 0.1 mM non-essential 
amino acids, 1 mM sodium pyruvate, and 0.01 mg/ml bovine insulin. Media for both cell 
types included tissue-culture grade 1.5 g/l sodium bicarbonate (1.5 g/l), and 100 U/ml 
penicillin plus 0.1 mg/ml streptomycin (Gibco catalog number 15140-122, Invitrogen, 
Carlsbad, CA). Both cell types were cultured at 37°C, 95% relative humidity, and 5% 
CO2. Dishes (60 mm, catalog number 430166, Corning Inc., Corning, NY) of RAW264.7 
cells were seeded at 2 x 106 cells per dish and grown for approximately 30 h before 
harvesting for lipid analysis. Dishes (100 mm, catalog number 430293, Corning Inc., 
Corning, NY) of MCF7 cells were seeded at 2 x 106 cells/ml and grown for approximately 
48 h. For the RAW264.7 cells, the cell culture conditions followed the standard protocol 
adopted by the Lipid MAPS Consortium (www.lipidmaps.org). 
 
Cell extraction 
Dishes of cells cultured as described above (typically 0.5 to 2 x 107 cells) were 
placed on ice, the medium was aspirated, and adherent cells were gently washed twice 
with 5 ml each of chilled PBS then once with 5 ml of chilled distilled water (which did not 
cause cell lysis as assayed by Trypan Blue exclusion, if added and removed rapidly).  
Using a rubber policeman, the cells were rapidly scraped into a corner of the tilted dish 
and mixed to a uniform suspension in the residual water (~0.3 ml) with a pipette from 
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which 50 µl was removed for cell quantitation by counting (or analysis of protein or DNA) 
and 200 µl for analysis of the fatty acyl-CoAs. This procedure avoids centrifugation of the 
cells after they have been removed from the Petri dish because a substantial percentage 
of RAW264.7 cells were broken during scraping; analysis of more robust cells can use 
centrifugation for the washes. 
The aliquot for fatty acyl-CoA analysis was placed in a screw-cap tube (13 x 100 
mm, catalog number 73750-13100, with a Teflon-lined cap, Kimble Chase, Vineland, NJ) 
on ice.  To this was added 500 µl of CH3OH containing 1 mM EDTA (added to the 
CH3OH from a 0.5 M aqueous stock) and 10 µl of an internal standard mixture that 
contained 100 pmol each of C15:0-, C17:0-, C23:0- and C25:0-CoA which were 
prepared in CH3OH/CHCl3 (2:1, v/v) containing 30 mM TEAA.  After a brief sonication 
(~0.5 min), 250 µl of CHCl3 was added, followed by another brief sonication, and the 
single-phase extraction mixture was incubated for 30 min in a 50° C heating block.  After 
cooling to room temperature, CHCl3 and H2O (250 µl each) were added with mixing by 
vortexing after each addition.  After brief centrifugation (2000 rpm for 5 min at room 
temperature), the fatty acyl-CoAs were in the upper phase and interface and most of the 
other lipids (which would interfere with the subsequent reverse phase LC) were in the 
lower phase.  The upper layer was removed with a Pasteur pipet and transferred into a 
screw-cap tube (13 x 100 mm, catalog number 73750-13100, with a Teflon-lined cap, 
Kimble Chase, Vineland, NJ), and the remainder (interface and lower layer) was re-
extracted twice (each time with brief centrifugation to separate the two phases cleanly) 
with 0.5 µl each of synthetic upper phase (H2O:CH3OH:CHCl3 (45:50:5, v/v/v), from 
which the upper phases were added to the same screw-cap tube as the first extract.  To 
the pooled upper phases was added 180 µl of CH3OH:CH3(CH2)2CH2OH:CHCl3 
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(50:25:25, v/v/v), which was found to help keep the very-long-chain fatty acyl-CoAs in 
solution for at least 24 hr at room temperature and / or at least 3 days at -20°C. 
 
Chromatographic conditions  
The HPLC separations utilized a Shimadzu SCL-10A VP system controller, two 
LC-10AD VP pumps, a DGU-14A degassing unit, a Perkin-Elmer Series 200 
autosampler, and a Phenomenex (Torrance, CA) Gemini C18 column (2 mm ID x 150 
mm with 5 µm particles) and a 2 x 4 mm guard column with the same packing material. 
The column was maintained at 40o C using a MetaTherm column oven (MetaChem, 
Torrance, CA).  
The flow rate was 200 µl per min in binary gradient mode with the following 
elution program: the column was equilibrated with mobile phase A (H2O/CH3CN, 85:15, 
v/v, containing 0.05% TEA), the sample was injected and mobile phase A was continued 
for 5 min, followed by a 14 min gradient to 50% mobile phase A and 50% B 
(H2O/CH3CN, 10:90, v/v, containing 0.05% TEA) during which the long- and very-long-
chain fatty acyl-CoAs elute.  Afterwards, the column was washed by a 1-min gradient to 
100% B and a 5 min hold at 100% B, followed by re-equilibration of the column by a 1 
min gradient to 100% A and a 5 min hold at 100% A before injection of the next sample. 
 
Mass spectrometry of fatty acyl-CoAs 
The analyses were conducted using an Applied Biosystems (Foster City, CA) 
4000 QTrap triple quadrupole/linear ion trap mass spectrometer. Dry N2 gas was used 
for nebulizing the column effluent (Gas 1), and for the desolvation gas (Gas 2), curtain 
and collision gases, with instrument settings of 35, 25, 15 (arbitrary units), and medium, 
respectively. The interface heater was on (100° C) and the Turbo V ESI source 
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temperature was 350° C. The ESI needle voltage was 5.5 kilovolts (kV) in positive ion 
mode and -4.5 kV in negative ion mode. 
 To establish the optimal parameters for MS and MS/MS, stocks of the fatty acyl-
CoA standards (~ 0.5 mM each) were prepared in CH3OH/CHCl3 (2:1, v/v), then diluted 
before use to 1 µM with H2O/CH3CN (50:50, v/v) containing 30 mM TEAA. The 
compounds were infused at 10 µl/min to optimize desolvation potential (DP), collision 
energy (CE), and collision-activated dissociation (CAD) gas to yield maximum sensitivity 
for the singly protonated (M + H)+ fatty acyl-CoA precursor ions in positive ion mode and 
for the singly deprotonated (M – H)- species in negative ion mode.  A narrow (6 Da) 
width Q1 scan was used to determine the optimum DP for each standard.  
The MS/MS parameters were determined by identifying the acyl-chain retaining 
product ions, which in positive ion mode resulted from loss of 507.0 Da from the (M + H)+ 
precursor, as has been previously observed (110, 115) and optimizing CE, collision cell 
exit potential (CXP) and CAD gas values for each molecular species (Table I).  
After the elution time for each fatty acyl-CoA of interest was determined using the LC 
conditions described in the preceding section, the compounds were dissolved in the 
corresponding proportions of mobile phase A and B for flow injection analysis (FIA) to re-
optimize source-dependent parameters to values appropriate for the higher flow rate 
(200 µl/min) of the HPLC used in this study (Table I). 
 
Quantitation of fatty acyl-CoAs in cultured cells 
For each new biological sample, the fatty acyl-CoA species of a cell extract that 
was not spiked with internal standards were first profiled to determine the minimum 
number of precursor-product pairs that were needed for the multiple reaction monitoring 
(MRM) protocol.  This was conducted using neutral loss (507.0 Da) scans during the  
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Table I. Mass Spectrometer Settings and Chromatographic Properties of Selected 
Fatty Acyl-CoAs 











(cps x 105) 
14:0 978.3 471.3 180, 50, 12.7 11.4 
2.2 
15:0 992.4 485.4 190, 50, 13.0 12.2 
2.3 
16:0 1006.4 499.4 180, 50, 13.3 12.7 
2.5 
17:0 1020.4 513.4 180, 53, 13.5 13.3 
2.5 
18:0 1034.4 527.4 190, 52, 14.3 14.1 
2.9 
αOH-18:0 1050.3 543.4 195, 55, 14.5 13.1 
2.1 
18:1 1032.4 525.4 185, 52, 13.9 13.1 
2.1 
18:2 1030.4 523.4 180, 52, 14.0 12.7 
ND 
18:3 1028.4 521.4 190, 50, 14.5 12.3 
ND 
20:0 1062.4 555.4 190, 52, 15.3 14.5 
2.4 
20:4 1054.4 547.4 180, 52, 15.0 12.3 
1.8 
22:0 1090.4 583.4 190, 53, 16.3 15.1 
2.0 
22:6 1078.4 571.4 190, 51, 16.0 12.3 
1.1 
23:0 1104.5 597.5 200, 55, 16.5 15.5 
1.9 
24:0 1118.5 611.5 210, 57, 17.0 15.9 
1.3 
24:1 1116.5 609.5 208, 57, 17.0 15.2 
2.0 
25:0 1132.5 625.5 218, 59, 17.5 16.2 
1.1 
26:0 1146.4 639.5 220, 58, 17.5 16.6 
0.84 
 
aNumber of linear chain carbon atoms:number of double bonds; αOH denotes an α-hydroxy fatty 
acyl chain 
bDesolvation potential (DP), collision energy (CE), and collison cell exit potential (CXP). 
cDuring LC the ion source conditions were: temperature at 350°C, Gas 1 at 35 arbitrary units, 
Gas 2 at 25 arbitrary units, electrospray needle voltage at 5.5 kV. 
dSlope of the linear regression of a calibration curve for each analyte (abcissa = pmol, ordinate = 
peak area (cps), y-intercept = 0); the slope has units of cps per pmol. All R-squared values were 
≥ 0.999, except C26:0 (0.991). 
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HPLC elution with three periods having DP, CE, and CXP settings that were appropriate 
for analytes that eluted during those times:  period 1 (0 to 11 min) scanned m/z values 
750 to 980 which encompassed CoASH to C14:0-CoA; period 2 (11 to 15.1 min) 
scanned m/z values 980 to 1070, which encompassed C14:0-CoA to C20:0-CoA; and 
period 3 (15.1 to 18 min) scanned m/z values 1050 to 1150, which encompassed C20:0-
CoA to C26:0-CoA. After identification of the analytes that were detectable (3 times 
signal to noise), the MRM program was built to include these, the internal standards, and 
sometimes additional analytes of potential interest.   
The fatty acyl-CoAs were quantitated by LC-ESI-MS/MS in positive ion mode 
utilizing the MRM pairs shown in Table I, which correspond to (M + H)+ precursor ions 
(selected with Q1), and the structure-specific product ion resulting from a neutral loss of 
507.0 Da (selected with Q3). The amount of each analyte of interest was calculated as 
follows: 1) LC chromatogram peaks for internal standards and endogenous fatty acyl-
CoAs were integrated using Analyst 1.4.2 software (Applied Biosystems, Foster City, 
CA) and peak areas were copied to spreadsheets, 2) for each endogenous analyte, a 
cognate internal standard was selected based upon either similarity of acyl chain length 
or similarity of LC elution time (whichever is most appropriate), and 3) the following 
equation was used to calculate pmol of analyte (pmola): 
 
pmola = (Aa / Ais) x (pmolis) x (Mis / Ma) 
 
where Aa = analyte peak area, Ais = internal standard peak area, pmolis = spiked pmol of 
internal standard, Mis = slope of the linear regression of the internal standard’s 
calibration curve, and Ma = slope of the linear regression of the analyte’s calibration 
curve. If desired, the observed peak areas (representing monoisotopic ions) may be 
isotopically corrected; however, this is not usually necessary if the analyte and internal 
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standard are similar (i.e., the correction is less than 2% per methylene difference in the 
fatty acyl chain length). 
The calibration curves for the fatty acyl-CoAs were prepared by serially diluting 
each compound and analysis by LC-ESI-MS/MS as described above.  In addition, 
calibration curves were generated for select fatty acyl-CoAs by spiking six different 
quantities from 0.1 to 5 pmol of the internal standards (C15:0-, C17:0-, C23:0- and 
C25:0-CoA) into RAW264.7 cell extracts and analyzing by LC-ESI-MS/MS.  The limit of 
detection (LOD) and the limit of quantitation (LOQ) were defined as 3 times signal to 
noise, and ten times signal to noise, respectively. Plotting quantities analyzed (abcissa) 
vs. observed peak areas (ordinate) was followed by linear regression (with y-intercept = 
0) to calculate the slope of this regression line (Table I). 
 
Validation of the extraction and LC-ESI-MS/MS conditions 
To determine the efficiency with which fatty acyl-CoAs were recovered, the three 
upper phases from the cell extraction procedure (see above) were collected individually 
and the lower layer was extracted an additional fourth time, then each was analyzed 
separately by LC-ESI-MS/MS and compared to the peak areas for fatty acyl-CoAs not 
carried through these extraction procedures. 
 
Statistical analysis 
All data shown are the results of at least three analytical replicates (LC-ESI-
MS/MS analyses) of at least three biological replicates (culture dishes) and are 
representative of at least two independent experiments (conducted on different days). 
Data are shown as means ± standard deviations; all statements of significant difference 




The goal of these experiments was to develop a quantitative LC-ESI-MS/MS 
analysis method for a wide range of fatty acyl-CoAs suitable for small samples, such as 
cultured mammalian cells. The strategy that was followed was to examine the ionization 
and fragmentation of purified fatty acyl-CoAs, to select candidate precursor ion-product 
ion pairs for multiple reaction monitoring (MRM) analysis, to determine LC conditions 
that separated a substantial number of species to allow unambiguous quantitation, and 
to identify internal standards and extraction conditions that are effective with biological 
samples, using two mammalian cell lines (RAW264.7 and MCF7) as prototypes. 
 
Characterization of fatty acyl-CoAs by MS and MS/MS 
The MS spectra of standard C16:0-CoA contain both (M + H)+ ions and (M + Na)+ 
adducts in positive ion mode (Figure 7A), and (M – H)- ions and (M – 2H + Na)- adducts 
in negative ion mode (Figure 7B) at the electrospray needle voltage yielding the most 
intense signal for singly (de)protonated precursor ions. The (M - H)- signal was 
approximately 7-fold more intense than the (M + H)+ signal for identical sample, infusion, 
solvent, and ion source conditions, except the polarity of the electrospray needle, which 
was at the maximum voltage setting in both ionization modes.  
The MS/MS spectra for collision-induced fragmentation of the (M + H)+ molecular 
ions of C16:0-CoA (m/z 1006.4) yielded highly abundant product ions of m/z 499.4 
(Figure 8, upper), which correspond to cleavage of the C-O bond of the 5’-ß-phosphate 
with charge retention on the acyl portion of the molecule. Less abundant product ions of 
m/z 428.4, 397.4, 261.1, 159.0, and 136.0 were also detected. Proposed fragmentations 
are shown (Figure 8, upper) which correspond to the m/z 428.4, 261.1 and 136.0 
product ions. The m/z 397.4 product ion also retains the acyl chain (see below). 
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Collision-induced fragmentation of the (M – H)- molecular ions of C16:0-CoA (m/z 
1004.4) yielded product ions of m/z 924.5, 657.4, 408.0, 328.1, and 159.0. The ion of 
m/z 657.4 corresponds to cleavage of the C-O bond of the 5’-α-phosphate, subsequent 
loss of water, and charge retention on the acyl portion of the molecule; the other product 
ions correspond to the proposed fragmentations shown (Figure 8, lower). 
The MS/MS fragmentations of all of the fatty acyl-CoAs analyzed shared 
similarities in positive and negative ion modes, and a systematic nomenclature for these 
product ions is proposed in Figure 9.  Positive ion mode MS/MS resulted in abundant 
product ions retaining the acyl moiety (Z ions; Figure 9A and 9B) as well as product ions 
derived from the coenzyme A moiety (A, B, and C ions; Figure 9A and 9B). At least one 
additional product ion resulting from a neutral loss of 609 Da retained the acyl moiety 
(m/z 383 and 523; Figure 9A and 9B, respectively). Similarly, negative ion mode MS/MS 
resulted in product ions retaining the acyl moiety (X ions; Figure 9D and 9E) as well as 
product ions derived from the coenzyme A moiety (A, B, and C ions; Figure 9D and 9E). 
Many of these product ions have been noted in earlier publications. For example, 
positive ion mode ESI-MS/MS has been shown to yield Z, B, and C ions and product 
ions resulting from a neutral loss of 609 Da (110, 113), as well as A ions and m/z 261 
and 159 products (110). Negative ion mode ESI-MS/MS has been shown to yield X, X-
H2O, X-HPO3, C, and C-H2O ions (111, 113) as well as B ions (113). 
The results from the MS and MS/MS analyses were used to choose precursor 
(selected by Q1) and product (selected by Q3) ion pairs for multiple reaction monitoring 
(MRM). For maximum sensitivity and specificity, the product ion should be both 
abundant and structure-specific for the acyl moiety, and these criteria are met by the 
positive mode Z product ion (e.g., m/z 499.4 for C16:0-CoA, Figure 8, upper), which is 




Figure 7. Mass spectra of C16:0-CoA in the high mass region using positive 
(A) and negative (B) ionization modes. Q1 scans using a triple quadrupole tandem 
mass spectrometer are shown. Labels above the peaks denote m/z values of the 
monoisotopic peaks and describe the (de)protonated or sodium adduct ions. Spectra 
(summation of 1 min scans) were collected during the infusion (10 µl / min) of C16:0-




































































































Figure 8. Tandem mass spectra of C16:0-CoA using positive (upper panel) 

























































































































































Figure 9. MS/MS spectra in positive ion mode (A, B) and negative ion mode (D, 
E) of C15:0-CoA (A, D) and C25:0-CoA (B, E). A proposed nomenclature for 
common fragmentations (C) is also shown. 
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mode, the X-H2O product ion was more intense than the positive mode Z product ion 
under virtually identical infusion conditions (Figure 8), although neither of the product 
ions that retain the acyl chain (e.g., m/z 657.4 and m/z 577.4 for C16:0-CoA, Figure 8, 
lower) could be optimized as the base peak of the tandem mass spectrum.  
 
Analysis of fatty acyl-CoAs by LC-ESI MS/MS 
LC-ESI-MS/MS analysis of fatty acyl-CoAs utilized MRM pairs corresponding to 
singly (de)protonated precursor ions (selected by Q1), and the most abundant structure-
specific product ion retaining the acyl chain (selected with Q3). For example, positive ion 
mode MRM analysis of C16:0-CoA utilized the MRM pair 1006.4 → 499.4 while negative 
ion mode MRM analysis utilized the pair 1004.4 → 657.4. The desolvation potentials, 
collision energies and collision cell exit potentials were optimized to yield maximum peak 
heights for the selected precursor and product ions in both polarities. Comparison of LC-
ESI-MS/MS peak areas of C16:0-, C18:1- and C24:1-CoA using both negative and 
positive mode MRM revealed that the positive ion mode was approximately 3-fold more 
sensitive (Figure 10A), therefore, ionization, dissociation and separation conditions were 
optimized for maximum sensitivity and specificity for each individual acyl-CoA species in 
positive ion mode (Table I and Figure 10B).  
The chromatographic conditions for Figure 10B (described in “Experimental 
Procedures”) were optimized for separation of saturated and monounsaturated fatty 
acyl-CoAs with chain lengths of C14 to C26 due to the interest of our laboratory in the 
precursors of sphingolipids.  There is baseline resolution of acyl-CoAs with acyl chain 
differences of only one methylene unit and/or a single double bond (Figure 10B).  The 
latter separation is advantageous because the (M + 2) isotopomer of monounsaturated 
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species match the MRM pair for the cognate saturated species, as seen in the small 
peak with the MRM pair for C18:0-CoA co-eluting with C18:1-CoA in Figure 10B as well 
as for the MRM pair for C24:0-CoA that co-elutes with C24:1-CoA.  These 
chromatographic conditions also resolve many other species, including α-hydroxy-fatty 
acyl-CoAs (as shown for α-hydroxy-C18:0-CoA with a retention time 13.1 min vs. 14.1 
min for the non-hydroxylated species, C18:0-CoA, Table I).  Even when there is only 
partial chromatographic resolution for some of the fatty acyl-CoAs (such as C22:0- and 
C24:1-CoA, Figure 10B, and C20:4- and C22:6-CoA, not shown), the analytes are 
usually distinguishable by their characteristic MRM pairs.  Shorter fatty acyl-CoAs elute 
earlier (for example, octanoyl-CoA, C8:0-CoA, elutes approximately 1 min after the void 
volume) and free CoASH elutes in the 5 min hold at 100% A after sample injection (data 
not shown).  Therefore, this procedure might be usable for shorter chain species, 
including other categories of CoA-thioesters that can be distinguished by the MRM pairs 
and LC mobility. 
For all of the fatty acyl-CoAs that were studied in depth by LC-ESI-MS/MS (i.e., 
species from C14 to C26), the limit of quantitation (LOQ) was on the order of 5 fmol, the 
linear range of quantitation was approximately 3 orders of magnitude (from the LOQ to 
at least 5 pmol) with R2 > 0.99 from linear regression analysis (Figure 11A and Table I).  
Figure 11A shows the log-log relationship between the signal intensities for several 
representative fatty acyl-CoAs, from which the slopes and other results presented in 
Table I have been derived by linear regression analysis.  In general, the covariance (SD 
divided by mean) for ten replicate injections of each standard was found to be <10% for 
0.1 to 1 pmol of the analyte, ~15% for 10 to 50 fmol, and approximately 20% at the LOQ 
(5 fmol) (data not shown). 
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Figure 10. LC-ESI-MS/MS of palmitoyl-, oleoyl-, and nervonoyl-CoA in positive and 
negative modes (A) and a wider range of fatty acyl-CoAs in positive mode (B). 
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 It is evident from Figures 10B and 10A that the relationship between peak area 
and pmol varies somewhat for different fatty acyl-CoAs, with a range of ~3 fold for the 
highest (C18:1-CoA) vs. the lowest (C26:0-CoA) studied here. This is not attributable 
solely to the increase in 13C isotopomers with additional carbon atoms, nor, as best we 
have been able to ascertain, to differences in the concentrations of the fatty acyl-CoA 
standards. To ensure that the differences in ion yield were not due to hydrolysis of the 
fatty acyl-CoA standards, representative stocks (C18:0-, C18:1-, C24:0-, and C24:1-
CoA) were analyzed for the amounts of free CoASH using this LC-ESI MS/MS method, 
and the mole % of free CoASH versus the fatty acyl-CoA was only 2 to 3%. 
 Thus, it appears that the signal intensities for the saturated species (solid circles, 
Figure 11B) are fairly constant for alkyl chain lengths of 14 to 20 carbons (with, perhaps, 
a slight peaking at C18), beyond which they decline.  The simplicity of this relationship 
allows a reasonably accurate estimation of amounts of the saturated fatty acyl-CoAs 
using a limited number of internal standards (such as the C15:0-, C17:0-, C23:0- and 
C25:0-CoAs) as described under “Experimental Procedures”.  Based on the similarity of 
the peak areas for C18:1- and C24:1-CoAs, it appears that alkyl chain length has less of 
an influence on monounsaturated fatty acyl-CoAs, however, it does appear that the 
number of double bonds affects signal intensity.  Only one α-hydroxy-fatty acyl-CoA was 
available for comparison (α-hydroxy-C18:0-CoA), and its behavior was similar to oleoyl-
CoA.  Therefore, each analyte of interest should be examined to ascertain how it 
behaves under the LC-ESI-MS/MS conditions, and sufficient internal standards used for 
estimation of the quantities of the species as judged necessary based on the level of 
accuracy that is required by the investigation. 
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Analysis of fatty acyl-CoAs in cell extracts 
Cell extracts were first examined by a neutral loss scan (507.0 Da) in positive ion 
mode because this fragmentation was common to all fatty acyl-CoA species including 
CoASH (e.g., Figure 9A and 9B, horizontal arrow) (110). Although this could be 
conducted by infusion of the extract, more analytes could be detected when LC was 
used to remove contaminants that suppress ionization, and to distinguish compounds 
that have overlapping MRM pairs, as discussed above. Accordingly, the 
chromatographic elution time was divided into three periods with distinct m/z scan, DP, 
CE, and CXP ranges as described under “Experimental Procedures.” The results for an 
MCF7 cell extract analyzed by this procedure are shown in Figure 12. The ions eluting at 
or near the void volume (MS/MS of region B in Figure 12) are consistent with coenzyme 
A (m/z 768.4), propionyl-CoA (m/z 824.4) and the isomers succinyl-CoA and 
methylmalonyl-CoA (m/z 868.4). The abundant peaks eluting from 11 to 15 min (MS/MS 
of region C in Figure 12) were consistent with C14:0-CoA (m/z 978.4), C16:1-CoA (m/z 
1004.4), C16:0-CoA (m/z 1006.4), C17:0-CoA (m/z 1020.4; internal standard), C18:1-
CoA (m/z 1032.4), and C20:4-CoA (m/z 1054.4). A cluster of low abundance peaks 
eluting between 15 and 18 min (MS/MS of region D in Figure 12) were consistent with 
C24:1-CoA (m/z 1116.5), C24:0-CoA (m/z 1118.5), C25:0-CoA (m/z 1132.5; internal 
standard), C26:1-CoA (m/z 1144.5) and C26:0-CoA (m/z 1146.5). When the extracts 
were analyzed without the internal standard spikes, the odd chain-length fatty acyl-CoAs 
were ≤ 10 fmol per 107 cells, which allowed the use of these compounds as internal 
standards. Additionally, the removal of sodium ions from samples by reverse-phase 
HPLC is confirmed by the absence of a sodium adduct ion (predicted m/z 1042.4) of the 
abundant internal standard C17:0-CoA (Figure 12C).
 39 
 
Figure 11. Relationships between peak area and fatty acyl-CoA amounts. A: 
Log-log plot of the means of peak areas ± SD (n = 4) for four representative analytes. 
B: Relationship between the slopes of the linear regression plots from Table I and the 
chain lengths of the fatty acyl-CoAs, with saturated species represented by closed 
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 Subsequent LC-ESI-MS/MS analyses of cell extracts utilize the LC conditions 
described under “Experimental Procedures” and MRM pairs for the internal standards, 
the analytes identified for the biological sample of interest by neutral loss scan profiling 
(above), and any additional fatty acyl-CoA analytes of interest because they might be 
encountered during the course of the particular experiment. For the RAW264.7 and 
MCF7 cells, there were 19 MRM pairs, which could be accommodated using dwell and 
settling times of 40 msec and 5 msec, respectively.  When the number of analytes 
exceeds the ability of the MRM program to scan them in the elution timeframe, it is 
possible to divide the chromatographic elution time into additional periods. 
Analysis of multiple samples can be conducted using an auto-injector because 
the analytes are stable and remain in solution for at least 24 hr at room temperature and 
at least 3 days at -20 °C, which was verified by repeated injections of samples stored 
under these conditions and analysis by LC-ESI-MS/MS.  However, this was only the 
case if the empirically derived conditions described under “Experimental Procedures” 
were followed—namely, the addition of an adequate amount of 
CH3OH:CH3(CH2)2CH2OH:CHCl3 (50:25:25, v/v/v) to the final extract to keep the very-
long-chain fatty acyl-CoAs in solution during storage and analysis. Samples stored at -20 
°C sometimes become cloudy, but a clear single phase can be restored by warming to 
room temperature and brief vortexing.   
Depending on the nature of the biological sample, it may be necessary to replace 
the guard column somewhat frequently (after approximately 50 samples) if the 
backpressure increases from ca 700 psi to 900 or 1000 psi, which results in shifting 
retention times, peak splitting, etc. during the gradient.  Clogging of needles and lines by 
the samples was uncommon. There was essentially no (i.e. ≤1%) carry-over of fatty acyl-
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CoAs from either standards or samples, which was tested by inserting autoinjector vials 
that contain only the solvents at various intervals between vials containing standards or 
samples. 
 
Quantitation of fatty acyl-CoAs in cell extracts 
For quantitation of the fatty acyl-CoAs in extracts, the peak areas of the analytes 
of interest were compared to the peak areas of the internal standards, as described in 
“Experimental Procedures”. To be reliable, this requires that the internal standard have 
the same recovery as the analyte under the extraction conditions used, and Figure 13A 
shows that this is the case. It is evident from the results that the odd chain-length spikes 
had recovery parameters similar to endogenous fatty acyl-CoAs of similar length and 
unsaturation. The necessity of the multiple extractions is also illustrated in Figure 13A 
because the recovery from each individual extraction differed among the species 
whereas the sum of the first three extractions (which are pooled when the method is 
followed as described in “Experimental Procedures”) was > 90% for all internal 
standards and endogenous analytes.   No significant difference between RAW264.7 and 
MCF7 cells was observed with respect to the percentage of total fatty acyl-CoAs 
recovered with each re-extraction. Similarly, the percentage of total of fatty acyl-CoAs 
recovered with each re-extraction did not significantly change if the number of cultured 
cells being extracted was between 5 x 106 and 2 x 107 (data not shown). 
The linearity of the method was not compromised by the cell extract, as shown in Figure 
13B where standard curves for two of the internal standards (C15:0- and C25:0-CoA) 
are compared for the standards alone versus spiked into a RAW264.7 cell extract (R2 ≥ 
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0.98).  However, the signal intensities were reduced by ~50% in the biological extracts, 
which increased the LOQ to ~10 fmol. 
 
Comparison of fatty acyl-CoAs in RAW264.7 and MCF7 cells 
Quantitation of fatty acyl-CoAs in RAW264.7 and MCF7 cell extracts was conducted 
using the LC positive ion mode ESI MS/MS method described under “Experimental 
Procedures” and the MRM pairs that were selected on the basis of the results of the 
neutral loss scan. As can been seen from Figure 14, there are significant differences 
between the two cell lines with respect to the types and amounts of fatty acyl-CoAs. 
Very-long-chain fatty acyl-CoAs comprise a greater proportion of the total fatty acyl-
CoAs’ in MCF7 cells than in RAW264.7 cells (i.e., > 50% versus < 10%, respectively).  
Indeed, MCF7 cells contain approximately as much C24:0- and C26:0-CoAs as C16:0- 
and C18:0-CoAs, and essentially equal amounts of C26:1- and C18:1-CoAs.  Oleoyl-
CoA (C18:1-CoA) is one of the major fatty acyl-CoA species in both cell lines, as has 
been noted for many types of biological samples (20, 59, 62, 63), but we have been 
unable to find any previous reports of such high amounts of very-long-chain fatty acyl-
CoAs in cells or tissues. Myristoyl-CoA (C14:0-CoA) was approximately 20% of the total 
fatty acyl-CoAs in RAW264.7 cells vs ~7% for MCF7 cells.  Overall, MCF7 cells had 
much higher amounts of total fatty acyl-CoAs (80.4 + 6.1 pmol per 106 cells) than 
RAW264.7 cells (12 + 1.0 pmol per 106 cells) (N =3, P < 0.01).  
For comparison, the quantities of very-long-chain fatty acids that have been reported for 
RAW264.7 cells (www.lipidmaps.org) and MCF7 cells (116), and the alkyl-chain length 
distribution of the ceramides from these cells, which were analyzed by published 
methods (74), are presented in Figure 15. 
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Figure 12. LC-ESI-MS/MS with neutral loss scanning (507.0 Da) of MCF7 cell 
extract. Dashed boxes labeled B to D on the total ion chromatogram indicate the time 




Figure 13. Recovery of fatty acyl-CoAs at each step of the extraction of MCF7 cells 
(A) and comparison of peak areas for analytes in solvent versus cell extracts (B). 
Results are means ± SD of analysis of three replicate Petri dishes. Circles are the 
C15:0-CoA and squares are the C25:0-CoA; closed symbols are analytes in methanol 
and open symbols are analytes in RAW264.7 cell extract. 
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2.4 Discussion 
This chapter describes an LC-ESI-MS/MS method for the quantitation of a broad 
variety of fatty acyl-CoA molecular species, and its application to RAW264.7 and MCF7 
cells.  In many respects, it is similar to previous methods that have combined LC with 
ESI-MS and ESI-MS/MS for analysis of fatty acyl-CoAs, (93, 110-113), however, the 
extraction and LC conditions were optimized to allow quantitation of fatty acyl-CoAs from 
at least C14 to C26 using positive ion mode ESI-MS/MS and MRM parameters for 
structure-specific precursor-product ion pairs for the analytes of interest and 
commercially available odd chain-length fatty acyl-CoAs as internal standards.  To the 
best of our knowledge, this is the first report of a method that is able to quantify intact 
fatty acyl-CoAs with saturated and monounsaturated alkyl chain lengths with >20 
carbons, which include the very-long-chain fatty acids found in the ceramide backbones 
of sphingolipids (e.g., C24:0, C24:1, C26:0 and C26:1) (117).While it was somewhat 
surprising that LC-ESI-MS/MS (MRM) was more sensitive in the positive than negative 
mode despite the high pH of the LC eluant (Figure 10), perhaps this is due to removal of 
sodium ions by the LC separation which increased the proportion of the (M + H)+ versus 
sodium adduct ions (Figure 7).  Since the LC is conducted at high pH, it is possible to 
conduct the LC-ESI MS/MS analysis in negative ion mode, if necessitated by particular 
samples or instrumentation limitations; however, the m/z 79.0 product (phosphate) ion 
that is utilized in the negative ion mode has a greater potential for artifacts.  
A major advantage of coupling HPLC to MS/MS is the resolution of isobaric 
analytes with different molecular structures, such as the naturally occurring (M + 2) 
isotopologue of C18:1-CoA, which can have the same precursor and product ion m/z 




Figure 14. Quantitation of the fatty acyl-CoAs of RAW264.7 and MCF7 cells. The 
cells were extracted and analyzed as described in Experimental Procedures. Results are 











Figure 15. Fatty acid and ceramide compositions of RAW264.7 and MCF7 cells. 
The mole percentage of very long-chain fatty acids relative to other fatty acids was 
calculated from data for RAW264.7 cells from Lipid MAPS (www.lipidmaps.org) and for 
MCF7 cells from Welsh et al. The SD’s of the latter data were not published. 
 
 48 
feature of some (93, 110) but not all (111) previously published LC-ESI-MS/MS analyses 
of fatty acyl-CoAs. 
The chain-length-determined differences in the recovery of fatty acyl-CoAs during 
repeated extraction (Figure 13) demonstrate the importance of using internal standards 
appropriate for the analytes of interest. This method could potentially be modified to 
include other molecular species of fatty acyl-CoAs after the validation of their recoveries 
with respect to these, or more appropriate, internal standards. 
The fatty acyl-CoA composition of RAW264.7 and MCF7 cells displayed a 
diverse set of fatty acyl-CoA species, including those which may participate in the 
modification of proteins such as C14:0-CoA (12), and those that connect lipid 
biosynthesis with lipid signal transduction pathways such as C20:4-CoA (53). The most 
obvious difference in the fatty acyl-CoA compositions of RAW264.7 versus MCF7 cells is 
the proportion of the total fatty acyl-CoAs that have C20 and longer chain-lengths, which 
amount to over half of the total in MCF7 cells but are near the limit of quantitation in 
RAW264.7 cells. It is interesting that the quantities of very-long-chain fatty acyl-CoAs in 
these cells do not exactly match the amounts of free fatty acids that have been reported 
for them (Figure 15, panel A) nor the relative amounts of very-long-chain fatty acids that 
are found in a more complex sphingolipid, such as ceramide (Figure 15, panel B).  
Indeed, the proportions of ceramides with very-long-chain fatty acids are similar for 
RAW264.7 cells and MCF7 cells, despite the former having barely detectable very-long-
chain fatty acyl-CoAs. Another difference was the 8-fold higher amounts of total fatty 
acyl-CoAs for MCF7 cells compared to RAW264.7 cells, which may reflect the often 
higher activity of fatty acid synthase in cancer cells, including this breast carcinoma cell 
line (118, 119).  
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Fatty acyl-CoA amounts have typically been estimated to be on the order of 
nanomoles per wet gram of tissue by previous studies of human muscle and adipose 
tissue (120), rabbit muscle (93) and rat tissues including liver (110-112, 121), brain (111, 
121, 122), muscle (121), and kidney (121). Since a gram of tissue typically contains 108 
to 109 cells (123), the amounts of fatty acyl-CoAs found in those studies are on the same 
order of magnitude (~10 pmol per 106 cells) as the fatty acyl-CoAs that have been 
obtained with RAW264.7 and MCF7 cells in this study.  
 Due to the sensitivity, breadth, and selectivity of this LC-ESI-MS/MS analysis, 
fatty acyl-CoAs can now be included in the list of compounds that can be analyzed in 
“lipidomics” studies of the roles of fatty acyl-CoAs in normal cell regulation and disease 
(107, 124-127). In addition, pharmacologic agents that affect the biosynthesis of fatty 
acyl-CoAs (i.e. triacsin C (34), sterculic acid (128), orlistat (129, 130), C75 (131), and 
cerulenin (132)), or that disrupt their utilization (i.e. inhibitors of mitochondrial oxidation 
(etomoxir) (133), glycerolipid biosynthesis (hypoglycin) (134), or sphingolipid 
biosynthesis (myriocin) (135)) can be re-investigated.  In addition to being adaptable for 
analysis of fatty acyl-CoAs with acyl chains longer or shorter than those described here 
(and stable-isotope labeled fatty acids for kinetic studies) (93), the neutral loss (507.0 
Da) scan should be able to detect and analyze CoA-thioesters with other compounds, 




SIMPLE: SPHINGOLIPID ISOTOPIC METABOLIC PRECURSOR LABELING 




Sphingolipid de novo biosynthesis is an important theme of this dissertation, with 
particular focus upon fatty acyl-CoA sphingolipid biosynthetic precursors. One approach 
that can be used to quantitate sphingolipids that are unambiguously the products of de 
novo biosynthesis is to treat cultured cells with [U-13C]-palmitate. This stable isotope-
labeled fatty acid is taken up by cells and converted to 13C-labeled palmitoyl-CoA, which 
then contributes to de novo sphingolipid biosynthesis. Analysis of cellular lipid extracts 
by LC-ESI-MS/MS for fatty acyl-CoAs and sphingolipids, as described in Chapters 2 and 
1, respectively, reveals the quantities of unlabeled and 13C-labeled analytes. 
The first cellular paradigm used to explore stable isotope-labeling of de novo 
sphingolipids with [U-13C]-palmitate was HEK293 cells; in this study, the specific 
contributions of this author were the extraction and quantitation of fatty acyl-CoAs, 
analysis of their isotopic enrichment, and analysis of sphingolipid isotopic enrichments. 
 
3.2 Introduction 
 Sphingolipids are integral to eukaryotic cellular membrane structures and are 
involved in many aspects of cell signaling (137-140).  For example, the initial products of 
                                                
2 This chapter is in preparation for publication; the authors are Haynes, C., Allegood, J., Wang, 
E., Kelly, S., Sullards, M., and Merrill, A. 
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de novo sphingolipid biosynthesis (sphingoid bases and ceramides) are utilized as cell 
signals.  Interest in both their structural roles and their biological activities has led to the 
development of methods to quantitate sphingolipids in many cell/tissue types, classically 
by thin-layer chromatography, gas chromatography, and high-performance liquid 
chromatography; more recently tandem mass spectrometric (MS/MS) detection (68, 75, 
77, 141) has been used in conjunction with HPLC resolution to quantify sphingolipids.  
Quantitation of sphingolipids can provide considerable insight in numerous studies, 
however, some signaling mechanisms could be more fully elucidated by the ability to 
distinguish, for example, ceramide (Cer) derived from de novo biosynthesis and Cer 
derived from catabolism of pre-existing sphingomyelin (SM) (142-145). 
Analysis of 13C-labeled palmitate incorporation into sphingolipids by mass 
spectrometry (MS) has been explored previously (94, 146, 147); however, in the method 
described here labeling with uniformly-labeled [13C]palmitate ([U-13C]-palmitate) and 
sphingolipid quantitation by LC-ESI-MS/MS were used to distinguish pre-existing 
sphingolipids and de novo biosynthesized sphingolipids. One reason for selecting [U-
13C]-palmitate is its incorporation into the sphingolipid de novo biosynthetic pathway at 
two points: initially by serine palmitoyltransferase (SPT) (4, 148), which catalyzes the 
condensation of serine and palmitoyl-CoA to form 3-keto-sphinganine, and later by one 
of several (dihydro)ceramide synthase (CerS) isoforms (8, 76, 149), which N-acylate 
sphinganine / sphingosine using fatty acyl-CoAs.   
Treatment of HEK293 cells with [U-13C]-palmitate resulted in four kinds of N-
acylated sphingolipid isotopologues [molecules with identical chemical structures and 
different isotopes at specific structural position(s)] and isotopomers [molecules with 
identical chemical structures and the same number of isotopic labels at different 
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structural position(s)] The isotopologues were either completely unlabeled, labeled on 
the sphingoid base or the N-acyl chain (isotopomers), or labeled on both the sphingoid 
base and N-acyl chain.  The MS/MS analysis described here distinguishes both the 
number and the position of label incorporations; mass shifts in precursor and product ion 
pair m/z values by either 16 or 32 Da indicate whether the label is present in either the 
sphingoid base of N-acyl fatty acid or both. Interestingly, in HEK293 cells, 13C-d18:1/13C-
16:0 Cer (but not SM) was the most abundant Cer isotopologue, suggesting a rapid turn-
over rate for Cer (but not SM) in this cell line. 
In addition, treatment of HEK293 cells with [U-13C]-palmitate resulted in [M + 16] 
fatty acyl-CoAs, including 16:0-, 18:0-, 16:1- and 18:1-CoA, indicating the activation of 
[U-13C]-palmitate to [M + 16] 16:0-CoA and its subsequent elongation (45) and 
desaturation (150). The utilization of these 13C-labeled fatty acyl-CoAs during 
sphingolipid de novo biosynthesis was confirmed by the quantitation of d18:1/13C-18:0 
Cer, d18:1/13C-24:0 Cer, and d18:1/13C-24:1 Cer in this cell line. Importantly, treatment 
with 0.1 mM [U-13C]-palmitate for 6 h resulted in ~ 60% isotopic enrichment of 16:0-CoA. 
Assuming that a single, well-mixed pool of 16:0-CoA is the biosynthetic precursor of 
d18:1/16:0 Cer, estimation of the rate of this sphingolipid’s de novo biosynthesis using 
the criterion of 13C-labeling results in a ~ 40% underestimate of this rate. 
The utility of this sphingolipid isotope metabolic precursor labeling experiment 
(SIMPLE) method is demonstrated by the quantitation of sphingolipids in HEK293 cells 
treated with [U-13C]-palmitate, and coupling SIMPLE with quantitation of the isotopic 
enrichment of biosynthetic precursor fatty acyl-CoAs provides corrections for 
sphingolipid biosynthetic rates that were inferred from 13C-labeled sphingolipid 
quantities. Collectively, treatment of cultured cells with stable isotope-labeled precursors 
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followed by LC-ESI-MS/MS analysis as described here provides greater dynamic detail 
regarding sphingolipid anabolism than has been previously available. 
 
3.3 Experimental procedures 
Reagents 
The internal standard cocktail (catalog number LM-6002) was provided by Avanti 
Polar Lipids (Alabaster, AL) in sealed ampoules and certified (64) to be > 95% pure and 
within 10% of the specified amount (250 µM); it was comprised of  the 17-carbon chain 
length sphingoid base analogs:  C17-sphingosine, (2S,3R,4E)-2-aminoheptadec-4-ene-
1,3-diol (d17:1-So); C17-sphinganine, (2S,3R)-2-aminoheptadecane-1,3-diol (d17:0-Sa); 
C17-sphingosine 1-phosphate, heptadecasphing-4-enine-1-phosphate (d17:1-S1P); and 
C17-sphinganine 1-phosphate, heptadecasphinganine-1-phosphate (d17:0-Sa1P); and 
the C12-fatty acid analogs of the more complex sphingolipids C12-Cer, N-(dodecanoyl)-
sphing-4-enine (d18:1/12:0-Cer); C12-Cer 1-phosphate, N-(dodecanoyl)-sphing-4-enine-
1-phosphate (d18:1/12:0-Cer1P); C12-sphingomyelin, N-(dodecanoyl)-sphing-4-enine-1-
phosphocholine (d18:1/12:0-SM); C12-glucosylceramide, N-(dodecanoyl)-1-β-glucosyl-
sphing-4-eine (d18:1/12:0-GlcCer); and C12-lactosylceramide, N-(dodecanoyl)1-β-
lactosyl-sphing-4-eine (d18:1/12:0-LacCer); as well as one very-long-chain Cer analog, 
C25-Cer, N-(pentacosanoyl)-sphing-4-enine (d18:1/25:0-Cer).  [U-13C]-palmitate (98%) 
was purchased from Cambridge Isotope (Andover, MA).  Phospholipase D 
(Streptomyces chromofuscus) was purchased from Biomol (Plymouth Meeting, PA).  
Fumonisin B1 (FB1) was obtained from Matreya (Pleasant Gap, PA).   
The HPLC grade solvents (acetonitrile, # EM-AX0145; chloroform, # EM-
CX1050; hexane, # JT9304-33; and methanol, # EM-MX0475, as well as ACS grade 
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formic acid, # EM-FX0440-7), were obtained from VWR (West Chester, PA), and acetic 
acid (ACS grade, # A38C-212) was obtained from Fisher (Pittsburg, PA). 
 
Cell culture 
 HEK293 cells were obtained from the American Type Culture Collection 
(Manassas, VA) (cat# CRL-1573). The cells were grown in 60-mm plastic culture dishes 
in DMEM supplemented with 10% FBS, 4 mM L-glutamine, 4.5 g/L glucose, 1.5 g/L 
sodium bicarbonate, 100 U/ml penicillin and 0.1 mg/ml streptomycin in ThermoForma 
Steri-cult CO2 incubators with 5% CO2 and 90% relative humidity at 37°C.  In labeling 
experiments cells were incubated with 0.1 mM [U-13C]-palmitate in a 1:1 molar complex 
with fatty acid-free bovine serum albumin.  In experiments involving FB1, an ethanol 
stock of FB1 was added to the cell culture media for a final concentration of 50 µM. 
 
Sphingolipid extraction from HEK293 cells 
 The harvesting of cells and sphingolipid extraction were performed as previously 
described (65).  An aliquot of the reconstituted extracts of N-acyl sphingolipids was 
saved for phospholipase D treatment.  
 
Phospholipase D treatment 
  1000 units of phospholipase D (PLaseD, from Streptomyces chromofuscus) were 
suspended in 0.1 ml of 3 mM decylglucopyranoside (Sigma, St. Louis, MO) and 100 mM 
Tris HCl (pH 8.0).  An aliquot of the complex fraction was treated with PLaseD and 
incubated for 15 min at 37°C in a heating block.  Samples were then dried under vacuum 
in a Savant AES2000 Automatic Environmental Speedvac and reconstituted in LC-ESI-
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MS/MS mobile phase for analysis. 
 
Liquid chromatography-electrospray ionization-tandem mass spectrometry of 
sphingolipids 
The analysis of sphingolipids by liquid chromatography-electrospray ionization-
tandem mass spectrometry (LC-ESI-MS/MS) was performed as previously described 
(65). Prior to selecting MRM pairs for each cell type, the variation in N-acyl chain length 
was determined, which allowed MRM transitions to correspond to the observed N-acyl 
species.  This was accomplished by precursor ion scans (m/z 184.1) of the extracts 
containing N-acyl sphingolipids, which indicate the molecular species of sphingomyelin 
(SM) present in the extract. SM was selected because they are typically abundant and 
are indicative of both sphingosine (So) and sphinganine (Sa) species. For example, in 
HEK293 cells, the major SM molecular species are d18:1/16:0, d18:1/18:0, and 
d18:1/24:1. 
 
Cell extraction and liquid chromatography-electrospray ionization-tandem mass 
spectrometry for fatty acyl-CoA quantitation 
Fatty acyl-CoAs were extracted from HEK293 cells, and analyzed by LC-ESI-
MS/MS as described previously (151). 
 
Calculation of isotopic enrichment 
 The isotopic enrichment of fatty acyl-CoAs, sphingoid bases, and sphingoid 
base-1-phosphates was calculated as follows: 




Tandem mass spectrometry 
Sphingolipids undergo structure specific fragmentation during positive ion mode 
ESI-MS/MS that allows the analysis of large numbers of molecular species, including 
both abundant (i.e. SM and Cer) and non-abundant species (i.e. sphingoid base 1-
phosphates (75).  Free sphingoid bases, sphingoid base 1-phosphates, Cer, and 
ceramide monohexose (CMH) fragment by a mechanism that involves a dehydration or 
loss of the 1-position moiety, dehydration at the 3-position, and cleavage of the amide 
bond of the N-acyl chain (if present) to form a conjugated carbocation of m/z 264.4 for 
d18:1 species or 266.4 for d18:0 species (Figure 16).  Utilization of [U-13C]-palmitate by 
SPT and/or CerS during sphingolipid de novo biosynthesis gave rise to 4 sets of 
isotopologues and isotopomers for N-acylated sphingolipids designated unlabeled (e.g. 
12C-d18:1/12C-16:0), base labeled (e.g. 13C-d18:1/12C-16:0), fatty acid labeled (e.g. 12C-
d18:1/13C-16:0), and dual labeled (e.g. 13C-d18:1/13C-16:0, Figure 17). In conformity with 
IUPAC nomenclature, the unlabeled, singly-labeled, and dual-labeled species are 
isotopologues and the singly-labeled species (i.e., base-labeled and dual-labeled) are 
isotopomers of each other. 
The SM phosphocholine moiety (184.1 m/z) is the most abundant product ion 
during positive mode ESI-MS/MS (Figure 16). Therefore, while the total number of 
carbon atoms and double bonds is determined for a given SM molecular species by its 
precursor m/z, the 13C-labeling of the sphingoid base vs. fatty acid cannot be 
distinguished for [M + 16] precursor ions; however, treatment of SM with phospholipase 
D (PLaseD) generates ceramide-1-phosphate (Cer-1-P) that yields sphingoid base 
 57 
product ions (see later). 
 
Incorporation of [U-13C]-palmitate into the fatty acyl-CoAs of HEK293 cells 
Analysis of the fatty acyl-CoA profile in HEK293 cells treated with 0.1 mM [U-
13C]-palmitate revealed an isotopic enrichment (see Materials and Methods) of ~ 60% for 
16:0-CoA at 6 h and that a portion of the 13C-labeled 16:0-CoA had been elongated and / 
or desaturated. (Figure 18). The isotopic enrichment was rapid for 16:0-CoA (35% by 1 
h), but elongated 18:0-CoA, and desaturated (16:1-CoA and 18:1-CoA) species showed 
a slower rate of enrichment.  The isotopic enrichments of 16:0-CoA, 16:1-CoA, 18:0-
CoA, and 18:1-CoA appeared to reach a steady-state between 3 and 6 h at 60%, 45%, 
20%, and 8%, respectively.  
It is possible that 13C-labeled 16:0-CoA could be partially oxidized and then re-
elongated to form 16:0- (or longer) CoA with fewer than 16 atoms of 13C. To examine 
this possibility, the sphingolipid profile in extracts of HEK293 cells treated with 0.1 mM 
[U-13C]-palmitate for 3 h was determined by precursor ion scans (m/z 184.1) of SM, 
allowing the determination of abundant sphingoid base and fatty acid combinations 
(Figure 19).  Since precursor ion scans did not detect [M + 14] species (Figure 19), this 
oxidation and re-elongation was not observed under these conditions.  
 
Incorporation of [U-13C]-palmitate into the sphingolipids of HEK293 cells 
To determine the sphingoid base and fatty acid combinations present in 
untreated HEK293 cells, extracts of HEK293 cells were analyzed using precursor ion 
scans (m/z 264.4 for d18:1 and m/z 266.4 for d18:0) to profile the corresponding 
molecular species of free sphingoid bases, Cer, and CMH.  The N-acyl chain lengths of 
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Cer and CMH in HEK293 cells were 16:0, 18:0, 20:0, 22:0, 24:1, 24:0, 26:1, and 26:0 
with both d18:1 and d18:0 sphingoid bases.  After [U-13C]-palmitate treatment of 
HEK293 cells, labeling of the sphingoid base was confirmed by the presence of [M + 16] 
precursor ions and [M + 16] product ions for Cer and CMH, and the elongation / 
desaturation of 13C-labeled 16:0-CoA was confirmed by the quantitation of 18:0, 24:1, 
and 24:0 Cer and CMH with [M + 16] precursor ions and [M + 0] product ions (as well as 
by [M + 32] precursor ions and [M + 16] product ions). 
To quantitate de novo sphingolipid biosynthesis, replicate dishes (N = 4) of 
HEK293 cells treated with [U-13C]-palmitate were sampled at 1 h intervals for 6 h.  A 
distribution of N-acyl chain lengths was observed for the unlabeled Cer (Figure 20, upper 
panel).  The most abundant Cer, d18:1/16:0-Cer, decreased from 100 ± 20 to 50 ± 10 
pmol/mg protein between 0 and 1 h, and stabilized between 3 and 6 h at 35 ± 5 pmol/mg 
protein.  Other chain lengths of unlabeled Cer showed a similar pattern.  For example, a 
decrease in d18:1/24:1-Cer was observed from 60 ± 10 to 40 ± 10 pmol/mg protein 
between 0 and 1 h, and then stabilization at 20 ± 5 pmol/mg protein between 3 and 6 h. 
Total unlabeled Cer decreased from 250 ± 70 to 110 ± 20 pmol/mg protein between 0 
and 6 h.  Minor species included d18:1/20:0, d18:1/26:1, and d18:1/26:0, each being 
present at < 3 pmol/mg protein. Unlabeled d18:1/16:0 and d18:1/24:0 Cer decreased by 
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R = N-acyl chain, R’ = glucose or galactose, R” = H or phosphate 
A 
B C 
Figure 16.  Major routes of dissociation of sphingolipids in positive ion mode 
with orifice and ring voltages at 30 eV and 180 eV, respectively, (sphingoid 
bases) or 40 eV and 220 eV, respectively, (complex species).  (A) Sphingomyelin 
fragments by loss of the phosphocholine moiety, which retains the charge.  (B) 
Fragmentation of ceramides (R’ = H) involves a double dehydration and loss of the N-
acyl moiety. Analogous losses during fragmentation were observed for 
glucosylceramides (R = glucose) and Cer1P (R = PO3). (C) Fragmentation of 
sphingoid bases and sphingoid base-1-phosphates involves a double dehydration (or 










































Figure 17. Isotopologues and isotopomers of d18:1 / C16:0 ceramide. The C16:0 
abbreviation indicates an N-acyl chain with 16 carbon atoms and 0 double bonds. In 
these examples, 0, 1, or 2 acyl chains (red structure) of ceramide were derived from 
[U-13C]-palmitate during de novo biosynthesis, and so the precursor ion m/z values 
are [M + 0], [M + 16], or [M + 32] Da. The MS/MS analysis distinguishes [M + 16] 
isotopomers into FA and BASE using the m/z value of the product ion (264.4 or 
280.4). 12C and DUAL designate [M + 0] and [M + 32] isotopologues, respectively. 
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decreased by 60%. This decrease in the quantity of unlabeled Cer may be attributable to 
the increasing quantity of 13C-labeled Cer over 6 hr and cellular processes aiming for a 
homeostatic (constant) Cer concentration. 
Alteration in the N-acyl chain length distribution over 6 h was observed in 
unlabeled Cer.  The d18:1/16:0 Cer decreased from 39% of total unlabeled Cer to 33% 
by 6 h; likewise, d18:1/24:0 Cer declined from 24% to 17% by 6 h.  The percent lost was 
almost compensated by an increase in d18:0/16:0 Cer, d18:1/18:0 Cer, and d18:1/22:0 
Cer, which increased from 1% to 3%, 8% to 14%, and 7% to 9% respectively. The 
proportion of d18:1/24:1 Cer remained constant at 20% over 6 h (Figure 20, lower, and 
Figure 21). The d18:1/20:0, d18:1/26:1, and d18:1/26:0 species each comprised less 
than 2% of total Cer. 
 The quantities of unlabeled CMH (Figure 22, upper panel) and SM (Figure 24, 
upper panel) were greater than the amounts of unlabeled Cer; furthermore the chain-
length distribution of CMH was predominantly 24:1 and 24:0 species in contrast to the 
predominance of 16:0 for SM and the approximate equivalence of 16:0, 24:1, and 24:0 
for Cer. As was observed for Cer, the quantities of unlabeled CMH and SM decreased 
between 0 and 6 h although a slight (non-significant) increase in unlabeled CMH at 1 
and 2 h was observed (Figure 22, upper panel). 
 [U-13C]-palmitate was readily incorporated into the sphingolipids of HEK293 cells.  
Labeling of only the N-acyl chain was designated the fatty acid labeled isotopomer of 
Cer (Figure 20, lower panel), CMH (Figure 22, lower panel), and SM (Figure 24, lower 
panel). The quantity of 12C-d18:1/13C-16:0 Cer was 20 and 30 pmol/mg protein after 1 
and 6 h, and the quantity of 12C-d18:1/13C-18:0 Cer was 5 pmol/mg protein between 1 
and 6 hr. Fatty acid labeled 12C-d18:0/13C-16:0 Cer as well as 12C-d18:1/13C-20:0 and 
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12C-d18:1/13C-22:0 Cer quantities were 0.5 to 1 pmol/mg protein by 1 h and 
approximately doubled after 6 h.  Fatty acid labeled 12C-d18:1/13C-26:1 and 12C-
d18:1/13C-26:0 Cer were not above the limit of quantitation (~ 0.1 pmol/mg protein) 
during 6 h. These results indicate both the generation, elongation, and desaturation of 
13C-labeled 16:0-CoA, and the utilization of 13C-labeled fatty acyl-CoAs by CerS in 
HEK293 cells. 
 The quantities of fatty acid labeled CMH (Figure 22, lower panel) and SM (Figure 
24, lower panel) are small compared to the unlabeled species, and their chain length 
distributions tend to recapitulate the distribution of the unlabeled species rather that the 
chain length distribution of fatty acid labeled Cer. For example, fatty acid labeled CMH 
(Figure 22, lower panel) is predominantly 22:0 and 24:1 rather than predominantly 16:0 
as was observed for fatty acid labeled Cer (Figure 20, lower panel). 
 N-acyl sphingolipids with 13C labeling of both the fatty acid and sphingoid base 
moieties were designated dual labeled isotopologues, and interestingly they were 
quantitatively the predominant isotopologues of Cer (Figure 21, upper panel) but not of 
CMH (Figure 23, upper panel) or SM (Figure 25, upper panel) between 3 and 6 h.  
Furthermore, comparison of the quantities of 16:0 dual labeled Cer, CMH, and SM to the 
quantities of the other two 16:0 labeled species (fatty acid and base labeled) showed 
that the dual labeled isotopologue was the most abundant in every case. The 13C-
d18:1/13C-16:0 Cer increased from an initial quantity of 25 ± 3 pmol/mg protein at 1 h to 
50 ± 3 pmol/mg protein at 6 h.  This increase represents a biosynthetic rate for 13C-
d18:1/13C-16:0 Cer of 5 pmol/(mg protein*h) between 1 and 6 h.  The 13C-d18:1/13C-18:0 
Cer quantity at 1 h was 3 ± 1 pmol/mg protein, and was 5 ± 1 pmol/mg protein after 6 h.  
The 13C-d18:1/13C-22:0 Cer was 3 pmol/mg protein after 6 h, while 13C-d18:1/13C-20:0, 
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13C-d18:1/13C-24:1, and 13C-d18:1/13C-24:0 Cer were less than 3 pmol/mg protein at all 
times. 
Incorporation of [U-13C]-palmitate into only the sphingoid base of Cer (Figure 21, 
lower panel), CMH (Figure 23, lower panel), and SM (Figure 25, lower panel) was 
designated base labeled isotopomer, and during 6 h the quantities of these labeled 
sphingolipids were ~ 6 to 8 pmol/mg protein or less; however, a trend of increasing 
quantity can be observed.  Unlike the other 13C-labeled Cer species, the base labeled 
isotopomer was not predominantly 16:0, instead all N-acyl chain lengths except 26 were 
observed.  
 The total quantity of 16:0 Cer at 6 h was 40 pmol/mg protein (unlabeled) + 30 
pmol/mg protein (fatty acid labeled) + 50 pmol/mg protein (dual labeled) + 4 pmol/mg 
protein (base labeled) = 124 pmol/mg protein. If one assumes that a single pool of 
palmitoyl-CoA (with ~ 60% isotopic enrichment) is available to both SPT and CerS, then 
both enzymes would utilize 13C-labeled palmitoyl-CoA 60% of the time. Therefore, 60% 
of de novo biosynthesized Sa will be 13C-labeled, and N-acylation of 13C-labeled Sa by 
CerS using 13C-labeled palmitoyl-CoA is again 60% likely, resulting in the prediction that 
60% x 60% = 36% of the de novo 16:0 Cer will be dual labeled. By the same 
assumption, 60% x 40% = 24% of the de novo 16:0 Cer will be base labeled, 40% x 60% 
= 24% of the de novo 16:0 Cer will be fatty acid labeled, and 40% x 40% = 16% of the 
de novo 16:0 Cer will be unlabeled. 
 Given a total Cer quantity of 124 pmol/mg protein (the amount observed at 6 h), 
predicted de novo amounts are 20 pmol/mg protein (unlabeled), 30 pmol/mg protein 
(fatty acid labeled), 50 pmol/mg protein (dual labeled), and 30 pmol/mg protein (base 
 64 
labeled). These predictions are similar to the observed quantities of dual labeled and 
fatty acid labeled 16:0 Cer. 
 The observed unlabeled 16:0 Cer amount (40 pmol/mg protein) was greater than 
the predicted de novo amount (20 pmol/mg protein), which could result from catabolism 
of, for example, unlabeled SM to yield Cer. The observed base labeled amount (4 
pmol/mg protein) was lower than the predicted de novo amount (30 pmol/mg protein), 
and the absence of detectable (> 0.1 pmol/mg protein) 13C-labeled Sa-1-P at any time 
(data not shown) indicated that accumulation of 13C-labeled Sa-1-P did not explain the 
“missing” 13C-labeled Sa. This difference between fatty acid labeled and base labeled 
amounts was also observed for 16:0 CMH and 16:0 SM, for which there were 3-fold and 
10-fold, respectively, more fatty acid labeled isotopomers. 
In summary, Figures 20 through 25 show the quantities of N-acyl sphingosine-based 
species of HEK293 cells cultured for 0 to 6 h in media containing 0.1 mM [U-13C]-
palmitate.  Base and fatty acid labeled SM were distinguished using PLaseD treatment 
(see above). The product of SPT, 3-keto-sphinganine, as well as sphinganine were 
presumably quickly metabolized because their quantities were consistently at or below 
the limit of detection (~ 0.1 pmol/mg protein).  Likewise the incorporation of label into 
dihydroceramide (DHCer) was observed, but DHCer was also presumably quickly 
desaturated to Cer, as evidenced by substantial quantities of labeled sphingosine-based 
species (Figures 20 and 21). A similar pattern was observed for dihydroceramide 
monohexose (DHCMH, Figures 22 and 23) and dihydrosphingomyelin (DHSM, Figures 




Figure 18. Isotopic enrichment of palmitoyl-, palmioleoyl-, stearoyl-, and oleoyl-
CoA in HEK293 cells after treatment with 0.1 mM [U-13C]-palmitate for 0 to 6 hr. 





























Isotopic enrichment = [M + 16] / {[M + 0] + [M + 16]} 
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Figure 19. Positive mode precursor ion scan (184.1 Da) of extracts of HEK293 
cells treated with 0.1 mM [U13C]-palmitate. The abundant sphingomyelin product 
ion (m/z 184.1) was used to survey molecular species present in the sample. 
Incorporation of one label (+16) or two labels (+32) are designated. Signal is 




Figure 20. Unlabeled (12C) and fatty acid labeled (FA) ceramide from extracts of 
HEK293 cells treated with 0.1 mM [U-13C]-palmitate for 0 - 6 h. Cells were grown 
in culture for the indicated duration, and then collected.  Lipids were extracted and 
analyzed as described in Experimental Procedures. Protein was determined by 
Lowery assay.  Results are the mean ± SD with N = 4, except C16:0 DHCer for 


























N-acyl chain length 
Time, h 
Time, h 
HEK293 unlabeled ceramide 

























































N-acyl chain length 
Time, h 
Time, h 
HEK293 dual labeled ceramide 
































Figure 21. Dual (DUAL) and base labeled (BASE) ceramide from extracts of 
HEK293 cells treated with 0.1 mM [U-13C]-palmitate for 0 - 6 h. Cells were grown 
in culture for the indicated duration, and then collected.  Lipids were extracted and 
analyzed as described in Experimental Procedures. Protein was determined by 
Lowery assay.  Results are the mean ± SD with N = 4, except C16:0 DHCer for 
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Figure 22. Unlabeled (12C) and fatty acid labeled (FA) ceramide monohexose 
from extracts of HEK293 cells treated with 0.1 mM [U-13C]-palmitate for 0 - 6 h. 
Cells were grown in culture for the indicated duration, and then collected.  Lipids 
were extracted and analyzed as described in Experimental Procedures. Protein was 
determined by Lowery assay.  Results are the mean ± SD with N = 4, except C16:0 




Figure 23. Dual (DUAL) and base labeled (BASE) ceramide monohexose from 
extracts of HEK293 cells treated with 0.1 mM [U-13C]-palmitate for 0 - 6 h. Cells 
were grown in culture for the indicated duration, and then collected.  Lipids were 
extracted and analyzed as described in Experimental Procedures. Protein was 
determined by Lowery assay.  Results are the mean ± SD with N = 4, except C16:0 
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Figure 24. Unlabeled (12C) and fatty acid labeled (FA) sphingomyelin from 
extracts of HEK293 cells treated with 0.1 mM [U-13C]-palmitate for 0 - 6 h. Cells 
were grown in culture for the indicated duration, and then collected.  Lipids were 
extracted and analyzed as described in Experimental Procedures. Protein was 
determined by Lowery assay.  Results are the mean ± SD with N = 4, except C16:0 
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Figure 25. Dual (DUAL) and base labeled (BASE) sphingomyelin from extracts 
of HEK293 cells treated with 0.1 mM [U-13C]-palmitate for 0 - 6 h. Cells were 
grown in culture for the indicated duration, and then collected.  Lipids were extracted 
and analyzed as described in Experimental Procedures. Protein was determined by 
Lowery assay.  Results are the mean ± SD with N = 4, except C16:0 DHCer for 
which not all SD values were available. 
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 Differential rates of [U-13C]-palmitate incorporation into N-acyl sphingolipids were 
observed when comparing Cer, CMH and SM.  While only 35% of the total Cer was 
unlabeled at 3 h, unlabeled CMH and SM were 85% and 96%, respectively, of their total 
quantities at 3 h.  SM comprised the quantitative majority of the N-acyl sphingolipids; 
however, label incorporation into SM at 3 h was low (3%). 
 
Phospholipase D treatment 
 Positive ion mode ESI-MS/MS analysis of SM did not yield abundant product ions 
indicative of sphingoid base vs. N-acyl labeling for [M + 16] precursor ions, therefore 
phospholipase D (PLaseD) treatment was used to convert SM to Cer-1-P, which 
fragments in a manner similar to Cer and provides quantitation of base labeled vs. fatty 
acid labeled SM isotopomeric derivatives. Before PLaseD treatment, the Cer-1-P 
isotopomers were quantitated to ascertain the pre-existing amount that should be 
subtracted from the SM-derived Cer-1-P quantity after PLaseD treatment. Total Cer-1-P 
quantities in 1 x 106 HEK293 cells were consistently less than 50 pmol (the sum of all N-
acyl chain lengths). 
 To distinguish base labeled vs. fatty acid labeled SM in HEK293 cells by the 
PLaseD conversion of SM to Cer-1-P, cells were grown for 3 h in media containing 0.1 
mM [U-13C]-palmitate (Figure 26).  Before PLaseD treatment, the quantity of Cer-1-P 
was 5 ± 2 pmol/mg protein for both fatty acid and base labeled isotopomers, and total [M 
+ 16] SM was 690 ± 20 pmol/mg protein.  After treatment with PLaseD, 70 ± 10 pmol/mg 
protein of 13C-d18:1/12C-(fatty acid) Cer-1-P was observed and 560 ± 20 pmol/mg protein 
of 12C-d18:1/13C-(fatty acid) Cer-1-P for a sum of 630 ± 20 pmol/mg protein, which 
represents a 91% recovery of the original SM.  The N-acyl chain length distribution of 
SM was also preserved with 13C-d18:1/12C-16:0, 13C-d18:1/12C-24:1, 12C-d18:1/13C-16:0 
and 12C-d18:1/13C-24:1 Cer-1-P being the most abundant chain lengths. These results 
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reveal that there was ~ 8-fold greater 13C-labeling of the fatty acid moiety compared to 
the sphingoid base moiety in the singly labeled SM in HEK293 cells. 
 
Correction based on isotopic labeling of the fatty acyl-CoAs of HEK293 cells 
Analysis of the fatty acyl-CoA profile in HEK293 cells treated with 0.1 mM [U-
13C]-palmitate revealed that the 16:0-CoA was ~ 60% 13C-16:0-CoA between 3 and 6 h.  
A portion of the 13C-16:0-CoA was elongated and / or desaturated (Figure 18), with 18:0-
CoA isotopic enrichment being 25% at 6 h, while 16:1-CoA and 18:1-CoA isotopic 
enrichments were 40% and 10%, respectively, at 6 h.   
Thus, considering this time (3 to 6 h) during which isotopic equilibrium for 16:0-
CoA 13C-labeling appears to have been established, and assuming that 16:0-CoA is a 
single, well-mixed precursor pool, the simplest prediction would be that in addition to the 
incorporation of 13C-16:0-CoA into de novo biosynthesized 16:0 Cer (~ 60%), there will 
also be incorporation of unlabeled precursor (12C-16:0-CoA) into de novo biosynthesized 
16:0 Cer (~ 40%). Between 3 and 6 h of HEK293 cell treatment with [U-13C]-palmitate, 
the average hourly quantity of 16:0-Cer with unambiguously de novo sphingoid bases 
was ~ [(45 ± 4) + (4 ± 0.5)] = 49 ± 4 pmol/ mg protein [dual labeled (13C-d18:1/13C-16:0) 
+ base labeled (13C-d18:1/12C-16:0)].  Based on the estimated isotopic enrichment of 
16:0-CoA of 60% during this period (Figure 18), and a total de novo 16:0-Cer = x, then 
49 pmol/mg protein = 0.6x, and x = 49 pmol/mg protein/0.6, or x = 82 pmol/mg protein. 
Thus, the quantity of de novo biosynthesized C16:0-Cer with a 12C sphingoid base was ~ 
82 - 49 = 33 pmol/mg protein.  This value is similar to the average hourly quantity of 
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Figure 26. Determination of the label position in singly labeled sphingomyelins 
using PLaseD treatment.  1000 units of PLaseD were suspended in 0.1 ml of 3 mM 
decylglucopyranoside and 100 mM Tris (pH 8.0). The reserved complex sphingolipid 
aliquot was treated with PLaseD and incubated for 15 min in a heating block at 37°C. 
Samples were then dried in a Speed-Vac and reconstituted in mobile phase for LC-
ESI-MS/MS analysis as described in Experimental Procedures.  
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labeled 16:0 Cer (26 ± 2 pmol) between 3 and 6 h, suggesting that a significant 
proportion of the observed quantities of these isotopologues could have been derived 
from de novo biosynthesis utilizing 12C-16:0-CoA. Thus, taking together the isotopic 
enrichment of the 16:0-CoA pool and the quantities of 16:0 Cer isotopologues and 
isotopomers in HEK293 cells leads to the hypothesis that the majority of 16:0 Cer was 
derived from de novo biosynthesis under the conditions described here. 
The average hourly amount of unambiguously de novo biosynthesized 16:0 CMH 
between 3 and 6 h was 11 ± 2 pmol/mg protein [dual labeled (13C-d18:1/13C-16:0) + base 
labeled (13C-d18:1/12C-16:0)].  Based on the estimated isotopic enrichment of 16:0-CoA 
of 60% during this period, a prediction of the average hourly amount of de novo 12C-
C16:0 CMH would be (see above) ~ 7 pmol/mg protein. This is a small quantity 
compared to the average hourly amount of 12C-d18:1/12C-16:0 CMH (72 ± 9 pmol/mg 
protein), and is similar to the average hourly amount of 12C-d18:1/13C-16:0 CMH (7 ± 2 
pmol/mg protein) between 3 and 6 h. Thus, taking together the isotopic enrichment of 
the 16:0-CoA pool and the quantities of CMH isotopologues and isotopomers in HEK293 
cells leads to the hypothesis that a modest portion of unlabeled 16:0 CMH was derived 
from de novo biosynthesis under the conditions described here. 
The average hourly amount of unambiguously de novo biosynthesized 16:0 SM 
between 3 and 6 h was 49 ± 14 pmol/mg protein [dual (13C-d18:1/13C-C16:0) + base 
(13C-d18:1/12C-C16:0)].  Based on the estimated isotopic enrichment of 16:0-CoA of 60% 
during this period, a prediction of the average hourly amount of de novo 12C-C16:0 SM 
would be (see above) 33 pmol/mg protein. This is a minute quantity compared to the 
average hourly amount of 12C-d18:1/12C-C16:0 SM (1040 ± 110 pmol/mg protein), and is 
similar to the average hourly amount of 12C-d18:1/13C-C16:0 SM (21 ± 6 pmol/mg 
protein) between 3 and 6 h. Thus, taking together the isotopic enrichment of the C16:0-
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CoA pool and the quantities of SM isotopologues and isotopomers in HEK293 cells 
leads to the hypothesis that only a small fraction of unlabeled 16:0 SM was derived from 
de novo biosynthesis under the conditions described here. 
 
Treatment of HEK293 cells with fumonisin B1 
 Fumonisin B1 (FB1) is an inhibitor of CerS (73, 152, 153), and exposure of 
HEK293 cells to FB1 for 24 and 48 h caused decreases in the quantities of unlabeled 
and 13C-labeled Cer.  The unlabeled Cer quantity at 24 h was 46 ± 2 pmol/mg protein in 
control cells and 27 ± 1 pmol/mg protein in FB1 treated cells.  An even larger difference 
was observed for 13C-labeled Cer after 24 h. The quantity of base labeled 13C-d18:1/12C-
(fatty acid) Cer was 13 ± 1 pmol/mg protein in control cells, but in FB1 treated cells was 
only 3 ± 1 pmol/mg protein.  The quantity of dual labeled 13C-d18:1/13C-(fatty acid) Cer 
was 36 ± 1 pmol/mg protein in control cells, but was only 4 ± 1 pmol/mg protein in FB1 
treated cells. Thus, an 86% reduction in the quantity of unambiguously de novo 
biosynthesized Cer (base labeled + dual labeled) was observed.  
 Changes in sphingoid base quantities were also informative regarding the 
responses to FB1 treatment (Figure 27).  In control cells 13C-Sa and 13C-Sa-1-P were 
below the limits of quantitation (~ 0.1 pmol/mg protein); however, they were the most 
abundant sphingoid bases in FB1 treated cells, having quantities of 79 ± 12 pmol/mg 
protein and 450 ± 67 pmol/mg protein, respectively.  Unlabeled Sa and Sa-1-P were 
observed to be 17 ± 4 pmol/mg protein and 88 ± 12 pmol/mg protein respectively in FB1 
treated cells, which yields a 0.18 Sa/Sa-1-P ratio and a 0.19 13C-Sa/13C-Sa-1-P ratio. 
These results indicate that FB1 inhibition of CerS resulted in the accumulation of a 





































































































Figure 27. Sphingoid bases from HEK293 cells treated with 0.1 mM [U-13C]-
palmitate ± 50 µM FB1 for the indicated times. 
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decreases in the quantity of de novo biosynthesized Cer. Collectively, these results 
show the utility of SIMPLE for determination of the metabolic reaction (CerS) that is 
inhibited (86%) by a pharmacological agent (FB1) during sphingolipid biosynthesis. 
  
3.5 Discussion 
Described here is a sensitive and selective LC-ESI-MS/MS method utilizing [U-
13C]-palmitate tracer for the quantitation of de novo biosynthesized sphingolipids.  
Utilizing an isotopic precursor to measure sphingolipid biosynthesis has been previously 
examined, but the SIMPLE method presented here has several distinct advantages over 
these previous reports (94, 146).  First, HPLC resolution of sphingolipid classes (Cer, 
CMH, and SM) in extracts of cellular lipids is faster and more selective than solid-phase 
extraction. Second, the multiple reaction monitoring (MRM) mode of tandem mass 
spectrometry utilized here provides sensitivity superior to the m/z scanning MS utilized 
previously. Third, the collision-induced dissociation (CID) fragmentation of sphingolipid 
precursor ions generated by relatively gentle electrospray ionization reveals the 
presence of three labeled isotopologues and isotopomers of N-acyl sphingolipids that 
were, in the previous reports, superimposed into two isotopic enrichment patterns (for 
palmitate and sphingosine) by the trimethylsilyl derivatization of Cer required before gas 
chromatography-electron impact-MS (GC-EI-MS).        
Fatty acid β-oxidation of the [U-13C]-palmitate coupled with re-elongation could 
produce non-uniformly labeled [13C]-palmitate, and lead to the misinterpretation of data, 
as previously stated (146).  To address this issue, precursor scans for m/z 184.1 (Figure 
4) and m/z 264.4 in [U-13C]-palmitate treated HEK293 cell extracts were performed, and 
did not show significant quantities of labeled N-acyl sphingolipids containing less than 16 
amu shifts due to the activity of this putative palmitate metabolism.  This conclusion was 
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based upon the sphingolipid fragmentations during positive ion mode ESI-MS/MS shown 
in Figure 16.  
During positive ion mode ESI-MS/MS, Cer and CMH fragment to produce the 
same conjugated carbocation as the sphingoid bases. SM species fragment differently 
and largely retain the charge on their phosphocholine moiety after dissociation; 
therefore, almost no charge remains on Cer moiety fragments to determine the 
sphingoid base vs. N-acyl labeling if the SM is singly-labeled. To determine the label 
position in the singly-labeled SM, extracts of HEK293 cells cultured with [U-13C]-
palmitate were treated with PLaseD to convert the SM to Cer-1-P.  The resulting Cer-1-P 
fragmented during positive ion mode ESI-MS/MS in a manner similar to Cer. The results 
indicated that Cer-1-P derived from SM had a ratio of ~ 8:1 for [12C]-d18:1/[13C]-(fatty 
acid) : [13C]-d18:1/[12C]-(fatty acid), revealing that the contribution of pre-existing 
sphingoid bases to SM biosynthesis in HEK293 cells is ~ 8-fold greater than the 
contribution of de novo sphingoid bases under these experimental conditions. 
 The immediate product of SPT is 3-ketosphinganine; however, [13C]-3-
ketosphinganine was below the limit of detection (~ 0.1 pmol/mg protein) in HEK293 
cells. The quantity of [12C]-3-ketosphinganine in HEK293 cells is also consistently low 
(less than 5% of the signal from Sa).  This implies that 3-ketosphinganine is rapidly 
reduced to Sa and does not accumulate under these experimental conditions. 
 It has been previously shown that when cells are treated with FB1, production of 
Cer is blocked and Sa accumulates (154-157).  The [U-13C]-palmitate tracer experiments 
described here independently confirm this conclusion by showing decreases in the 
quantity of [13C]-N-acyl sphingolipids, and provide additional details regarding the fate of 
labeled Sa demonstrated by the accumulation of [13C]-labeled Sa-1-P.  
 Chain length-specific differences were observed in the relative quantities of the 
isotopologues and isotopomers of N-acyl sphingolipids in HEK293 cells.  For example, 
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the quantity of [13C]-d18:1/[13C]-16:0 Cer was equal to or greater than the quantity of any 
other isotopomer between 2 and 6 h, including the quantity of presumably pre-existing 
[12C]-d18:1/[12C]-16:0, while in contrast the quantity of [13C]-d18:1/[13C]-18:0 (and longer) 
Cer was equal to or less than the quantities of either the [12C]-d18:1/[12C] or [13C]-
d18:1/[12C] isotopomers from 0 to 6 h. The [12C]-d18:1/[13C]-(fatty acid) isotopomer was 
of the lowest relative quantity for all chain lengths except C16:0, for which it was the  
second-lowest abundance isotopomer (the [13C]-d18:1/[12C]-16:0 Cer was the least 
abundant). 
 The relative abundances of isotopomers for CMH and SM largely recapitulated 
the chain length-dependent variations described above for Cer with certain exceptions. 
First, the quantities of CMH and particularly SM [12C]-d18:1/[12C]-(fatty acid) species 
were greater than the quantities of any labeled isotopomer for all chain lengths between 
0 and 6 h, in contrast to the robust isotopic enrichment of Cer, especially 16:0 Cer. As 
observed for Cer, the [13C]-d18:1/[13C]-16:0 species of CMH and SM was the most 
abundant labeled 16:0 isotopologue, while for chain lengths longer than 16:0 the [13C]-
d18:1/[12C]-(fatty acid) was typically the most abundant labeled isotopomer. The results 
for CMH preclude definitive statements about [12C]-d18:1/[13C]-(fatty acid) isotopomers 
due to the apparent presence of these isotopomers at 0 hr; this observation is explained 
by the previously described presence of α-hydroxy fatty acid moieties on CMH (158). 
 Quantitation of unlabeled and 13C-labeled fatty acyl-CoAs provides a correction 
factor for the estimates of sphingolipid biosynthesis, if one assumes a single, well-mixed 
precursor pool of fatty acyl-CoAs. Between 3 and 6 hr this correction for palmitoyl-CoA is 
~ 40%, and is even higher for elongated 13C-labeled fatty acyl-CoAs, such as stearoyl-
CoA (Figure 18). This suggests that at least some of the unlabeled N-acyl sphingolipids 
could have been generated by de novo biosynthesis utilizing unlabeled fatty acyl-CoA 
substrates, with the remainder of the unlabeled sphingolipids likely being derived from 
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catabolism of more complex species. Thus, measurement of the fatty acyl-CoA 
biosynthetic precursor pools for sphingolipids allows the estimation of de novo 
biosynthetic and turnover contributions. 
 Overall, these results are both consistent with previous knowledge about 
sphingolipid de novo biosynthesis and suggestive of new hypotheses regarding this 
complicated metabolic process. The rapid and robust isotopic labeling of 16:0 Cer 
indicates that de novo biosynthesis accounts for the majority of this metabolite pool 
under these experimental conditions, while the slow and minimal labeling of SM 
indicates a minor contribution of de novo biosynthesis to this metabolite pool under 
these conditions. These results, as well as the 13C-labeling of 16:0 CMH being 
intermediate between those of 16:0 Cer and 16:0 SM, are consistent with the step-wise 
biosynthesis of sphingolipids, beginning with sphinganine and ceramide in the 
endoplasmic reticulum (ER), followed by CMH in the ER and cis-Golgi (159), and then 
SM in the trans-Golgi and plasma membrane. The decrease in isotopic labeling as the 
N-acyl chain length increases for Cer, CMH, and SM is also consistent with the 
requirement for elongation of the 13C-labeled palmitoyl-CoA in the ER before its 
utilization as substrate by CerS isoforms. 
  [U-13C]-palmitate treatment in conjunction with LC-ESI-MS/MS analysis yields 
highly informative data regarding the quantities of sphingolipid isotopomers.  It is also 
important to note that pharmacological impairment of sphingolipid biosynthetic pathways 
can be detected, as demonstrated by FB1 treatment resulting in a ~85% decrease of 13C-
labeled Cer amount, and in [13C]-Sa accumulating up to amounts 5-fold greater than 
either [13C]-So or [13C]-So-1-P in control cells.  Thus, a hypothesis generated by these 
experiments is a substantial contribution of de novo biosynthesis to the C16:0 Cer 
metabolite pool. In brief, the sphingolipid isotopic metabolic precursor labeling 
experiment (SIMPLE) allows a deeper exploration of biosynthetic rates and 
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METABOLOMIC ANALYSIS OF THE CONSEQUENCES OF ELEVATION OF SERINE 
PALMITOYLTRANSFERASE ACTIVITY BY STABLE OVEREXPRESSION OF SPTLC1 
AND SPTLC2 IN HEK293 CELLS:  A USEFUL APPROACH TO TEST CURRENT 
DOGMA AND RAISE NEW HYPOTHESES3 
 
4.1 Summary 
 Sphingolipids and fatty acyl-CoAs can be labeled with stable isotopes by 
treatment of cultured cells with [U-13C]-palmitate, as described in Chapter 3. A cellular 
paradigm for increased de novo biosynthesis of sphingolipids is the over-expression of 
serine palmitoyltransferase (SPT) in HEK293 cells, which results in greater quantities of 
sphingolipids in SPT1/2 cells both with and without [U-13C]-palmitate treatment, 
compared to HEK293 cells. 
One approach for a more sophisticated analysis of the isotopic enrichment data 
involved calculating the dynamic (time-dependent) isotopic enrichment of fatty acyl-CoAs 
and sphingolipids, and using this information to estimate metabolic parameters of a 
particular analyte pool (i.e. palmitoyl-CoA) such as its isotopic enrichment at labeling 
steady-state, and its fractional turn-over rate per unit time. Using these estimated 
parameters and the analyte pool size (determined by LC-ESI-MS/MS quantitation) the 
rate of appearance of unlabeled analyte was determined, which is synonymous with the 
forward rate of de novo biosynthesis for that analyte. In this study, the specific 
contributions of this author were the extraction and quantitation of fatty acyl-CoAs, 
                                                
3  This chapter is in preparation for publication; the authors are Wei, J., Allegood, J., Wang, E., 
Kelly, S., Haynes, C., Park, H., Carton, J., Uhlinger, D., Sullards, M., and Merrill, A. 
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 Sphingolipids are an incredibly diverse family of compounds that are found in 
eukaryotes and some prokaryotes and viruses (74) where they have structural functions 
as well as participating in cell recognition and cell signaling (160, 161).  Sphingolipids 
are elaborations of a category of lipid backbones called “sphingoid bases” or “long-chain 
bases,” of which the three most commonly encountered in mammalian sphingolipids are 
sphingosine (So), sphinganine (Sa, dihydrosphingosine) and phytosphingosine (4-
hydroxydihydrosphingosine) (61).  
 Sphingoid base biosynthesis is catalyzed by serine palmitoyltransferase (SPT), a 
family of pyridoxal 5’-phosphate-dependent enzymes that condense serine and 
palmitoyl-CoA to make the “traditional” sphingoid bases (sphinganine, sphingosine, etc.) 
(4-6), and they also accommodate alanine to make 1-deoxysphinganine and glycine to 
make 1-desoxymethylsphinganine (73). So far, at least three isoforms (SPT1, SPT2 and 
SPT3, and their corresponding genes, SPTLC1, SPTLC2 and SPTLC3) have been 
identified in humans (162-164). Both SPTLC1 and SPTLC2 are expressed widely in 
mouse and human tissues (21, 163), while the SPTLC3 is expressed in certain tissues 
and is absent in HEK293 cells (164).  The minimal requirement for SPT activity is a 
heterodimer of SPT1 with SPT2 and/or SPT3 (4, 164, 165), and in at least some cases, 
other associated proteins may be involved (166, 167). 
 SPT is generally regarded to be rate-limiting for de novo sphingolipid 
biosynthesis (168, 169), and changes in activity have been correlated with up-regulation 
of this pathway by agents such as endotoxin (170), retinoic acid (171), 4-HPR (172), 
etoposide (173) and UV light (174-176) etc.  However, there have been no studies of 
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how elevation of SPT activity alone, by transient or stable transfection with cDNA for 
SPTLC1 and SPTLC2, affects this pathway and, possibly, compromises cell survival 
since downstream metabolites such as sphingoid bases and ceramides are growth 
inhibitory and cytotoxic (160, 177).  Mouse and Chinese hamster SPTLC1 and SPTLC2 
genes have been over-expressed in HEK293 cells (163) and CHO cells (22), 
respectively, but the effects on flux through the pathway and the sphingolipid profile 
have not been reported. 
 Therefore, to explore this fundamental question of sphingolipid biosynthesis, a 
HEK293 cell line was generated that stably over-expresses SPT1 and SPT2 proteins, it 
was confirmed that this elevates SPT activity, and the effects of the higher sphingoid 
base biosynthesis on production of the downstream species was evaluated using liquid-
chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), 
which also allowed the monitoring of sphingoid base de novo biosynthesis using [U-13C]-
palmitate as a stable isotope-labeled precursor.  The studies confirmed some aspects of 
the current dogma about SPT and sphingolipid biosynthesis (i.e., SPT over-expression 
not only increased the rate of sphingolipid biosynthesis but also increased the amounts 
of sphingolipids in the cells), and also illustrated how downstream steps can become 
rate-limiting, and raised several interesting new questions and hypotheses. 
 
4.3 Experimental procedures 
Materials 
 The HEK293 cells were obtained from the American Type Culture Collection 
(Manassas, VA).  All tissue culture plastic ware was obtained from Corning (Corning, 
NY). Fetal bovine serum was supplied by Hyclone (Logan, Utah). Anti-BiP antibody was 
from StressGen, Inc. (Victoria, BC, Canada). The secondary antibodies were Alexa 
Fluor-conjugated goat anti-rabbit and anti-mouse obtained from Molecular Probes, Inc. 
 87 
(Eugene, OR). The affinity purified polyclonal rabbit anti-human primary antibodies 
raised against SPT1 peptides have been previously described (21). C6-NBD-SM and 
C6-NBD-Cer are from Avanti Polar Lipids (Alabaster, AL). Protease inhibitor cocktail was 
obtained from Roche (Indianapolis, IN).  
 The internal standard cocktail (catalog number LM-6002) was provided by Avanti 
Polar Lipids (Alabaster, AL) in sealed ampoules and certified (64) to be > 95% pure and 
within 10% of the specified amount (250 µM); it was comprised of  the 17-carbon chain 
length sphingoid base analogs:  C17-sphingosine, (2S,3R,4E)-2-aminoheptadec-4-ene-
1,3-diol (d17:1-So); C17-sphinganine, (2S,3R)-2-aminoheptadecane-1,3-diol (d17:0-Sa); 
C17-sphingosine 1-phosphate, heptadecasphing-4-enine-1-phosphate (d17:1-S1P); and 
C17-sphinganine 1-phosphate, heptadecasphinganine-1-phosphate (d17:0-Sa1P); and 
the C12-fatty acid analogs of the more complex sphingolipids C12-Cer, N-(dodecanoyl)-
sphing-4-enine (d18:1/C12:0-Cer); C12-Cer 1-phosphate, N-(dodecanoyl)-sphing-4-
enine-1-phosphate (d18:1/C12:0-Cer1P); C12-sphingomyelin, N-(dodecanoyl)-sphing-4-
enine-1-phosphocholine (d18:1/C12:0-SM); C12-glucosylceramide, N-(dodecanoyl)-1-β-
glucosyl-sphing-4-eine (d18:1/C12:0-GlcCer); and C12-lactosylceramide, N-
(dodecanoyl)1-β-lactosyl-sphing-4-eine (d18:1/C12:0-LacCer); as well as one very-long-
chain Cer analog, C25-Cer, N-(pentacosanoyl)-sphing-4-enine (d18:1/C25:0-Cer).  [U-
13C]-palmitate (98%) was purchased from Cambridge Isotope (Andover, MA). 
 The HPLC grade solvents (acetonitrile, # EM-AX0145; chloroform, # EM-
CX1050; hexane, # JT9304-33; and methanol, # EM-MX0475, as well as formic acid 
(ACS grade, # EM-FX0440-7), were obtained from VWR (West Chester, PA), and acetic 




 HEK293 cells and SPT1/2 cells were grown in DMEM / F12 medium (1:1) (Gibco 
BRL, MD) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U / ml) and 
streptomycin (100 µg /ml) at 37 °C in a humidified 5 % CO2 atmosphere.  
 
Generation of SPT1 and SPT2 over-expressing cell lines 
 SPTLC1 and SPTLC2 were cloned from human monocytes. Briefly, total RNA 
from cells treated for 4 hr with 1 mM dexamethasone was isolated using the RNeasy 
RNA isolation kit (Qiagen, Valencia, CA).  The SPT gene-specific RNA was reverse 
transcribed and PCR amplified using Superscript One-Step RT-PCR System (Invitrogen, 




CTAGTCTAGAGGCTCAGTCTTCTGTTTGTTC.  The SPT1 gene was cloned into 
pcDNA3.1NEO and SPT2 was cloned into pcDNA3.1ZEO.  The expression plasmids 
were transfected separately or co-transfected into HEK293 cells using Superfect 
(Qiagen, Valencia, CA) according to the manufacture’s directions.  50 mg of plasmid 
DNA were mixed with 30 ml of the Superfect reagent in 500 ml serum-free media 
(DMEM, 2 mM L-glutamine) and incubated at room temperature for 15 minutes.  The 
liposomes were added to 5 ml of serum-containing media (DMEM, 10% FBS, 2 mM L-
glutamine, 10 Units/ml penicillin, 10 ug/ml streptomycin) and incubated on 5X106 
HEK293 cells for 2 hours at 37oC, 5% CO2.  The cells were washed and the serum-
containing media was replaced.   400 mg/ml geneticin or 200 mg/ml zeocin were added 
to the culture media 48 hours after transfection to select for cells stably expressing SPT1 
or SPT2, repsectively. The co-transfection was selected in media containing both 
geneticin and zeocin.  The media was changed every 4 days. After 2 weeks, surviving 
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colonies were selected and grown in individual wells of a 6-well plate.  3 colonies for 
each transfection, SPTLC1, SPTLC2, SPTLC1/SPTLC2, pcDNA 3.1 NEO vector control 
and pcDNA3.1Zeo vector control, were selected and checked by RT-PCR for the 
transfected gene transcript and by Western blot for recombinant protein expression.  The 
highest expressing cell line for each gene transfection and vector controls were selected 
for further study. 
 
Western blotting 
 50 µg of microsomal membrane protein were loaded on a 10 % SDS-PAGE gel 
(BIO RAD, Hercules, CA). For Western blotting, the gel was transferred to nitrocellulose 
membrane using Tris-glycine buffer with 20 % methanol, as the transfer medium, for 1 
hour at 100 V (constant), in a transfer unit (BIO RAD, Hercules, CA). After blocking 
overnight at 4 oC with 5% milk/TBST (Tris buffered saline with 0.05 % Tween 20) the 
membrane was incubated with rabbit anti-SPT1 serum diluted in 5% milk/TBST for 2 
hours and then with a AP-conjugated secondary antibody and its substrate using a ECF 
western blotting kit (GE Healthcare, Piscataway, NJ).  
 
SPT activity assay 
 SPT activity was assayed as previously described (178). Data of specific activity 
for SPT represent results from 2 or more assays conducted under the same conditions. 
Values are presented as mean ± SD of all acquired values.   
 
Immunofluorescence confocal microscopy 
 Cells were cultured on glass cover-slips (VWR, Inc., West Chester, PA) in a 24-
well plate and fixed with 4 % formaldehyde in PBS at room temperature for 15 min. 
Fixed cells were permeabilized with 0.1 % Triton X-100 for 5 min, blocked in 10 % fetal 
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bovine serum in PBS (serum-PBS) for 30 min and then subjected to indirect 
immunofluorescence staining. Cells were incubated for 1 h at room temperature, with 
rabbit anti-SPT1 or rabbit anti-SPT2 primary antibody and mouse anti-Bip antibody, then 
washed 3 times with PBS-serum for 5 min each, and incubated for 1 h at room 
temperature with Alexa Fluor 488 anti-rabbit or Alexa Fluor 568 anti-mouse secondary 
antibody. Stained cells were rinsed in PBS and mounted in Fluoromount G (Southern 
Biotechnology Associates, Inc., Birmingham, AL) before observing under a Zeiss LSM 
510 inverted laser scanning confocal microscope (Heidelberg, Germany). 
 
[U-13C]-Palmitate isotopic labeling 
 Uniformly labeled [13C]-palmitate was mixed with fatty acid-free bovine serum 
albumin (BSA) at 1:1 molar ratio to make a 1 mM solution which was further diluted to a 
final concentration of 0.1 mM with complete cell culture medium just before use and filter 
sterilized. Twenty-four hours before the experiment cells were seeded in 100 mm Petri 
dishes in complete growth medium. Just before treatment, medium was removed from 
the Petri dish and [U-13C]-palmitate/BSA medium mixture was applied to the cells for a 
certain period of time. 
 
Liquid chromatography-electrospray ionization-tandem mass spectrometry of 
sphingolipids 
 The method has been described previously (68, 74). All data were collected 
using a Perkin Elmer Series 200 MicroPump system coupled to a PE Sciex API 3000 
triple quadrupole mass spectrometer equipped with a Turbo Ion-Spray source.  Free 
sphingoid bases and the Cer-1-P were separated by reverse phase HPLC using a binary 
solvent system and a Supelco 2.1 mm i.d. x 5 cm Discovery C18 column and a flow rate 
of 1 ml/min.  Mobile phase A consisted of CH3OH/H2O/HCOOH (58:41:1) (v/v/v) with 5 
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mM ammonium formate.  Mobile phase B consisted of CH3OH/HCOOH (99:1) (v/v) with 
5 mM ammonium formate.  Before every run, the column was equilibrated for 0.4 min 
with 60:40 (A/B) prior to injection. After sample injection (50 µL by a Perkin Elmer Series 
200 autosampler), the column was eluted with 60:40 A/B for 0.5 min, followed by a 1.8 
min linear gradient to 100% B, which was held for 5.3 min and followed by a 0.5 min re-
equilibration with 60:40 A/B before the next run.  
 The complex sphingolipids (ceramides, monohexosylceramides, and 
sphingomyelins) were separated by normal phase HPLC using a binary solvent system 
and a Supelco 2.1 mm i.d. x 5 cm LC-NH2 column at a flow rate of 1.5 ml/min.  Mobile 
phase A consisted of CH3CN/CH3OH/CH3COOH (97:2:1) (v/v/v) with 5 mM ammonium 
acetate.  Mobile phase B consisted of CH3OH/H2O/CH3(CH2)3OH/CH3COOH 
(64:15:20:1) (v/v/v/v) with 5 mM ammonium acetate. Before every run the column was 
equilibrated for 0.5 min at 98:2 A/B prior to injection. After sample injection, the column 
was eluted with 98:2 A/B for 1.1 min, followed by a 0.2 min linear gradient to 82% A, 
which was held for 0.4 min, and then followed by a 0.8 min linear gradient to 100% B.  
The column was then re-equilibrated at 98:2 A/B for 0.5 min. 
 In the API 3000 triple quadrupole mass spectrometer, dry ultra high-purity N2 was 
used as the nebulizing gas at a flow rate of 6 liters/min.  The ionspray needle was held 
at 5500 V, and the orifice and ring voltages were kept low (30-40 V and 180-220 V, 
respectively) to prevent collisional decomposition of molecular ions prior to entry into the 
first quadrupole, and the N2 Turbo Ion Spray gas temperature was 500 °C.  N2 was used 
to collisionally induce dissociations in Q2, which was offset from Q1 by 30-40 V.  Q3 was 
then set to pass molecularly distinctive product ions. A multiple reaction monitoring 
(MRM) method was created by setting Q1 and Q3 to pass the precursor and product 
ions of the most abundant sphingolipid molecular species.  For example, for Cer, these 
transitions occur at m/z 538.7/264.4, 566.5/264.4, 594.6/264.4, 622.7/ 264.4, 
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648.7/264.4, 650.7/264.4, which correspond to Cer with a d18:1 sphingoid base and 
16:0, 18:0, 20:0, 22:0, 24:1, and 24:0 N-acyl chain, respectively.  The dwell time was 25 
ms for each transition.  Quantitation was achieved by spiking the samples prior to 
extraction with the synthetic internal standards. 
 Prior to selecting MRM pairs for each cell type, the variation in fatty-acyl chain 
length was determined, which allowed MRM transitions to be tailored for the major N-
acyl species.  This was usually accomplished by precursor ion scans of m/z 184.4, the 
structure specific fragmentation indicative of SM.  SM were chosen because they are 
typically abundant and are indicative of both sphingosine (So) and sphinganine (Sa) 
based species. For example, in HEK293 cells, the major SM are 16:0, 18:0, and 24:1. 
 
Cell extraction and liquid chromatography-electrospray ionization-tandem mass 
spectrometry of fatty acyl-CoA species 
 Fatty acyl-CoAs were extracted from HEK293 cells and quantitated by LC-ESI-
MS/MS as described previously (3). 
 
Quantitation of sphingolipid isotopologues and isotopomers by LC-ESI-MS/MS 
 Sphingolipids [sphingoid bases and (dihydro)N-acyl species] were extracted from 
samples of cultured cells and quantitated by LC-ESI-MS/MS essentially as described 
previously (74) . To quantitate sphingoid bases labeled with [U-13C]-palmitate, additional 
multiple reaction monitoring (MRM) pairs corresponding to [M + 16] precursor ions and 
[M + 16] product ions were used. To quantitate N-acyl (dihydro)sphingolipids labeled 
with a single [U-13C]-palmitate moiety, MRM pairs corresponding to [M + 16] precursor 
ions and both [M + 0] and [M + 16] product ions were used, providing discrimination of 
labeling on the N-acyl and sphingoid base moieties, respectively. These [M + 16] 
isotopomers are designated FA and BASE. To quantitate N-acyl (dihydro)sphingolipids 
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labeled with two [U-13C]-palmitate moieties, MRM pairs corresponding to [M + 32] 
precursor ions and [M + 16] product ions were used; the [M + 32] isotopologue was 
designated DUAL. Unlabeled [M + 0] sphingolipids were designated 12C. The MRM 
extracted ion chromatogram peak areas of all four sphingolipid isotopologues and 
isotopomers were integrated (Analyst 1.4), converted to picomoles using the peak areas 
of the internal standards, and normalized to the mg of protein in the extracted sample. 
 
Calculation of N-acyl sphingolipid isotopic enrichment 
 The presence of 13C labeled N-acyl sphingolipids (tracer; DUAL, BASE, and FA 
species) together with unlabeled sphingolipids (tracee; 12C isotopologue) allows the 
calculation of the isotopic enrichment (tracer / tracer + tracee) of a particular molecular 
species, such as C16:0 Cer. The approach taken was to quantitate 12C, BASE, DUAL, 
and FA isotopologues and isotopomers (pmol per mg protein) and to calculate the 
enrichment of a particular N-acyl chain length as the number of labeled acyl chains 
divided by the total number of acyl chains: 
 
(1 x BASE)+(2 x DUAL)+(1 x FA) / (2 x 12C)+(2 x BASE)+(2 x DUAL)+(2 x FA) 
 
Calculation of the rate of appearance of tracee using enrichments and measured N-acyl 
sphingolipid quantities 
 One method for the quantitation of metabolic flux is calculation of the rate of 
appearance of tracee (Ra) using measurements of the isotopic enrichment of metabolites 
over time (88). This approach was applied to N-acyl sphingolipids by plotting enrichment 
(see above) vs. time, and showed that (in both cell types) some sphingolipids, such as 
C16:0-Cer, achieved isotopic equilibrium (a plateau in enrichment) during the 6 hr [U-
13C]-palmitate treatment while others, such as C24:0- and C24:1-Cer, did not (Figure 
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39). Curve-fitting (Prism 4.0) was performed upon the enrichment plot data using the 
following formula (88):  
€ 
Et = Ep 1− e
−kt( ) 
 
in which Et is the enrichment at time t, Ep is the plateau enrichment at isotopic 
equilibrium, and k is the metabolite pool’s fractional turn-over rate per unit time. 
 
Using the estimations of Ep and k together with the measured quantities of 12C 
sphingolipids (Q; tracee pool size), the following equation (88) was used to calculate the 
rate of appearance (Ra) of tracee (unlabeled N-acyl sphingolipid): 
 
Ra (tracee) = k Q 
 
Thin layer chromatography 
 TLC was performed as described previously (179). Neutral GSLs and acidic 
GSLs were dissolved in chloroform/methanol (2:1, v/v) separately and applied to silica 
gel-coated plates with glass backing (Merck, Darmstadt, Germany). The neutral GSL 
plate was developed with a solvent system of chloroform/methanol/water (65:35:8, v/v/v) 
and detected with orcinol reagent. The acidic GSLs plate was developed with a solvent 
system of chloroform/methanol/0.2% CaCl2 (55:45:10, v/v/v) and detected with resorcinol 
reagent. 
  
In vitro sphingomyelinase activity assay 
 The methods for nSMase assay and aSMase assay have been thoroughly 
described before (180) and the modified part is described below. Cells were collected in 
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the lysis buffer as described (180) plus protease inhibitor cocktail (Roche, Indianapolis, 
IN). For this experiment, instead of using radiolabeled SM as a substrate, fluorescent 
NBD-labeled SM (C6-NBD-SM) was used at 2 nmol per 100 µl reaction. Each reaction 
was performed in triplicate and stopped by adding 1.4 ml of HPLC solvent that was 
composed of 90% methanol and 10% aqueous phase (5 mM K2HPO4). The sample was 
centrifuged at 2500 rpm for 8 min and 1.2 ml of the supernatant was transferred to a 
glass HPLC sample tube. C6-NBD-SM and C6-NBD-Cer were diluted separately or 
together in the HPLC solvent as a standard. For each analysis 100 µl  of sample was 
injected onto the HPLC column and the isocratic flow rate of the solvent was 2 ml / min. 
BCA protein assay (Pierce, Rockford, IL) was used to determine the protein 
concentrations.       
 
In situ sphingomyelinase activity assay 
NBD-C6-SM was dissolved in ethanol to make a 5 mM solution. Fatty acid free 
BSA was dissolved in PBS to make a 2 mM stock solution. The two solutions were 
mixed at 1:1 molar ratio and sonicated. Then the NBD-C6-SM/BSA complex was diluted 
to 5 µM working solution in complete cell culture medium and filter sterilized. Twenty-four 
hr before the experiment cells were seeded in 60 mm dishes in complete growth 
medium. The old medium was replaced with the medium containing NBD-C6-SM/BSA 
and the cells were incubated for 7 hr before they were collected for analysis. 
 
4.4 Results 
Sphingolipid de novo synthesis pathway 
 The de novo synthesis of sphingolipids begins with the condensation of serine 
and palmitoyl-CoA by SPT to form 3-keto-Sa which is reduced to Sa. This Sa may be 
acylated by a family of (dihydro)ceramide synthases (CerS) using different fatty acyl-
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CoAs to form the corresponding DHCer subspecies (Figure 28). In mammals, six genes 
that encode CerS have been cloned (7, 9, 181, 182). Individual ceramide synthase 
isoforms show substrate preference for specific fatty acyl-CoA chain lengths, thus 
generating (dihydro)ceramides with distinct acyl chain lengths. For example, CerS1 
shows a significant preference for stearoyl-CoA, whereas CerS5 and CerS6 
preferentially catalyze the acylation of Sa with myristoyl- and palmitoyl-CoAs (8, 9). The 
DHCer are reduced to Cer by dihydroceramide reductase (DES) and both DHCer and 
Cer are converted to complex sphingolipids (SM, DHSM, CMH, DHCMH) by adding 
different moieties to the 1-hydroxyl oxygen atom. 
 
Generation of a functional HEK293/SPTLC1/SPTLC2 stable cell line 
 Since SPT is the first enzyme of sphingolipid de novo biosynthesis it would be 
interesting to know the impact of increasing SPT activity on the pathway. To explore this 
issue a SPT over-expression cell model was constructed. The SPTLC1 and SPTLC2 
cDNAs were cloned from human monocytes and inserted into pcDNA3.1NEO and 
pcDNA3.1ZEO separately. The expression plasmids were transfected separately or co-
transfected into HEK293 cells. Antibiotic selection was used to generate cells stably 
expressing SPTLC1 or SPTLC2 or SPTLC1/SPTLC2. For convenience we call these 
transformants SPT1, SPT2 and SPT1/2 cells. Using quantitative real-time PCR analysis 
significant elevations of SPTLC1 and/or SPTLC2 mRNA were detected in these cell lines 
(data not shown). When microsomal fractions were isolated and resolved by SDS-PAGE 
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Figure 28. Diagram of the sphingolipid de novo biosynthesis pathway. d18:0 
denotes sphingoid bases with an 18-carbon chain and 0 double bonds. C16:0 
denotes an N-acyl chain with 16 carbons and 0 double bonds.  
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amounts of SPT1 and/or SPT2 increased significantly in the stable transfected cells 
compared with either wild type or empty vector-transfected HEK293 cells (Figure 29A). 
 The above results showed that over-expression of SPT1 and SPT2 was 
successful and then the next question was whether the over-expressed proteins were 
functional. Previous studies showed that SPT activity was mainly detected in the 
microsomal fraction (183).  Microsome fractions were isolated from the same set of cells 
as those used for Western blotting for in vitro SPT enzyme activity assay. There was no 
significant change of SPT activity in SPT1 stably transfected cells while a 3.5-fold SPT 
activity increase was observed in SPT2 stably transfected cells, which is consistent with 
the previous finding that SPT2 is the catalytically active subunit of the SPT enzyme (163) 
(Figure 29A, bar graph). Co-expression of SPTLC1 and SPTLC2 caused SPT activity to 
increase 5-fold suggesting a cooperative effect between the two subunits (22) (Figure 
29A, bar graph). The high SPT activity made the SPT1/2 stable cells a useful model in 
studying sphingolipid de novo synthesis and this cell model was used for our further 
studies. The sub-cellular localizations of the over-expressed SPT1 and SPT2 in SPT1/2 
cells were examined using an anti-SPT1 or anti-SPT2 antibody. The fluorescence 
staining of SPT1 or SPT2 co-localizes with the staining of BiP protein, an endoplasmic 
reticulum (ER) marker (Figure 29B). This result is consistent with the previous finding 
that SPT activity is enriched in the microsomal fraction (169, 183) and that 
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Figure 29. Characterization of SPTLC transfected cell lines.  (A) Protein analysis 
and in vitro enzyme activity assay. 50 µg of microsomal membrane protein from 
untransfected HEK293 cells (Lane 1), cells tranfected with vector controls 
(pcDNA3.1NEO, lane 2 and pcDNA3.1ZEO lane 3), SPTLC1 transfected cells (Lane 
4), SPTLC2 tranfected cells (Lane 5), or cells co-transfected with SPTLC1 and 
SPTLC2 (lane 6) was applied for Western blotting (upper two panels) and SPT 
enzyme activity assay (lower bar graph). The nitrocellulose membrane was probed 
with either anti-SPT1 antibodies (upper panel) or anti-SPT2 antibodies (lower panel). 
The enzyme activity assay data represent the mean of three independent 
experiments. (B) Co-localization of SPT1 or SPT2 with Bip, an ER marker protein. 
SPT1/2 cells grown on glass coverslips were immunostained with rabbit anti-SPT1 
antibody or rabbit anti-SPT2 antibody and mouse anti-Bip antibody followed by 
AlexaFluor 488 (green) anti-rabbit and AlexaFluor 568 (red) anti-mouse secondary 
antibody. Bar: 10 µm. 
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An in situ SPT activity assay was developed using stable isotope-labeling and LC-ESI-
MS/MS 
 To explore changes in the de novo biosynthesis of sphingolipids an in situ assay 
using stable isotope labeling was developed. Uniformly [13C]-labeled palmitate was used 
as a tracer to follow the synthesis of sphingolipids. After conversion to [13C]-labeled 
palmitoyl CoA it can be condensed with serine by SPT to form sphingoid bases (3-
ketoSa and Sa), and  [13C]-labeled fatty acyl-CoA can also be incorporated at the N-acyl 
position by CerS to form DHCer. Using MS/MS the sphingoid base labeling and N-acyl 
labeling can be distinguished. If an N-acyl sphingolipid molecule is labeled only on the 
sphingoid base moiety it was designated BASE. If it is labeled only on the N-acyl moiety 
it was designated FA. If it is labeled on both the sphingoid base and N-acyl moieties it 
was designated DUAL. Unlabeled N-acyl sphingolipids were designated 12C. Only the 
DUAL and BASE isotopologues are considered to have originated by de novo 
biosynthesis because labeling of the sphingoid base unambiguously indicates that they 
were biosynthesized from serine and [13C]-labeled palmitoyl-CoA by SPT. The FA 
isotopomer may not represent de novo biosynthesis because the unlabeled sphingoid 
base may have come from catabolism of pre-existing N-acyl sphingolipids. The details of 
this assay are described in the Experimental Procedures section. 
 
The dynamics of de novo synthesis of sphingoid bases in SPT1/2 cells versus HEK293 
cells  
 Both SPT1/2 cells and HEK293 cells were treated with [U-13C]-palmitate and 
collected every hour for 6 hours. Then lipids were extracted from the cell pellets, 
resolved by a reverse phase C18 column and analyzed by LC-ESI-MS/MS. The first 
intermediate of the sphingolipid de novo biosynthesis pathway is 3-ketosphinganine 
produced by SPT but in HEK293 cells [13C]-Sa was below the detection limit (~ 0.1 
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pmol/mg protein) and the amount of [12C]-Sa was constant (~ 10 pmol/mg protein) for the 
first 6 h after [U-13C]-palmitate treatment (Figure 30A, upper left). This observation 
suggests that the endogenous Sa (~ 10 pmol/mg protein) is derived from catabolism of 
pre-existing N-acyl sphingolipids and since the downstream products of the de novo 
biosynthesis pathway in HEK293 cells were [13C]-labeled (Figure 32), the absence of 
[13C]-labeling of Sa indicates that the de novo biosynthesized Sa was quickly converted 
to DHCer. Both [13C]-labeled and unlabeled [12C]-Sa rapidly accumulated in SPT1/2 
cells, reached a maximum (and similar) quantity after 2 h of [U-13C]-palmitate treatment, 
and then decreased and stabilized in quantity (Figure 30A, upper left ). The above 
observation suggests that SPT enzyme activity significantly increased in SPT1/2 cells 
and the elevated Sa quantity exceeded the capacity of CerS in those cells. 
 To determine whether the SPT substrate pool of palmitoyl-CoA was the same in 
HEK293 cells and SPT1/2 cells the quantities of labeled and unlabeled palmitoyl-CoA 
([13C]-Pal-CoA and [12C]-Pal-CoA, respectively) were measured. Both cell types were 
treated with either 0.1 mM [U-13C]-palmitate / BSA complex or with BSA alone (control) 
for 2 h and then collected for lipid extraction. The lipid samples were analyzed by LC-
ESI-MS/MS as described previously. As shown in Figure 31B, in both types of cells, [U-
13C]-palmitate treatment did not affect the endogenous pool of [12C]-Pal-CoA (black bar 
vs. white bar, p > 0.1) and the quantity of [13C]-Pal-CoA was about 3-fold that of [12C]-Pal 
CoA after 2 h of treatment.  Without [U-13C]-palmitate treatment, the quantity of [12C]-Pal-
CoA was higher in HEK293 cells than in SPT1/2 cells; with [U-13C]-palmitate treatment, 
the quantities of both [12C]-Pal-CoA and [13C]-Pal-CoA were slightly but significantly 
higher in HEK293 cells than in SPT1/2 cells. This observation suggests that the amount 
of palmitoyl-CoA substrate for SPT (and the isotopic enrichment of this pool) was not the 
origin of the greater quantities of sphingolipids in SPT1/2 cells compared to HEK293 
cells. The higher amount of [13C]-Sa in SPT1/2 cells as observed above indicates higher  
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Figure 30. The dynamic changes of sphingoid bases in HEK293 cells and 
SPT1/2 cells after [U-13C]-palmitate treatment. Lipids were extracted from replicate 
dishes (N = 4) of HEK293 cells and SPT1/2 cells treated with 0.1 mM [U-13C]-
palmitate for different periods of time (0 to 6 hr) followed by analysis of sphingoid 
bases by LC-ESI-MS/MS. Both labeled ([13C]) and unlabeled ([12C]) sphinganine (Sa, 
upper left), sphinganine-1-phosphate (Sa-1-P, upper right), sphingosine (So, lower 
left) and sphingosine-1-phosphate (So-1-P, lower right) were measured. 
Sa Sa1P 
So S1P 
SPT1/2 13C SPT1/2 12C HEK 12C HEK 13C 
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Figure 31. Quantitation of fatty acyl-CoAs in HEK293 and SPT1/2 cells. HEK293 
cells and SPT1/2 cells were treated (lower panels) or not (upper panels) with 0.1 mM 
[U-13C]-palmitate for 2 h. Lipid were extracted from the cells and analyzed by LC-ESI-
MS/MS as described in Experimental Procedures.  Both labeled (black bars) and 
unlabeled fatty acyl-CoAs (white bars) were quantitated. The mean and SD of four 
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SPT activity. The lower amount of Pal-CoA in SPT1/2 cells is possibly caused by more 
vigorous consumption of this substrate by elevated SPT activity in SPT1/2 cells. 
 Sa can be converted to either DHCer by CerS or to Sa-1-P by sphingosine 
kinase. The quantity of [13C]-Sa-1-P significantly increased over 6 h in SPT1/2 cells but 
was not detectable in HEK293 cells (Figure 30A, upper right). Another sphingoid base is 
So which in HEK293 cells was more abundant than Sa (50 pmol / mg protein vs. 10 
pmol / mg protein). In HEK293 cells, no increase in [12C]-So quantity was observed after 
[U-13C]-palmitate treatment and [13C]-So increased after 2 h of treatment (Figure 30A, 
bottom left). In SPT1/2 cells, during the 6 h of [U-13C]-palmitate treatment, the quantity of 
[12C]-So increased from 112 to 288 pmol / mg protein, consistently higher than the 
quantity of [13C]-So, which increased from 0 to 109 pmol/ mg protein. Furthermore, there 
was no increase of either labeled or unlabeled So in SPT1/2 cells during the first hour of 
[U-13C]-palmitate treatment. These observations are consistent with the fact that So is 
derived exclusively from the catabolism of CMH, SM or Cer and, unlike Sa, cannot be 
directly generated by de novo biosynthesis (184). A similar observation was made for 
the phosphorylated metabolite So-1-P (Figure 30A, bottom right). Thus, unlike [13C]-Sa 
and [13C]-Sa1P, [13C]-So and [13C]-S1P are affected much less by the over-expression of 
SPT and do not fully recapitulate the consequent increase in de novo biosynthesis.  
 
The dynamics of de novo biosynthesis of complex sphingolipids in SPT1/2 cells versus 
HEK293 cells 
 To quantify de novo synthesized N-acyl sphingolipids, the sum of DUAL and 
BASE labeled isotopologues was used, which represents unambiguous de novo 
biosynthesis. The first N-acyl sphingolipid in the de novo biosynthesis pathway is 
DHCer, which is formed by the N-acylation of Sa by CerS. The quantity of [13C]-DHCer in 
SPT1/2 cells rapidly increased to 600 pmol / mg protein during the first 2 h of [U-13C]-
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palmitate treatment, reached a maximum between 2 to 4 h, and then decreased to 415 
pmol / mg protein (Figure 32A) at 6 h. In contrast, in HEK293 cells the quantity of [13C]-
DHCer increased slowly to 15 pmol / mg protein after 2 h of [U-13C]-palmitate treatment 
and to 114 pmol / mg protein after 6 h (Figure 32A). Therefore, 2 h after treatment, the 
quantity of [13C]-DHCer in SPT1/2 cells was 40-fold that of HEK293 cells. DHCer can be 
reduced to Cer or converted to 1-O-modified sphingolipids such as DHCMH and DHSM. 
Both DHCMH and DHSM quantities were significantly increased over 6 h in a similar 
pattern in SPT1/2 cells while the increase in HEK293 cells was much smaller (Figures 
32B and 32C). The de novo biosynthesis of Cer showed a pattern similar to that of 
DHCer in HEK293 cells and SPT1/2 cells (Figure 32D). An increase in the quantity of 
[13C]-CMH over 6 h was observed in both cell lines after [U-13C]-palmitate treatment, but 
was more rapid in SPT1/2 cells (Figure 32E). SM originating from de novo biosynthesis 
also accumulated over 6 h in both cell lines, however, unlike other sphingolipids its 
quantity was lower in the SPT1/2 cells than that in HEK293 cells (Figure 32F). 
 In HEK293 cells, the quantities of de novo biosynthesized unsaturated 
sphingolipids are higher than the quantities of their corresponding dihydro-species, while 
the opposite was true in SPT1/2 cells if the DUAL and BASE isotopologues of DHCer 
and Cer (after 3 h of treatment) are added and compared in the two types of cells 
(Figure 32G). Together with the presence of [13C]-Sa in SPT1/2 cells but not HEK293 
cells (Figure 30) this result suggests that over-expression of SPT in SPT1/2 cells 
increases the flux of downstream molecules which exceed the capacities of downstream 
enzymes. For example, the [13C]-Sa quantity exceeded the capacity of CerS and the 
[13C]-DHCer quantity exceeded the capacity of DES.   
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Figure 32. The dynamic changes of de novo synthesis of complex 
sphingolipids in HEK293 cells and SPT1/2 cells after [U-13C]-palmitate 
treatment. HEK293 cells and SPT1/2 cells (N = 4 dishes) were treated with 0.1 mM 
[U-13C]-palmitate for 0 to 6 h. Sphingolipid extractions from those cells were analyzed 
by LC-ESI-MS/MS for DHCer (A), DHCMH (B), DHSM (C), Cer (D), CMH (E) and SM 
(F). At each time the quantity shown for each complex sphingolipid is a sum of the 
total [13C] dual labeled subspecies and the total [13C] base labeled subspecies.  (G) 
De novo biosynthesized dihydro-sphingolipids and their desaturated species are 




















The distribution of de novo synthesized sphingolipids with varying acyl-chain lengths in 
SPT1/2 cells versus HEK293 cells 
 Most sphingolipids are built upon So or Sa sphingoid bases and can have 
various lengths of fatty acyl-chains. Acyl chains designated C16:0, C18:0, C20:0, C22:0, 
C24:0, C24:1, C26:0 and C26:1 were observed to be the most common ones in HEK293 
and SPT1/2 cells. These different subspecies of N-acyl sphingolipids are generated by 
acylation of Sa or So by different CerS isoforms which prefer certain chain lengths of 
fatty acyl-CoA substrates (7, 9, 181, 182). For example, CerS1 prefers stearoyl-CoA 
(C18:0-CoA) and CerS5/6 prefers palmitoyl-CoA (C16:0-CoA) (Figure 28). To compare 
the sphingolipid subspecies with varying N-acyl chain lengths the sum of DUAL and 
BASE isotopologue quantities was used. The majority of [13C]-labeled subspecies of 
each N-acyl sphingolipid were increased in SPT1/2 cells, however, the quantity of [13C]-
SM decreased compared to HEK293 cells (Figure 33).  
 Among all the unambiguously de novo subspecies of DHCer, Cer, DHSM and 
SM, those with a C16:0 N-acyl chain (derived from palmitoyl-CoA) are the most 
abundant in both HEK293 cells and SPT1/2 cells (Figure 33). The subspecies 
distribution of unambiguously de novo DHCMH and CMH is different from that of other 
N-acyl sphingolipids and the C16:0 species is not the dominant species in either cell line 
(Figure 33, middle panels). Among all the sphingolipid subspecies (except those of SM) 
the fold increase of molecules with C18:0 acyl chains is the highest in SPT1/2 cells 
(Figure 33). For example, C18:0 DHCer, Cer and CMH quantities in SPT1/2 cells are 47-
fold, 11-fold and 8-fold greater, respectively, than those species in HEK293 cells; C18:0 
DHCMH and DHSM were below the detection limit in HEK293 cells but became quite 




Figure 33. Comparison of sphingolipids with different N-acyl chains in HEK293 
cells and SPT1/2 cells. Sphingolipids were extracted from HEK293 cells (white bars) 
and SPT1/2 cells (black bars) treated with 0.1 mM [U-13C]-Pal for 3 h and analyzed by 
LC-ESI-MS/MS. The value shown is the sum of [13C] dual labeled and [13C] base 
labeled molecules, which represents unambiguous de novo biosynthesis. The x-axis 
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 When the proportionate change of each Cer subspecies was compared in 
HEK293 and SPT1/2 cells, the biggest difference was seen for C18:0 Cer (Figure 34). 
Using the sum of DUAL and BASE isotopologue quantities to represent unambiguously 
de novo biosynthesized sphingolipids, the proportion of C18 Cer was 13% in HEK293 
cells and 24% in SPT1/2 cells (Figure 34A). To exclude the possibility of an effect arising 
from substrate pool difference, C18:0-CoA was quantitated by LC-ESI-MS/MS. As 
previously observed for C16:0-CoA, the quantity of [12C]-18:0-CoA was greater in 
HEK293 cells in the absence of [U-13C]-palmitate treatment, and the quantities of [13C]-
C18:0-CoA and [12C]-C18:0-CoA were greater in HEK293 cells with [U-13C]-palmitate 
treatment (Figure 31), showing that differences in the stearoyl-CoA pool are not the 
origin of increased C18:0 N-acyl sphingolipids in SPT1/2 cells. Furthermore, when the 
[12C]-Cer subspecies were measured without adding [U-13C]-palmitate, the proportion of 
C18 Cer still had the highest increase, from 8% in HEK293 cells to 18% in SPT1/2 cells 
(Figure 34B). 
 These results suggest that elevation of sphingolipid subspecies quantities is not 
a simple recapitulation of SPT over-expression, and they also confirm that [U-13C]-
palmitate treatment per se is not causing the increase in C18:0 Cer proportion. The 
disproportionate increase in C18 Cer might indicate a connection between SPT and 
ceramide synthase 1 (CerS1). Consistent with this hypothesis, CerS1 mRNA was found 
to be elevated in SPT1/2 cells by quantitative PCR analysis (Y. Liu, personal 
communication) suggesting that elevation of SPT activity may affect the gene expression 





Figure 34. Distribution of ceramide subspecies with various N-acyl chain 
lengths. (A) The proportion of DUAL and BASE Cer isotopologues was determined in 
HEK293 cells (left) and SPT1/2 cells (right) after 3 h of [U-13C]-palmitate labeling. (B) 
The proportions of 12C Cer isotopologues were determined in HEK293 cells (left) and 
SPT1/2 cells (right) without adding [U-13C]-palmitate. 
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Sphingolipid differences between SPT1/2 cells vs. HEK293 cells without [U-13C]-
palmitate treatment 
 The above data showed increased de novo biosynthesis of sphingolipids in 
SPT1/2 cells versus HEK293 cells with [U-13C]-palmitate treatment. To explore the effect 
of SPT over-expression in the steady state, HEK293 and SPT1/2 cells without any [U-
13C]-palmitate treatment were analyzed (Figures 34B and 35). Quantitation of all the 
unlabeled sphingolipids species and comparison of HEK293 and SPT1/2 cells showed 
that a significant increase was seen in Cer (4.5-fold), DHCer (3.7-fold) and DHCMH (1.8-
fold), no change was seen in CMH and a decrease was seen in SM (1.9-fold) and DHSM 
(1.6-fold). Compared with the data for de novo biosynthesized sphingolipids (Figures 32 
and 33), the elevation of sphingolipid quantities in the steady state of SPT1/2 cells was 
lower, but showed similar trends including lower quantities of DHSM compared to 
HEK293 cells. 
 To examine more complex glycosphingolipids (GSL) in the two cell lines thin 
layer chromatography (TLC) was used. TLC of neutral GSL showed significant increases 
in the quantities of CMH, LacCer and Gb3 in SPT1/2 cells (Figure 36, left panel). 
Elevation of quantities of acidic GSL, such as GM3, GM2, and GM1, were also observed 
for SPT1/2 cells by TLC (Figure 36, right panel). These results show that over-
expression of SPT increases not only the immediate products of de novo sphingolipid 
biosynthesis, but also more distant metabolites along the pathway. 
 The proportions of N-acyl sphingolipids were compared in HEK293 cells and 
SPT1/2 cells. From the most abundant to the least abundant species for HEK293 cells 
they are SM (65%), CMH (17%), DHSM (8%), Cer (6%), DHCer (3%) and DHCMH (1%) 
while the abundances for SPT1/2 cells are SM (34%), Cer (28%), CMH (20%), DHCer 
(11%), DHSM (5%), DHCMH (2%). The proportion of Cer and DHCer dramatically 
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Figure 35. Comparison of sphingolipid totals in HEK293 cells and SPT1/2 cell 
extracts without [13C]-palmitate treatment. The total quantity of each N-acyl 
sphingolipid was determined by LC-ESI-MS/MS analysis in replicate dishes (N = 4) of 






















































































Figure 36. Comparison of glycosphingolipids (GSL) in HEK293 and SPT1/2 cells 
by TLC. Samples from HEK293 cells and SPT1/2 cells were applied to two TLC 
plates. (A) Neutral GSL visualized by Orcinol staining. Lanes 1 and 8 are standards 
and from lanes 2 to lane 7 are HEK293 cells, SPT1/2 cells, SPT1 cells, SPT2 cells, 
cells stably transfected with empty vectors NEO or ZEO, respectively. (B) Acidic GSL 
visualized by Resorcinol staining. Lane 1 and 2 are standards and from 3 to 8 are in 




increased in SPT1/2 cells while that of SM decreased. Therefore, elevation of SPT 
activity not only increased the absolute quantities of sphingolipids (Figure 32) but also 
changed the relative proportions of the sphingolipid classes.  
 
Comparison of the rate of appearance of ceramide in HEK293 and SPT1/2 cells 
 To determine whether SPT over-expression increased the rate of appearance 
(Ra) of N-acyl sphingolipids, a previously described approach (88) that uses quantitation 
of stable isotope labeled metabolites and mathematical modeling to estimate Ra for 
tracee molecules (e.g. 12C C16:0-Cer) was used. This was applied to Cer in [U-13C]-
palmitate treated HEK293 and SPT1/2 cells by 1) measuring the quantities of 12C, 
BASE, DUAL and FA isotopologues and isotopomers of Cer, 2) calculating the 
enrichment of each N-acyl species at 1 hr intervals from 0 to 6 hr, 3) plotting enrichment 
vs. time for each Cer N-acyl species, 4) using curve-fitting to estimate the plateau 
isotopic enrichment (Ep) and fractional turn-over rate (k) of each analyte (Figure 37), 
and, 5) using the estimates of Ep, k, and the measured quantities of 12C Cer (Q, tracee 
quantity) to calculate the rate of appearance (Ra) of 12C Cer in pmol / mg protein * hr. 
 Values of Ra, k, and Ep for Cer in HEK293 and SPT1/2 cells are shown in Table 
II. For example, C16:0-Cer Ep was 0.548 ± 0.005 in HEK293 cells and 0.441 ± 0.01 in 
SPT1/2 cells; C16:0-Cer k was 1.15 ± 0.05 in HEK293 cells and 0.87 ± 0.08 in SPT1/2 
cells (mean and SEM, N = 4). The physiological interpretation of Ep is that the C16:0-Cer 
enrichment at isotopic equilibrium is 54.8% and 44.1% in HEK293 and SPT1/2 cells, 
while the value of k implies that the C16:0-Cer pool is completely turned over 1.15 and 
0.87 times per hour in HEK293 and SPT1/2 cells, respectively. The C16:0-Cer Ep (p < 
0.0001) and k (p < 0.03) values were significantly different between the two cell types, 
as well as the C26:0-Cer Ep (p < 0.01) values and the C18:0-, C22:0-, and C26:0-Cer k 
(p < 0.005, 0.0008, and 0.02) values.
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Table II. Estimated values of tracee rate of appearance (Ra), fractional turn-over 
rate (k), and plateau isotopic enrichment (Ep) for ceramide in HEK293 cells (HEK) 
and SPT1/2 cells (SPT). The units of Ra are pmol per mg protein * hr, ceramide N-acyl 
chain lengths are designated x:y, where x = number of carbon atoms and y = number of 
double bonds, the correlation coefficient (R2) is shown for curve fits, and estimation of a 
value for Ep > 1 is designated NA. Significant (p < 0.05) differences in Ep and k are 
designated *, and tracee (12C) quantities at 0 hr (Q) were used to calculate Ra from k. 
Data are derived from 4 replicate Petri dishes of each cell type. 
 
 
  16:0 18:0 20:0 22:0 24:1 24:0 26:1 26:0 
          
Ra HEK 111.6 24.1 4.0 12.3 13.9 4.0 0.6 0.6 
Ra SPT 303.2 110.0 15.6 21.2 39.9 NA 3.0 1.4 
k HEK 1.15 * 1.24 * 1.30 0.652 * 0.296 0.066 0.296 0.479 * 
k SPT 0.874 * 0.528 * 0.590 0.178 * 0.241 NA 0.267 0.106 * 
Ep HEK 0.548 * 0.314 0.355 0.287 0.151 0.423 0.219 0.251 * 
Ep SPT 0.441 * 0.321 0.345 0.421 0.125 NA 0.140 0.381 * 
R2 HEK 0.999 0.989 0.952 0.995 0.988 0.987 0.842 0.951 
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Figure 37. Isotopic enrichment of ceramide in HEK293 (A) and SPT1/2 cells (B). 
The isotopic enrichment of each ceramide N-acyl chain length was calculated using 
data for the unlabeled, fatty acid labeled, dual labeled, and base labeled 
isotopologues and isotopomers as the number of labeled acyl chains divided by the 
total number of acyl chains. This was plotted vs. time, and the data was curve-fit 
using Prism 4.0. This estimated the plateau isotopic enrichment (Ep) and the 
fractional turn-over rate of the pool (k) of each ceramide species. The physiological 
interpretation of Ep is the plateau isotopic enrichment of the analyte, and of k is the 
fractional turn-over rate per hr of the ceramide pool. Data are shown as the mean of 
replicate Petri dishes (N = 4). 
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 To calculate whether SPT over-expression increased the rate of appearance of 
tracee (Ra), Cer k values were multiplied by the 12C isotopologue Cer quantities at 0 hr. 
For example, C16:0-Cer Ra was 112 and 303 pmol / mg protein hr in HEK293 and 
SPT1/2 cells, respectively, an increase of 2.7-fold associated with SPT stable over-
expression. The fold increase of Ra values in SPT1/2 cells for other chain lengths of Cer 
(where R2 during curve-fitting was > 0.9) was similar to C16:0-Cer [i.e. C22:0-Cer (1.7-
fold), C24:1-Cer (2.9-fold), and C26:0-Cer (2.5-fold)]. However, some increases of Ra 
values in SPT1/2 cells were higher [i.e. C18:0-Cer (4.6-fold) and C20:0-Cer (3.9-fold)], 
consistent with the increased proportion of C18:0-Cer and the induction of CerS1 mRNA 
transcription in the SPT1/2 cell line.  
 
Comparison of the rate of appearance and de novo biosynthesis of non-ceramide N-acyl 
sphingolipids in HEK293 and SPT1/2 cells 
 Using the above approach to estimate the rate of appearance of d18:1 N-acyl 
sphingolipids other than Cer (e.g. SM, CMH) either resulted in values of Ep > 1 (isotopic 
enrichment of > 100%, which is not possible), or low values (< 0.90) of R2. Neither of 
these Cer metabolites appeared to reach isotopic equilibrium in 6 hr in either cell type. 
Regarding dihydrosphingolipids, in HEK293 cells only C24:0-DHCer resulted in 
satisfactory modeling (R2 > 0.9, Ep < 1), whereas in SPT1/2 cells all DHSM, many 
DHCer, and half of the DHCMH molecular species resulted in satisfactory modeling. The 
Ra of C24:0-DHCer was 1.4 pmol per mg protein hr in HEK293 cells and 11 pmol per mg 
protein hr in SPT1/2 cells, which is a 7.9-fold increase.  
 
Identification of novel sphingolipid species in SPT1/2 cells 
 SPT prefers serine as its substrate, however, sphingoid bases generated from 
alanine and glycine were also recently identified in mammalian cells (73) and they are 
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quite abundant in cells treated with fumonisin B1, a (dihydro)ceramide synthase inhibitor 
(73). Condensation of alanine and palmitoyl-CoA by SPT generates 1-deoxysphinganine 
(1-deoxy-Sa) and its N-acylated form is 1-deoxy dihydroceramide (1-deoxy-DHCer). 
Condensation of glycine and palmitoyl-CoA produces 1-desoxymethyl sphinganine (1-
desoxyMe-Sa) and its N-acylated form is 1-desoxyMe-DHCer. After incubating the cells 
with [U-13C]-palmitate for 36 h both 1-deoxy-Sa and 1-desoxyMe-Sa were dramatically 
elevated in SPT1/2 cells compared with HEK293 cells (Figure 38). Among the [13C]-
labeled sphingoid bases 1-deoxy-Sa was lower than So but significantly higher than 
other species, while in HEK293 cells, 1-deoxy-Sa was at the same level as all other 
sphingoid bases except for So (Figure 40). Both the BASE and DUAL isotopologue 
quantities showed that 1-deoxy-DHCer and 1-desoxyMe-DHCer were significantly 
increased in SPT1/2 cells compared with HEK293 cells (Figure 40B). It was remarkable 
that the amount of 1-deoxy-DHCer was comparable to that of Cer in SPT1/2 cells. Unlike 
Cer for which the C16 acyl-chain was the most abundant subspecies, the C18 
subspecies was the most abundant for 1-deoxy-DHCer and 1-desoxyMe-DHCer. 
 
Analysis of the decrease of SM in SPT1/2 cells 
 An interesting observation regarding SPT1/2 cells is that unlike other 
sphingolipids species the amount of SM decreases. Is this because sphingomyelinase 
activity is higher in SPT1/2 cells? To address this question, the activities of both acidic 
and neutral SMase (aSMase and nSMase, respectively) were measured in vitro for 
HEK293 and SPT1/2 cells. Fluorescent NBD-labeled SM was used as a substrate and 
after reaction the samples were analyzed by HPLC.  As shown in Figure 39, the aSMase 
activity is slightly but significantly higher in SPT1/2 cells than in HEK293 cells, whereas 
activity of nSMase in SPT1/2 cells is about 50% of that in HEK293 cells (Figure 39). The 

















Figure 38. Quantitation of novel sphingolipid species after [U-13C]-palmitate 
labeling. (A) [13C]-labeled sphingoid bases were measured in replicate dishes (N = 3) 
of HEK293 cells (H, white bars) and SPT1/2 cells (S, black bars). (B) Quantitation of 
N-acylated forms of the novel sphingoid bases. 1-deoxy-DHCer and 1-desoxMe-
DHCer with different N-acyl chain lengths were measured in HEK293 cells and 
SPT1/2 cells and compared with Cer. From the left to the right are the sum of all 
subspecies, C16, C18, C20, C22, C24:1, C24, C26:1, C26. The left panel is [13C]-
base labeling and the right panel is [13C]-dual labeling. 
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SM degradation was also measured in situ by incubating HEK293 cells and SPT1/2 cells 
with C6-NBD-SM for 7 hours and then the cells were collected and extracted in methanol 
at 37° C for one hour. After centrifugation, the supernatant was analyzed by HPLC and 
NBD fluorescence was measured, and normalized by protein amount, from which the 
percentage of SM signal over total NBD signal was calculated. The remaining SM was 
8% in HEK293 cells and 15% in SPT1/2 cells after 7 hours of NBD-SM treatment, which 
suggests that SM degradation is faster in HEK293 cells than in SPT1/2 cells, and 
accounts for the decrease in SM. The most likely explanation is that DHSM is produced 
instead (Figures 32C and 33). 
 
The composition of CMH in HEK293 cells and SPT1/2 cells  
Ceramide monohexose (CMH) is a collective term for glucosylceramide (GlcCer) 
and galactosylceramide (GalCer). The former is synthesized in the Golgi and the latter in 
the ER. GlcCer and GalCer were quantitated in HEK293 and SPT1/2 cells via a 
specialized HPLC-ESI-MS/MS method designed to resolve these isobaric analytes (74). 
As shown in Figure 40, HEK293 and SPT1/2 cells synthesize GlcCer ranging in N-acyl 
chain lengths from C16 to C26 and varying in saturation (C24:0 – C24:1, C26:0 – 
C26:1). In HEK293 cells, the amount of C16 GlcCer is 100 ± 20 pmol/mg of protein, 
which is not significantly different from the C24:1 quantity (70 ± 20 pmol/mg of protein), 
or the C24:0 quantity (70 ± 20 pmol/mg of protein) (Figure 40, upper left). However in 
SPT1/2 cells, the amount of C16:0 GlcCer is 250 ± 50 pmol/mg of protein, which is more 
than twice the quantity of C24:0 and of C24:1 (Figure 40, lower left). In HEK293 cells, 
the amount of C16:0 GlcCer is 100 ± 20 pmol/mg of protein, which is more than 5 times 
higher than the amount of C18:0 GlcCer, 15 ± 3 pmol/mg of protein (Figure 40, upper 




Figure 39. Comparison of neutral and acidic sphingomyelinase activities in 
HEK293 cells and SPT1/2 cells. Enzyme activities of acidic sphingomyelinase 
(aSMase) and neutral sphingomyelinase (nSMase) were measured in vitro using a 
C6-NBD-SM substrate and HPLC analysis as described in Experimental 




Figure 40. Comparison of ceramide monohexose quantities in HEK293 (upper 
panels) and SPT1/2 (lower panels) cells. The quantities of glucosylceramide 
(GlcCer, left panels) and galactosylceramide (GalCer, right panels) of varying N-acyl 
chain lengths (16, 18, etc) were determined by LC-ESI MS/MS analysis as described 
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of protein and 120 ± 20 pmol/mg of protein (Figure 40, lower left). Thus it can be seen 
that SPT1/2 cells not only have an increase in total GlcCer quantity, but also a significant 
change in the distribution of chain lengths. 
 GalCer was 3 to 10-fold elevated in quantity in SPT1/2 cells compared to 
HEK293 cells (Figure 40, right panels). The most abundant N-acyl chain lengths of 
GalCer in SPT1/2 cells are C16:0, C18:0, and C24:1, while they were C16:0, C24:0, and 
C24:1 in HEK293 cells. 
 
4.5 Discussion 
 Sphingolipid biosynthesis is one of the most complex metabolic processes of 
mammalian cells, involving hundreds of enzymes, multiple pathways for intra- and extra-
cellular trafficking and transport, and dozens (at least) of associated biological functions 
that are regulated by the types and amounts of sphingolipids that are present.  
Previously over-expression of SPT has been demonstrated in mammalian cells (22, 
163), however, its molecular impact on the de novo biosynthesis pathway has not been 
fully investigated. To study the impact of SPT on the sphingolipid de novo biosynthesis 
pathway, a biological model that has elevated SPT activity and an analysis method that 
can quantify various sphingolipids are required. Furthermore, stable isotope labeling is 
needed for differentiating sphingolipid de novo synthesis and turnover pathways. We 
generated a cell line stably expressing SPT1 and SPT2 and with 5-fold higher SPT 
activity than its parental cell line. The [U-13C]-palmitate stable isotope labeling of cultured 
cells followed by LC-ESI-MS/MS analysis allowed the quantitation of de novo 
biosynthesis of sphingolipids. The downstream metabolites were measured at each step 
along the pathway. Not only the total amount of each sphingolipid molecule but also 
each subspecies with different fatty acyl chain lengths were quantitated. The results 
revealed the molecular consequences of increasing SPT activity: while the majority of 
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the downstream metabolite quantities increased, unexpectedly the quantity of SM 
decreased; sphingolipid subspecies with various fatty acyl chain lengths increased 
disproportionally and C18 subspecies showed the greatest increase.  
 In the past, studies have focused on So, Cer and their derivatives which were 
potent bioactive lipids involved in cell growth, death, senescence, adhesion, migration, 
inflammation, angiogenesis and intracellular trafficking (160, 185, 186). Recently, Sa, 
dihydro-sphingolipids and their derivatives, which are typically of low quantity in cells, 
have been found to be bioactive (187-189). De novo synthesized Sa and dihydro-
sphingolipids have been found to play a role in 4HPR induced cancer cell apoptosis 
(187). De novo generated Sa and DHCer were increased in tumor cells by celecoxib, a 
COX-2 specific inhibitor, and were suggested to contribute to the anti-proliferative effects 
of celecoxib (189). L-threo-Sa, a synthetic stereoisomer, induces autophagy in solid 
tumor cells (188). So far few studies have analyzed those species, furthermore, 
traditional TLC cannot differentiate dihydro-species from the cogent desaturated 
species, which might have masked the effect of dihydro-species in some studies.    
 Some novel de novo synthesized sphingolipids, such as 1-deoxy-Sa and its 
acylated form, were found to be quite abundant in [U-13C]-palmitate treated SPT1/2 cells. 
This suggests that the sphingolipid de novo biosynthesis pathway may be more 
complicated than is currently appreciated. New molecular species could be generated 
under certain circumstances and some previous sphingolipid studies using various 
stress stimuli might need to be carefully re-interpreted. Recently it was reported that 1-
deoxy-Sa (spisulosine) isolated from the Arctic surf clam (Spisula polynyma) induced 
prostate tumor cell death by increasing the de novo synthesis of Cer (190). If 
mammalian SPT can generate 1-deoxy-Sa under certain circumstances it would be 
interesting to know what are the targets of the novel compound.  
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 The de novo biosynthesis of all other sphingolipids increased in SPT1/2 cells 
while that of SM decreased. This is apparently not caused by elevated degradation of 
SM (Figure 38) but rather by an impairment of SM biosynthesis, i.e. the accumulation of 
DHSM (which uses the same SM synthase) in SPT1/2 cells (Figures 32C and 33), since 
the ratio of DHCer to Cer is much higher (3:2) in SPT1/2 cells than in HEK293 cells 
(1:4). It is likely that DHCer competes with Cer for the synthesis of SM.  
 In addition, the data showed that the quantities of not only GlcCer but also 
GalCer increased in SPT1/2 cells. Since the amount of GalCer was 3 to 8-fold lower in 
HEK293 cells the ratio of GalCer / GlcCer is higher in SPT1/2 cells than it is in HEK293 
cells (Figure 40). It is known that GalCer is synthesized in the lumen of the ER (159) and 
GlcCer in the Golgi (191). The increased quantity of Cer in the ER compartment of 
SPT1/2 cells may provide more substrate for GalCer synthase, which resides in the 
same compartment, while the production of GlcCer could be limited by the ER to Golgi 
transportation of Cer. Thus any promoters of sphingolipid de novo biosynthesis, such as 
agents that can up-regulate SPT and CerS, may cause the same effect. Whether this 
effect plays a role in the biological consequences of those stimuli needs to be further 
characterized.  
It was interesting that SPT1/2 cells did not show any cytotoxicity despite the 
remarkable accumulation of various sphingolipid molecules (e.g. Cer) that have been 
reported to have these effects. Furthermore, no toxicity was observed in SPT1/2 cells 
even after 36 hours of [U-13C]-palmitate treatment. The mechanism(s) by which the 
SPT1/2 cells are able to tolerate these large quantities of sphingolipids is presently 




STABLE ISOTOPE LABELING OF FATTY ACYL-COAS VIA DE NOVO FATTY ACID 
BIOSYNTHESIS USING [1-13C]-ACETATE TREATMENT OF RAW264.7 CELLS4 
 
5.1 Summary 
 Fatty acyl-CoAs are intermediates in the metabolism of many lipids. In cultured 
mammalian cells, two sources of the palmitoyl moiety of palmitoyl-CoA include palmitate 
from de novo fatty acid biosynthesis (via fatty acid synthase [FAS] activity) and palmitate 
from the extracellular medium (via fatty acid uptake and acyl-CoA synthetase [ACSL] 
activity). The separate contributions of extracellular palmitate and de novo fatty acid 
biosynthesis to the palmitoyl-CoA pool were quantitated in RAW264.7 mouse 
macrophage-like cells by treatment with [U-13C]-palmitate and [1-13C]-acetate, 
respectively, followed by liquid chromatography-electrospray ionization-tandem mass 
spectrometric analysis of palmitoyl-CoA. Exogenous [U-13C]-palmitate (0.1 mM) labeled 
~ 60% of the palmitoyl-CoA after 6 hr, and [1-13C]-acetate (0.1 mM) labeling indicated by 
mass isotopomer distribution analysis (MIDA) and isotopomer spectral analysis (ISA) 
that ~ 60% of palmitoyl-CoA was newly biosynthesized after 6 hr. The similar labeling of 
palmitoyl-CoA by these different biosynthetic inputs indicates a rapid turn-over rate for 
palmitoyl-CoA from both de novo fatty acid biosynthesis and uptake of exogenous fatty 
acid in RAW264.7 cells with and without Kdo2-Lipid A treatment. In this chapter, the 
specific contribution of the author was all work shown, except the culturing and treatment 
of cells. 
 
                                                
4 This chapter is in preparation for publication; the authors are Haynes, C., Wang, E., Kelly, S., 
Sullards, M., and Merrill, A. 
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5.2 Introduction 
 Fatty acyl-CoAs are intermediates in the metabolism of many lipids. In cultured 
mammalian cells, two sources of the palmitoyl moiety of palmitoyl-CoA include palmitate 
from de novo fatty acid biosynthesis (via fatty acid synthase [FAS] activity (119)) and 
palmitate from the extracellular medium (via fatty acid uptake (192) and acyl-CoA 
synthetase [ACSL] activity (28, 35)). The de novo biosynthesis of C16 palmitate by FAS 
uses one C2 unit from acetyl-CoA and seven C2 units from malonyl-CoA (8 C2 → C16); 
acetyl-CoA is converted to malonyl-CoA by acetyl-CoA carboxylase (ACC). Thus, all 16 
of the carbon atoms of de novo biosynthesized palmitate are derived from acetyl-CoA, 
and treatment of cultured cells with [1-13C]-acetate can add 0 to 8 atoms of 13C to each 
newly biosynthesized palmitate molecule. Extracellular palmitate, in contrast, is present 
as a component of the serum required to grow most mammalian cell lines, and 
represents in vivo bloodstream fatty acids that are derived from adipose and dietary 
sources. Several mechanisms of fatty acid uptake by cultured cells have been 
demonstrated (25, 26, 192). Intracellular palmitate may be bound to carrier proteins such 
as fatty acid binding protein (37) or activated to palmitoyl-CoA by fatty acyl-CoA 
synthetases (27, 29-32). Thus, treatment of cultured cells with [U-13C]-palmitate can add 
0 or 16 atoms of 13C to each newly biosynthesized palmitoyl-CoA molecule. 
 Treatment of cultured cells with stable isotope-labeled substrates of these two 
metabolic pathways (i.e. acetate and palmitate) followed by fatty acyl-CoA extraction and 
palmitoyl-CoA quantitation by liquid chromatography-electrospray ionization-tandem 
mass spectrometry (LC-ESI-MS/MS) (3) is a powerful technique that can distinguish the 
contributions of de novo palmitate biosynthesis and extracellular palmitate to palmitoyl-
CoA. A triple quadrupole tandem mass spectrometer was used in multiple reaction 
monitoring (MRM) mode, with precursor and product ion pairs corresponding to mass 
isotopologues of palmitoyl-CoA with labeled palmitoyl moieties. In this way, [M + 0] 
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unlabeled and [M + 16] [U-13C]-palmitate labeled palmitoyl-CoA were easily 
distinguished, as well as [M + 1] through [M + 4] palmitoyl-CoA isotopologues labeled by 
[1-13C]-acetate. 
 To determine the contribution of extracellular palmitate to cellular palmitoyl-CoA, 
RAW264.7 mouse macrophage-like cells were treated with 0.1 mM [U-13C]-palmitate (in 
a 1:1 molar complex with fatty-acid free albumin) for times ranging from 0.5 to 24 hr. 
Quantitation of [M + 0] (unlabeled) and [M + 16] (labeled) palmitoyl-CoA isotopomers 
indicated rapid and robust utilization of the [U-13C]-palmitate (presumably via ACSL); 
more than 50% of the total palmitoyl-CoA was [M + 16] within 3 hr. 
 Treatment of cultured cells with palmitate has been reported to cause changes in 
their metabolism (98, 193) and gene transcription (99, 194). In order to avoid these 
unintended consequences of palmitate treatment, and to explore the quantitative 
contribution of de novo fatty acid biosynthesis to palmitoyl-CoA, an alternative method 
for stable isotope-labeling of fatty acyl-CoAs was employed. RAW264.7 cells were 
treated with 0, 0.1, or 1.0 mM [1-13C]-acetate for 6, 12, and 24 hr. In this experimental 
approach, the stable isotope-labeled acetate is taken up by cells, activated to form 
labeled acetyl-CoA, carboxylated to form labeled malonyl-CoA, and then fatty acid 
synthase (FAS) polymerizes one acetyl-CoA and seven malonyl-CoA molecules into one 
palmitate molecule. 
 A particular isotopic enrichment of acetate in the biosynthetic precursor pool for 
FAS generates a unique “fingerprint”, or mass isotopologue distribution (MID), in the 
structure-specific product ion of newly biosynthesized palmitoyl-CoA. A second factor to 
consider is that mixing of pre-existing and newly biosynthesized palmitoyl-CoA will cause 
the MID observed by LC-ESI-MS/MS to be the sum of an unlabeled and a labeled 
distribution. Two approaches can be used for the analysis of MID’s to estimate the 
isotopic enrichment of the biosynthetic precursor pool, and the fraction of newly 
 129 
biosynthesized molecules; mass isotopomer distribution analysis (MIDA), as described 
by Hellerstein and Neese (14), and isotopomer spectral analysis (ISA), as described by 
Kelleher and Masterson (15). 
 To determine the quantitative contribution of de novo palmitate biosynthesis to 
palmitoyl-CoA, RAW264.7 mouse macrophage-like cells were treated with 0, 0.1, and 
1.0 mM [1-13C]-acetate for 6, 12, and 24 hr. Quantitation of [M + 0] through [M + 4] 
palmitoyl-CoA followed by both MIDA and ISA analysis indicated robust utilization of this 
metabolic precursor after 6 hr; 60% of the total palmitoyl-CoA was determined to have 
been newly biosynthesized after treatment with both concentrations of [1-13C]-acetate. In 
addition, the higher concentration of labeled acetate increased the isotopic enrichment of 
the FAS precursor pool from ~ 4% to ~ 6%. 
 The similar extent of palmitoyl-CoA labeling (~ 60%) by both 0.1 mM [U-13C]-
palmitate and 0.1 mM [1-13C]-acetate indicates a rapid turn-over rate for cellular 
palmitoyl-CoA, and also suggests future investigations. For example, the relative 
contributions of extracellular palmitate and de novo fatty acid biosynthesis to palmitoyl-
CoA could be determined if both palmitate and acetate were simultaneously present in 
cell media. 
 
5.3 Experimental procedures 
Materials 
 Fatty acyl-CoA standards with purity ≥ 99% were provided by Avanti Polar Lipids, 
Inc. (Alabaster, AL). Methanol and chloroform (EMD, Darmstadt, Germany) were HPLC 
grade. Triethylamine was from Sigma-Aldrich (St. Louis, MO). Both [U-13C]-palmitate and 




Cell culture and treatment with stable isotope-labeled substrates 
 RAW264.7 mouse macrophages were cultured in DMEM + 10% FCS at 37°C, 
95% relative humidity and 5% CO2. Media included 0.1 mM [U-13C]-palmitate: fatty-acid 
free BSA (in a 1:1 molar ratio) or [1-13C]-acetate (0, 0.1, and 1 mM) as indicated. Cells 
were collected after 0.5, 1, 2, 4, 8, 12, and 24 hr ([U-13C]-palmitate experiment) or after 
6, 12, and 24 hr (1.0 mM [1-13C]-acetate experiment). 
 
Extraction of fatty acyl-CoAs 
 For the experiment with 1.0 mM [1-13C]-acetate at 12 and 24 hr, fatty acyl-CoAs 
were extracted and analyzed as previously described (151). 
 For all other experiments, RAW264.7 cells were rinsed twice with ~ 5 ml each of 
4°C PBS in their culture dishes, scraped up in ~ 2 ml of 4°C PBS using a rubber 
policeman, centrifuged in a bench-top unit at a low speed, and the PBS was aspirated. 
Methanol containing 1 mM EDTA (0.5 ml) and internal standards (10 µl of a 2:1 
methanol/chloroform (v/v) solution containing a total of 100 pmol each pentadecanoyl-
CoA [C15:0-CoA] and pentacosanoyl-CoA [C25:0-CoA]) were added to the cell pellet, 
followed by 3 water-bath sonications for 15 sec each. Chloroform (0.25 ml) was added to 
each pellet followed by 1 water-bath sonication for 15 sec. After heating for 30 min at 
50°C in a dry block, chloroform (0.25 ml) was added and the mixture vortexed for 30 sec. 
Water was added and the mixture vortexed for 30 sec. Centrifugation at 2500 rpm for 5 
min separated the mixture into upper (aqueous) and lower (organic) layers with a protein 
disc interface. The upper layer (~550 µL) was removed with a Pasteur pipet, and 
analyzed by HPLC-ESI-MS/MS. 
 
Quantitation of fatty acyl-CoAs by LC-ESI-MS/MS 
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 Resolution of fatty acyl-CoA species used a modification of the reverse-phase 
chromatographic method of Sun (93), et al. and multiple reaction monitoring (MRM) 
MS/MS detection. Briefly, solvent A was 85:15 water / acetonitrile (v/v) containing 0.05% 
triethylamine (TEA), and solvent B was 10:90 water / acetonitrile (v/v) containing 0.05% 
TEA. The flow rate was 200 µL per min and the column was a Waters XTerra MS C18 
2.1 x 30 mm (2.5 µm particles) with a 2.1 x 10 mm guard. The pump program of Sun et 
al. was changed for this (smaller) column to retain the same number of column volumes 
at each step of the (shorter) program. 
 Each palmitoyl-CoA MRM pair consisted of a (M + H)+ precursor ion and a 
product ion generated by a 507.0 Da neutral loss, a fragmentation of fatty acyl-CoAs 
which has been previously reported4. Each palmitoyl-CoA isotopomer had its own MRM 
pair; for example, the [M + 0] isotopomer MRM pair was m/z 1006.4 → 499.4, the [M + 1] 
MRM pair was m/z 1007.4 → 500.4, etc. Quantitation was achieved by comparison of 
palmitoyl-CoA isotopomer peak areas to the peak area for the pentacosanoyl-CoA 
(C15:0-CoA) internal standard (100 pmol) added at the beginning of cellular extraction. 
 
Calculation of palmitoyl-CoA isotopic enrichment after [U-13C]-palmitate treatment 
 The isotopic enrichment of the palmitoyl-CoA was calculated as follows: 
 
Eq. 2 
Where [M + 16] and [M + 0] indicate the extracted ion chromatogram peak areas for the 
MRM pairs 1022.4 → 515.4 and 1006.4 → 499.4, respectively. 
 
Mass isotopomer distribution analysis (MIDA) of [1-13C]-acetate labeling 
  
! 
M +16[ ] ÷ M + 0[ ] + M +16[ ]{ }
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Table III. Table of p-values for the palmitoyl-CoA product ion.  
For each [M + n] isotopologue, n refers to the mass shift relative to the monoisotopic product ion. 
 
 
Table IV. Table of molar fractions for the palmitoyl-CoA product ion. 
Molar fraction 
[M + 0] / 
€ 




[M + 1] / 
€ 




[M + 2] / 
€ 




[M + 3] / 
€ 




     
p   =   0.000 0.6912 0.2228 0.0711 0.0150 
0.001 0.6857 0.2266 0.0723 0.0154 
0.002 0.6804 0.2303 0.0735 0.0158 
0.003 0.6750 0.2340 0.0747 0.0163 
0.004 0.6697 0.2376 0.0760 0.0168 
0.005 0.6644 0.2412 0.0772 0.0172 
0.006 0.6592 0.2446 0.0785 0.0177 
0.007 0.6540 0.2481 0.0798 0.0182 
0.008 0.6488 0.2514 0.0811 0.0186 
0.009 0.6437 0.2547 0.0824 0.0191 
0.01 0.6386 0.2580 0.0838 0.0196 
Each molar fraction is the quotient of a particular isotopologue and the sum of all measured 
isotopologues. 
Isotopologue [M + 0] [M + 1] [M + 2] [M + 3] [M + 4] [M + 5] 
       
Exact m/z 499.357 500.357 501.357 502.357 503.357 504.357 
p   =   0.000 0.6893 0.2222 0.0709 0.0149 0.0024 0.0003 
0.001 0.6838 0.2259 0.0721 0.0154 0.0025 0.0003 
0.002 0.6783 0.2296 0.0733 0.0158 0.0026 0.0003 
0.003 0.6729 0.2333 0.0745 0.0162 0.0027 0.0004 
0.004 0.6675 0.2368 0.0757 0.0167 0.0028 0.0004 
0.005 0.6622 0.2403 0.0770 0.0172 0.0029 0.0004 
0.006 0.6569 0.2438 0.0782 0.0176 0.0030 0.0004 
0.007 0.6516 0.2472 0.0795 0.0181 0.0031 0.0004 
0.008 0.6464 0.2505 0.0808 0.0186 0.0032 0.0004 
0.009 0.6412 0.2538 0.0821 0.0190 0.0033 0.0005 
0.01 0.6360 0.2570 0.0835 0.0195 0.0034 0.0005 
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Table V. Table of molar excesses for the palmitoyl-CoA product ion. 
Excess isotopologue E[M + 1] E[M + 2] E[M + 3] 
    
p   =   0.000 0.0000 0.0000 0.0000 
0.001 0.0038 0.0012 0.0004 
0.002 0.0075 0.0024 0.0009 
0.003 0.0112 0.0036 0.0013 
0.004 0.0148 0.0049 0.0018 
0.005 0.0184 0.0061 0.0023 
0.006 0.0219 0.0074 0.0027 
0.007 0.0253 0.0087 0.0032 
0.008 0.0287 0.0100 0.0037 
0.009 0.0320 0.0114 0.0042 
0.01 0.0352 0.0127 0.0046 
Each E[M + n] is the change in the abundance of the nth isotopologue as p increases. 
 
 
Table VI. Table of ratios of molar excesses for the palmitoyl-CoA product ion. 
Ratio of excess 
isotopologue 
E[M + 1] / 
€ 




E[M + 2] / 
€ 
E M + x[ ]
x=1
3
∑   
E[M + 3] / 
€ 




    
p   =   0.001 0.6999 0.2190 0.0811 
0.002 0.6966 0.2215 0.0819 
0.003 0.6933 0.2241 0.0826 
0.004 0.6899 0.2266 0.0834 
0.005 0.6866 0.2292 0.0842 
0.006 0.6833 0.2317 0.0851 
0.007 0.6800 0.2341 0.0859 
0.008 0.6767 0.2366 0.0867 
0.009 0.6734 0.2391 0.0875 
0.01 0.6701 0.2415 0.0884 
Each ratio of excess is a quotient of the excess for that isotopologue divided by the sum of all 
measured excesses. 
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 The analytical workflow of MIDA (14) is summarized below. First, the molecular 
formula of the palmitoyl-CoA product ion (C37H66N7O17P3S) was used to calculate 
(software courtesy of Dr. Richard Neese) a table of p-values (Table III). This software 
used information about the natural isotopic abundances of different elements and the 
input molecular formula to calculate the abundances of palmitoyl-CoA product ion 
isotopologues, beginning with [M + 0] and ending with isotopologues having a fractional  
abundance of less than 1 x 10-8 (only [M + 0] through [M + 5] are shown in Table III). The 
first row of p-values is the MID of the palmitoyl-CoA product ion when p = 0; this is the 
un-enriched or “natural” MID of the product ion. Subsequent rows show the palmitoyl-
CoA product ion MID with increasing values of p, up to a user-specified value of p (only 
p up to 0.01, or 1%, is shown in Table III). It should be emphasized that any given row of 
p-values indicates the MID that would be observed if 100% of the palmitoyl-CoA was 
newly biosynthesized.  
 
Mass isotopomer distribution analysis (MIDA) of [1-13C]-acetate labeling 
 The analytical workflow of MIDA (14) is summarized below. First, the molecular 
formula of the palmitoyl-CoA product ion (C37H66N7O17P3S) was used to calculate 
(software courtesy of Dr. Richard Neese) a table of p-values (Table III). This software 
uses information about the natural isotopic abundances of different elements and the 
input molecular formula to calculate the abundances of palmitoyl-CoA product ion 
isotopologues, beginning with [M + 0] and ending with isotopologues having a fractional 
abundance of less than 1 x 10-8 (only [M + 0] through [M + 5] are shown in Table III). The 
first row of p-values is the MID of the palmitoyl-CoA product ion when p = 0; this is the 
un-enriched or “natural” MID of the product ion. Subsequent rows show the palmitoyl-
CoA product ion MID with increasing values of p, up to a user-specified value of p (only 
p up to 0.01, or 1%, is shown in Table III). It should be emphasized that any given row of 
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p-values indicates the MID that would be observed if 100% of the palmitoyl-CoA 
measured by LC-ESI-MS/MS had been newly biosynthesized during the treatment time 
from a biosynthetic precursor pool of acetyl-CoA with stable isotope enrichment p. 
 Second, Table III was used to generate a table of molar fractions (Table IV). 
Each entry in Table IV is a fraction: 
 
Eq. 3 
which relates the abundance of isotopologue [M + x] to the sum of the abundances of 
the first four isotopologues . This is essentially a normalization operation that converts 
the comprehensive isotopologue frequencies (p-values) into frequencies that reflect the 
limited ability of the LC-ESI-MS/MS analysis to quantitate every possible labeled 
isotopologue; in the experiments described here the [M + 3] isotopologue was the 
highest labeled mass that was above the limit of quantitation on the instrument used. 
Thus, each row in the table of molar fractions (Table IV) represents the normalized 
abundances of the MID at a given value of p and a given experimental sensitivity. 
 Third, Table IV was used to generate a table of molar excesses (Table V). The 
first row (where p = 0) of the table of molar fractions (Table IV) is subtracted from each 
subsequent row to calculate the excesses of each labeled isotopologue at different 
values of p. Thus, each row in the table of molar excesses represents the changing 
frequency of isotopologues as a function of p (again assuming that 100% of the 
palmitoyl-CoA had been biosynthesized during the 6 hr of treatment with [1-13C]-
acetate). In MIDA nomenclature these molar excess values are Ax*, the asymptotic value 
that is approached by each isotopomer at a given value of p as the fraction of newly 
biosynthesized palmitoyl-CoA approaches 100%. 
 Fourth, Table V was used to generate the table of ratios of molar excesses 
(Table VI). Each value in Table VI is a fraction: 
! 




that represents the normalized excess [M + x] isotopologue as a function of p. This is the 
key calculation of MIDA. Ratios of molar excesses are used because they are 
independent of the fraction of newly synthesized palmitoyl-CoA; in other words ratios of 
molar excesses are not influenced by a mixture of pre-existing and newly-biosynthesized 
polymers (palmitoyl-CoA in this case). The mathematical proof of this independence has 
been previously described by Hellerstein and Neese (14).  
 Fifth, Table VI was used to generate a plot of ratios of molar excesses vs. p for 
[M + 1] through [M + 3] (Figure 41). This plot shows theoretical relationships between 
ratios of molar excesses and p, and so the actual values of p during these experiments 
were easily estimated by calculating the observed ratios of molar excesses for the [M + 
1] through [M + 3] isotopologues and using the linear regressions shown in Figure 41 to 
calculate p. 
 Sixth, the table of molar excesses (Table V) was used to generate a plot of molar 
excesses (Ax*) vs. p for the [M + 1] through [M + 3] isotopologues (Figure 42). On this 
plot, each curve represents the asymptotic (maximum) molar excess for that 
isotopologue as a function of p. Using the actual values of p estimated as shown in 
Figure 1 for [M + 1] through [M + 3], the linear regressions shown in Figure 42 were used 
to calculate the Ax*-value of that isotopologue if 100% of the palmitoyl-CoA had been 
newly biosynthesized. Finally, the observed molar excesses of [M + 1] through [M + 3] 
were divided by the cogent derived Ax*-value, resulting in estimates of the fraction of 
newly biosynthesized palmitoyl-CoA. 
 
! 
E M + x[ ] ÷ E M + 0[ ] + E M +1[ ] + E M + 2[ ] + E M + 3[ ]{ }
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Figure 41. Plots of calculated ratios of molar excess vs. acetate isotopic 
enrichment for the [M + 1] through [M + 3] isotopologues of the palmitoyl-CoA 
product ion. The independence of ratios of molar excesses from the fraction of newly 
biosynthesized palmitoyl-CoA allows the estimation of p. For example, after treatment of 
RAW264.7 cells with 0.1 mM [1-13C]-acetate for 6 hr, the observed ratios for [M + 1] 
through [M + 3] were 0.625, 0.265, and 0.114, respectively. These lead to estimates of p 
having been 0.025, 0.021, and 0.036, respectively, or 0.027 ± 0.008. 
y = -3.2111x + 0.7021 
R² = 0.99987 
y = 2.2136x + 0.2196 
R² = 0.99823 
y = 0.9975x + 0.0783 
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Figure 42. Calculated molar excesses of palmitoyl-CoA product ion 
isotopologues [M + 1] through [M + 3]. The estimates of p obtained from the [M + 
1] through [M + 3] isotopologues in Figure 41 were substituted into the polynomial 
trendlines shown here to obtain the molar excess values representing 100% newly 
biosynthesized palmitoyl-CoA. Observed molar excesses were divided by these 
asymptotic values to estimate the fraction of newly biosynthesized palmitoyl-CoA. For 
example, after treating RAW264.7 cells with 0.1 mM [1-13C]-acetate for 6 hr, the 
estimated p-values for [M + 1] through [M + 3] were 0.025, 0.021, and 0.036, 
respectively, resulting in estimated molar excesses (asymptotes) of 0.078, 0.028, and 
0.019, respectively. The observed molar excesses for the [M + 1] through [M + 3] 
isotopologues were 0.044, 0.019, and 0.008, respectively, resulting in an estimate of 
0.55 ± 0.13, or ~ 55% newly biosynthesized palmitoyl-CoA. 
y = -25.5x2 + 3.7x 
R! = 0.99 
y = 5.1x2 + 1.3x 
R! = 0.99 
y = 3.3x2 + 0.4x 
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Isotopomer spectral analysis (ISA) of [1-13C]-acetate labeling 
 The analytical work-flow of ISA (15) is summarized below. The central concept of 
ISA is to model the biosynthetic reaction of interest as the mixing of labeled and 
unlabeled monomers to form labeled polymers, which in turn mix with unlabeled (pre-
exisitng) polymers, Figure 43. The key parameters of ISA are the precursor dilution 
factor, D, and the time-dependent proportion of newly biosynthesized polymer, g(t). In 
the model shown in Figure 43, D is the contribution of labeled monomer from the 
compartment tracer A to mix A and (1 - D) is the contribution of unlabeled monomer from 
the compartment natural A to mix A. Note that both labeled and natural monomers are 
associated with unique MID’s in this modeling approach, making ISA flexible in terms of 
accounting for the natural occurrence of stable isotopes in natural A, isotopic impurity of 
the labeled tracer in tracer A, the use of multiple stable isotope-labeled substrates in one 
experiment (tracer A, tracer B), etc. 
 In the ISA model, mix A is not accessible to the experimenter, and represents the 
true in situ biosynthetic precursor pool for the polymerization reaction, which was de 
novo fatty acid biosynthesis in this case. Activity of FAS converted eight acetate-derived 
two-carbon units into one C16 palmitate molecule in the compartment synthesis B, which 
was activated to palmitoyl-CoA by acyl-CoA synthetases. The newly biosynthesized (and 
isotopically labeled) palmitoyl-CoA mixed with pre-existing (and unlabeled) palmitoyl-
CoA in the compartment sampled B, which was quantitated with LC-ESI-MS/MS. By 
measuring the MID of palmitoyl-CoA in sampled B, the parameters D and g(t) were 
determined, as detailed below. 
 First, the MID’s of acetate in the compartments natural A and tracer A were 
specified: in the experiment described here natural A contained acetate isotopologues   
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Figure 43. Model of biosynthesis used for isotopomer spectral analysis (ISA). The 
mass isotopologue distributions (MID’s) of acetate in natural A and tracer A were 
specified at the beginning of the experiment, and sampled B represents palmitoyl-CoA 
analyzed by LC-ESI-MS/MS. The fractional contribution of tracer A to mix A is D, and the 
fractional contribution of synthesis B to sampled B is G. 
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with N0 = 0.989, N1 = 0.011, and N2 = 0.0001, while tracer A contained [1-13C]-acetate 
isotopologues with T0 = 0.01, T1 = 0.98, and T2 = 0.01.Assignment of these values 
accounted for both the natural abundance of 13C and the manufacturer’s stated 98% 
purity of the [1-13C]-acetate tracer. 
 Second, the mixing of natural A and tracer A in the compartment mix A was 







Equations 5-7 describe the abundance of mix A compartment isotopologues (X0, X1, and 
X2) as functions of the sums of the flux (D) of tracer isotopologues (T0, T1, and T2) and 
the flux (1 – D) of natural isotopologues (N0, N1, and N2). 
 Third, equations based on multinomial probability were written describing the 
abundance of every palmitate isotopologue that accounted for 1) the combinations and 
permutations of X0, X1, and X2 as mix A is converted to synthesis B by FAS, 2) the 
combinations and permutations of N0, N1, and N2 in the pre-existing palmitate, and 3) the 
fractional flux contribution of mix B to sampled B, which was g(t): 
 
Eq. 8 
























" = g(t)(X0 + X1 + X2)8 + [1# g(t)](N0 + N1 + N2)8
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 Because the tracer and natural acetate isotopologue abundances were defined 
at the beginning of the experiment, Xi was expressed in terms of Ti and Ni (Eq. 5-7), and 
Eq. 8 was re-written so that all of its isotopologue terms were known values: 
 
Eq. 9 
Equation 9 is a multinomial expression for the sum of all possible ways of generating all 
sixteen isotopologues of completely unlabeled to completely labeled palmitate. By 
expanding the exponential terms on the right-hand side of Eq. 9 into a polynomial 
expression (which, incidentally, has 6435 terms) and grouping the terms by their 
isotopologue molecular weight, sixteen equations resulted describing the combinations 
and permutations of Ni and Ti that formed the sixteen isotopologues of palmitate. 
Importantly, these equations were linear with respect to g(t), and hence were easily 
solved for that parameter. 
 Fourth, the values initially assigned to Ni and Ti were substituted into these 
sixteen equations, and each was re-arranged so that g(t) was alone on the left-hand 
side. After substituting the observed value for the abundance of isotopologue Pi into the 
cogent equation, the only remaining variable was D. For the [M + 0] to [M + 3] 
isotopologues , a plot was made of the solutions to each equation, with D on the x-axis 
and g(t) on the y-axis, by varying D from 0 to 1, solving for g(t), and plotting the value of 
g(t). This plot graphically showed the only values of D and g(t) that would have resulted 
in the observed abundance of Pi, given the known values of Ni and Ti. Lastly, the 
solution curves for the [M + 0] to [M + 3] isotopologues were overlaid on a single plot, 
and the convergence of the solution curves indicated the values of D and g(t) that were 
consistent with all of the observed isotopologue abundances.  
! 
Pi = g t( ) D T0 + T1 + T2( ) + 1"D( ) N0 + N1 + N2( )[ ]
8






 The application of ISA to data for [1-13C]-acetate labeling of palmitoyl-CoA in 
RAW264.7 cells required implementation of the above steps using Mathematica 
(Wolfram Software) by this author. The general strategy was: 1) to begin with Eq. 9 
which is specific to the formation of palmitate from acetate, 2) expand the right-hand 
side, 3) create a list of the terms in this expanded polynomial, 4) evaluate each term to 
determine which of the sixteen isotopologues it represented based on the superscript 
(stoichiometry) and subscript (isotopomer) of each Ni and Ti component, 5) sort the 
terms into sixteen lists (equations) based on which of the sixteen palmitate 
isotopologues each represented, 6) substitute into each equation the values of Ni and Ti 
assigned at the beginning of the experiment, 7) solve each of the sixteen equations for 
g(t), 8) substitute the observed isotopologue abundances into the cogent equations for 
the four most abundant isotopologues , 9) vary D from 0 to 1 and plot the resulting g(t) 




Labeling of fatty acyl-CoAs by [U-13C]-palmitate treatment 
 To determine the isotopic enrichment of palmitoyl-CoA in RAW264.7 cells either 
with (Figure 44, red lines) or without (Figure 44, black lines) 100 ng/ml Kdo2-Lipid A, 
cells were cultured as described in Experimental Procedures with 0.1 mM [U-13C]-
palmitate:BSA (in a 1:1 molar ratio) in the medium. After extracting fatty acyl-CoAs from 
the cells, palmitoyl-CoA, both [M + 0] (m/z 1006.4; (Figure 44, upper left) and [M + 16] 
(m/z 1022.4; (Figure 44, upper right) was quantitated. 
 The results show that the quantity of [M + 0] palmitoyl-CoA initially decreased for 
the first 2 hr, then increased between 4 and 24 hr, and there was a slight (but not 
significant) increase in the quantity of unlabeled palmitoyl-CoA associated with Kdo2-
 144 
Lipid A treatment. The quantity of [M + 16] palmitoyl-CoA increased between 0.5 and 24 
hr, and there was a significantly higher amount of labeled palmitoyl-CoA at 24 hr with 
Kdo2-Lipid A treatment. Isotopic enrichment of palmitoyl-CoA reached ~ 0.6, or 60%, 
either with or without Kdo2-Lipid A treatment by 6 hr, and was constant between 6 and 
24 hr (Figure 44, lower panel). These observations indicate rapid and robust isotopic 
labeling of cellular palmitoyl-CoA by extracellular [U-13C]-palmitate, presumably via acyl-
CoA synthetase activity, and also indicate achievement of isotopic equilibrium (Figure 
44, lower panel) during labeling with extracellular [U-13C]-palmitate. 
 To determine whether the labeled palmitoyl-CoA was metabolized by elongases 
and desaturases, control RAW264.7 cell extracts were analyzed for C16:1- and C18:0-
CoA. Both analytes were measured as unlabeled and [M + 16] species, and the 
quantities (Figure 45, upper panels) and isotopic enrichment (Figure 45, lower panels) 
are shown. Both of these fatty acyl-CoAs appeared to reach isotopic equilibrium, but at a 
lower isotopic enrichment than precursor palmitoyl-CoA. These results indicate 
desaturation and elongation of the labeled palmitoyl-CoA in this cell type. 
 
Labeling of palmitoyl-CoA by [1-13C]-acetate treatment 
 To measure the contribution of de novo palmitate biosynthesis to palmitoyl-CoA 
quantitites, RAW264.7 cells were treated with 0, 0.1, and 1.0 mM [1-13C]-acetate for 6 hr, 
and with 0 and1.0 mM [1-13C]-acetate for 12 and 24 hr. After extraction of fatty acyl-
CoAs, palmitoyl-CoA isotopologues from [M + 0] to [M + 4] were quantitated using LC-
ESI-MS/MS. This provided a mass isotopologue distribution (MID) for the palmitoyl-CoA 
product ion (Figure 46), which was analyzed by mass isotopomer distribution analysis 
and isotopomer spectral analysis, as described below. 
 
MIDA of palmitoyl-CoA labeling by [1-13C]-acetate treatment 
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 MIDA begins with the generation of a table of p-values specific to the molecule 
being analyzed (Table III). In MIDA nomenclature, p is the isotopic enrichment of the 
biosynthetic precursor pool for the polymerization reaction of interest. In the experiments 
described here, p = the isotopic enrichment of malonyl-CoA in the biosynthetic precursor 
pool for FAS, and when p = 0 there is no isotopic labeling. 
 The calculated MIDs of the palmitoyl-CoA product ion are shown in Figure 46, 
white bars, and in Figure 47. The central panel of Figure 47 shows that a vertical line at 
any given value of p indicates the unique MID at that p-value. For example, if p = 0 
(Figure 47, upper right), the “natural” MID of the palmitoyl-CoA product ion is predicted; 
the [M + 1], [M + 2], etc. isotopologues result from the natural abundance of isotopes 
such as 13C, 18O and 2H. It should be noted that comparing the calculated MID at p = 0 
(Figure 46, blue bars) to the observed MID in unlabeled RAW264.7 cells (Figure 46, 
white bars) resulted in low (< 6%) error, indicating the accuracy of both the software 
prediction and the LC-ESI-MS/MS quantitation. 
 If one assumes that p = 0.05 (Figure 47, lower left) or p = 0.10 (Figure 47, lower 
right), it is obvious that the MID shifts toward labeled molecules, creating a unique 
“fingerprint” of the palmitoyl-CoA product ion isotopic enrichment for a given isotopic 
enrichment of the acetyl-CoA biosynthetic precursor. The observed MIDs of the 
palmitoyl-CoA product ion after 6 hr of treatment with 0.1 mM [1-13C]-acetate (Figure 46, 
grey bars) and 1.0 mM [1-13C]-acetate (Figure 46, black bars) showed the expected 
dose-dependent shift towards labeled molecules. It must be emphasized that these 
predicted MIDs represent a sample that is 100% the product of de novo fatty acid 
biosynthesis. 
 After generating tables of molar fractions (Table IV), molar excesses (Table V) 
and ratios of molar excesses (Table VI) as detailed in Experimental Procedures, a plot 
was generated of ratios of molar excesses vs. p for the [M + 1] through [M + 3] 
 146 
 
Figure 44. Quantities (upper panels) and isotopic enrichment (lower panel) of 
palmitoyl-CoA in RAW264.7 cells treated with 0.1 mM [U-13C]-palmitate. In both 
panels red lines indicate Kdo2-Lipid A treatment and black lines indicate control cells. 
Dashed lines in the upper panels indicate achievement of isotopic enrichment 
equilibrium (at~ 60%) after 6 hr. The quantities of [M + 16] palmitoyl-CoA at 24 hr were 
significantly different between control and Kdo2-Lipid A treated cells (p < 0.05 by 
Student’s t-test). Isotopic enrichment was calculated as described in Experimental 


























































































Figure 45. Quantities and isotopic enrichments of C16:1- and C18:0-CoA in 
RAW264.7 cells treated with 0.1 mM [U-13C]-palmitate. The upper panels show 
the quantity of unlabeled (solid lines) and labeled (dashed lines) fatty acyl-CoA. The 
lower panels show isotopic enrichment, calculated as labeled / (unlabeled + labeled). 
Results are the mean and range of duplicate Petri dishes. 
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Figure 46. Mass isotopologue distributions (MID’s) of the palmitoyl-CoA product 
ion. The MID calculated for the unenriched product ion (blue) had less than 6% error 
compared to the observed MID with 0 mM [1-13C]-acetate (white). Treatment with 0.1 
mM [1-13C]-acetate (grey) and 1.0 mM [1-13C]-acetate (black) showed the expected 
dose-dependent shift towards labeled isotopologues. Data shown are the mean ± SD of 




Figure 47. Calculated mass isotopologue distributions (MIDs) for the palmitoyl-
CoA product ion. The central panel shows predicted fractional abundances of [M + 0] 
through [M + 5] (boxed numbers) with vertical lines at p = 0, 0.05, and 0.10. The MIDs at 




isotopologues (Figure 41). After treatment of RAW264.7 cells with 0.1 mM [1-13C]-
acetate for 6 hr, the observed ratios of molar excesses for [M + 1] through [M + 3] 
isotopologues of the palmitoyl-CoA product ion (0.62, 0.27, and 0.11, respectively) were 
used in conjunction with this plot to estimate a p-value of 0.027 ± 0.008, or ~ 2.7% 
isotopic enrichment of the acetyl-CoA pool that was the biosynthetic precursor for 
palmitoyl-CoA. 
 This estimate of p was used in conjunction with a plot of molar excesses vs. p 
(Figure 42) to determine the asymptotic molar excess approached by the [M + 1] through 
[M + 3] isotopologues as the fraction of newly biosynthesized palmitoyl-CoA approached 
100%. The observed molar excesses of [M + 1] through [M + 3] isotopologues were 
divided by these asymptotic values, resulting in an estimated fraction of 0.55 ± 0.13, 
meaning ~ 55% of the palmitoyl-CoA pool had been biosynthesized after 6 hr of 
RAW264.7 cell treatment with 0.1 mM [1-13C]-acetate. 
 Treatment of RAW264.7 cells with 1.0 mM [1-13C]-acetate (a ten-fold higher 
concentration than in the above experiment) for 6 hr resulted in an estimated p-value of 
0.056 ± 0.02, or ~ 5.6% enrichment (two-fold higher than was calculated for 0.1 mM [1-
13C]-acetate treatment) and an estimate of 0.55 ± 0.13, or ~ 52% newly biosynthesized 
palmitoyl-CoA (not significantly different from the result for 0.1 mM [1-13C]-acetate 
treatment). This outcome indicates that the higher concentration of [1-13C]-acetate 
labeled the biosynthetic precursor pool to a greater extent, but did not affect the rate of 
biosynthesis of palmitoyl-CoA by FAS. 
 In addition to palmitoyl-CoA, the experiment with 1.0 mM [1-13C]-acetate 
treatment quantitated isotopologues of myristoyl-, palmitoleoyl-, stearoyl-, and oleoyl-
CoA after 12 and 24 h of treatment. Interestingly, the calculated value of p was non-
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Figure 48. Graphical output of Mathematica program for the estimation of D and g(t) 
during palmitoyl-CoA biosynthesis. Isotopomer spectral analysis (ISA) was used as 
described in Experimental Procedures to estimate the parameters D and g(t) for RAW264.7 
cells treated with 1.0 mM [1-13C]-acetate for 6 hr. Observed isotopologue abundances for 
[M + 0] through [M + 3] were used. 
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that they are biosynthesized and / or elongated using distinct pools of malonyl-CoA 
derived from acetyl-CoA. Furthermore, the fraction of newly biosynthesized polymers 
was also non-identical when comparing these species, and treatment with Kdo2-Lipid A 
caused (in some cases) significant changes in p, in f, and in quantity. These results are 
summarized in Table VII. 
 
ISA of palmitoyl-CoA labeling by [1-13C]-acetate treatment 
 ISA of palmitoyl-CoA labeling after 6 hr of treating RAW264.7 cells with 1 mM [1-
13C]-acetate using the [M + 0] through [M + 3] isotopologues indicated that D = 0.1 and 
g(6 hr) = 0.6 (Figure 48), meaning there was a 10% fractional flux of tracer A to mix A 
and that 60% of the palmitoyl-CoA in sampled B was derived from synthesis B. 
Compared to the MIDA analysis, for which p = 0.056 ± 0.02 and the fraction of newly 
biosynthesized palmitoyl-CoA was 0.55 ± 0.13, both methods of calculating isotopic 
enrichment reached the same conclusion regarding the fraction of newly biosynthesized 
palmitoyl-CoA (~ 60%) and similar estimates of the contribution of the labeled acetate to 
the biosynthetic precursor pool for FAS (6% vs. 10%). Thus, both ways of calculating the 
contribution of de novo palmitate biosynthesis to the palmitoyl-CoA pool indicated that 
despite the moderate concentration of [1-13C]-acetate tracer in the medium (1 mM) and 
the modest labeling of the acetyl-CoA biosynthetic precursor pool for FAS (6 to 10%), 




Table VII. Calculated values of p and f, and quantitation for fatty acyl-CoAs after 12 
and 24 h ± Kdo2-Lipid A (KLA) treatment in the presence of 1.0 mM [1-13C]-acetate. 
Fatty acyl-
CoA Treatment, time 
p (acetate 
enrichment, %) 
f (fraction of 
new polymers, 
%) 
Q (pmol / ug 
DNA) 
     
C14:0  (4) (4) (3) 
 Control, 12 h 7.1 ± 1.9 40 ± 5 0.9 ± 0.1 
 KLA, 12 h 8.5 ± 1.4 38 ± 5 0.8 ± 0.1 
 Control, 24 h 6.0 ± 0.5 * 54 ± 4 * 1 ± 0.1 
 KLA, 24 h 13 ± 2.6 * 31 ± 8 * 1 ± 0.2 
     
C16:0  (5) (5) (3) 
 Control, 12 h 4.5 ± 0.3 * 73 ± 7 * 1.3 ± 0.1 * 
 KLA, 12 h 6.0 ± 0.8 * 42 ± 3 * 1.6 ± 0.1 * 
 Control, 24 h 5.0 ± 0.5 62 ± 8 1.3 ± 0.1 
 KLA, 24 h 4.7 ± 0.1 64 ± 6 1.5 ± 0.2 
     
C18:0  (5) (5) (3) 
 Control, 12 h 6.5 ± 1 49 ± 9 0.4 ± 0.1 * 
 KLA, 12 h 6.3 ± 1 39 ± 7 0.6 ± 0.1 * 
 Control, 24 h 5.2 ± 1 48 ± 2 0.6 ± 0.1 • 
 KLA, 24 h 6.2 ± 1 48 ± 7  0.9 ± 0.1 • 
     
C16:1  (4) (3) (3) 
 Control, 12 h 10 ± 2.4 35 ± 8 1.0 ± 0.14 * 
 KLA, 12 h 7.1 ± 1.4 30 ± 2 0.4 ± 0.02 * 
 Control, 24 h 10 ± 1.8 36 ± 8 0.9 ± 0.03 • 
 KLA, 24 h 6.9 ± 2.5 35 ± 6 0.3 ± 0.01 • 
     
C18:1  (5) (4,5) (3) 
 Control, 12 h 5.1 ± 0.2 * 49 ± 5 * 1.5 ± 0.18 * 
 KLA, 12 h 3.3 ± 0.2 * 65 ± 6 * 0.9 ± 0.04 * 
 Control, 24 h 5.9 ± 1.1 • 50 ± 13 3.2 ± 0.16 • 
 KLA, 24 h 13 ± 2.8 • 25 ± 4 0.9 ± 0.05 • 
 
The number in parenthesis above each column shows the number of isotopologues used to 
calculate the results; the symbols * and • denote a significant difference (p < 0.05 by Student’s t-
test) for adjacent rows’ entries. 
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5.5 Discussion 
 The goal of this study was to use treatment with stable isotope-labeled 
precursors ([U-13C]-palmitate and [1-13C]-acetate) to compare the utilization of 
extracellular palmitate (192) and de novo fatty acid biosynthesis (195), respectively, for 
the production of palmitoyl-CoA in RAW264.7 mouse macrophage-like cells. Treatment 
of this cell type with Kdo2-Lipid A has been shown to cause extensive changes in the 
transcription of genes encoding enzymes of lipid metabolism, including fatty acyl-CoA 
metabolism (www.lipidmaps.org); therefore stable isotope labeling of fatty acyl-CoAs 
was also measured in the presence of Kdo2-Lipid A in some experiments. 
 Extracellular 0.1 mM [U-13C]-palmitate labeled ~60% of the palmitoyl-CoA pool 
between 4 and 24 hr in control cells, and treatment with Kdo2-Lipid A increased the 
quantities of both unlabeled and labeled palmitoyl-CoA (Figure 44, upper panels), so that 
there was no significant difference in palmitoyl-CoA isotopic enrichment ± Kdo2-Lipid A 
(Figure 44, lower panel). The [U-13C]-palmitate treatment also resulted in the labeling of 
palmitoyl-CoA metabolites, including desaturated palmitoleoyl-CoA and elongated 
stearoyl-CoA, and these fatty acyl-CoAs reached isotopic equilibrium at enrichments 
(50% and 40%, respectively) lower than that of palmitoyl-CoA (60%; Figures 44 and 45). 
This is consistent with an additional metabolic step (elongation (196) or desaturation 
(197)) causing a reduction in the amount of tracer (labeled palmitoyl-CoA) entering the 
pool of unlabeled palmitoleoyl- and stearoyl-CoA. 
 Treatment with 0.1 m [1-13C]-acetate followed by MIDA analysis (198-202) 
showed that ~ 60% of the palmitoyl-CoA pool was newly biosynthesized after 6 h, as 
well as ~ 3% labeling of the precursor malonyl-CoA pool. Treatment with a higher 
concentration of [1-13C]-acetate (1 mM) again indicated that ~ 60% of the palmitoyl-CoA 
pool was newly biosynthesized (via analyses with MIDA and ISA (86, 87, 198, 203-206)), 
and indicated an increased labeling (MIDA, 6%; ISA, 10%) of the malonyl-CoA precursor 
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pool. These results indicate that de novo palmitate biosynthesis labels palmitoyl-CoA to 
a similar extent (~ 60%) as extracellular palmitate labels palmitoyl-CoA, and that higher 
concentrations of acetate tracer increase the isotopic enrichment of the acetate 
precursor pool, but do not change the fraction of newly biosynthesized palmitoyl-CoA. 
This is in agreement with the results of palmitate labeling in NIH3T3-L1 cells using [1,2-
13C]-acetate, which showed a similar increase in precursor enrichment but not the 
fraction of new polymers with increasing concentrations of tracer (87). 
 In the presence of Kdo2-Lipid A, the isotopic enrichment of the acetate precursor 
pool for palmitoyl-CoA after 12 h significantly (p < 0.05) increased from 4.5 ± 0.3% to 6.0 
± 0.8%, while the fraction of newly biosynthesized palmitoyl-CoA significantly decreased 
from 73 ± 7% to 42 ± 3%. Taken together with the significant increase in palmitoyl-CoA 
quantity after 12 h caused by Kdo2-Lipid A (1.6 ± 0.1 pmol/µg DNA vs. 1.3 ± 0.1 pmol/µg 
DNA), these results indicate that a smaller amount of new palmitoyl-CoA (42% vs. 73%) 
is more isotopically enriched (6% vs. 4.5%) with Kdo2-Lipid A treatment, and that the 
contribution of unlabeled palmitoyl-CoA from (for example) extracellular or catabolic 
sources is not large enough (1.6 vs. 1.3 pmol/µg DNA, a 23% increase) to explain the 
smaller amount of new palmitoyl-CoA. A lower rate of de novo palmitate biosynthesis 
would be consistent with these observations, and Kdo2-Lipid A does cause a 60-70% 
reduction in the transcription of fatty acid synthase in RAW264.7 cells 
(www.lipidmaps.org). 
 The acetate isotopic enrichments, fractions of newly biosynthesized analyte, and 
quantities of select fatty acyl-CoAs are shown in Table VII, and some of these results are 
also in agreement with previously observed changes in gene expression in RAW264.7 
cells caused by Kdo2-Lipid A treatment. For example, the quantity of monounsaturated 
fatty acyl-CoAs (i.e. C16:1- and C18:1-CoA) decreased significantly (p < 0.05) in the 
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presence of Kdo2-Lipid A after 12 and 24 h of treatment, consistent with a ~ 50% 
reduction in the transcription of stearoyl-CoA desaturase (www.lipidmaps.org). 
 In contrast to palmitoyl-CoA, Kdo2-Lipid A treatment resulted in oleoyl-CoA 
significantly (p < 0.05) decreasing in acetate precursor enrichment (5.1 ± 0.2% vs. 3.3 ± 
0.2%) and significantly increasing in the fraction of newly biosynthesized analyte (49 ± 
5% vs. 65 ± 6%) compared to control cells. Taken together with the aforementioned 
significant decrease in the quantity of oleoyl-CoA (1.5 ± 0.2 vs. 0.9 ± 0.04 pmol/µg DNA), 
after 12 h, these results suggest that newly biosynthesized oleoyl-CoA is becoming a 
larger proportion of the metabolite pool as its total quantity diminishes. 
 The results of 1.0 mM [1-13C]-acetate labeling also showed that a substantial 
amount of myristoyl-CoA (12, 207, 208) was newly biosynthesized after 12 h (40 ± 5%). 
Compared to the small amount of myristoyl-CoA labeling observed with [U-13C]-palmitate 
treatment (~ 5%, data not shown), this result is consistent with de novo fatty acid 
biosynthesis producing myristate as well as palmitate, which has been demonstrated in 
vitro (104) for recombinant human fatty acid synthase. In addition, after 24 h of Kdo2-
Lipid A treatment, the myristoyl-CoA showed significantly higher acetate precursor 
enrichment (13 ± 3% vs. 6 ± 5%) and a significantly lower fraction of newly 
biosynthesized analyte (31 ± 8% vs. 54 ± 4%), which is consistent with increased 
labeling of the polymerized myristate, and a reduction in the biosynthesis of myristate, 
such as the aforementioned 60-70% reduction in fatty acid synthase transcription 
caused by Kdo2-Lipid A treatment of RAW264.7 cells (www.lipidmaps.org). 
 In summary, both extracellular fatty acids and de novo fatty acid biosynthesis 
rapidly (~ 6 h) and robustly (~ 60%) contributed to the intracellular palmitoyl-CoA pool of 
RAW264.7 cells, as shown by treatment with the stable isotope tracers [U-13C]-palmitate 
and [1-13C]-acetate. In addition, the elongation and desaturation of palmitoyl-CoA was 
 157 
observed after treatment with both tracers, as indicated by mass-shifted C16:1 and 
C18:0-CoA. Several of the changes in gene expression caused by Kdo2-Lipid A 
treatment (www.lipidmaps.org), such as decreased transcription of stearoyl-CoA 
desaturase (47, 48, 150, 209-212) and fatty acid synthase, were reflected by the 
changes in fatty acyl-CoA quantites and/or isotopic enrichment. The labeling of 
myristoyl-CoA with [1-13C]-acetate confirms previous findings (104) about the 
biosynthesis of this species, and is an example of the power of stable isotope labeling 
experiments to quantitate metabolic activities in cultured mammalian cells with 




 The development of a method for quantitation of unlabeled and stable isotope-
labeled fatty acyl-CoAs by LC-ESI-MS/MS in small samples of biological material 
[Chapter 2 and (3)] provides important information about the metabolism of complex 
lipids, such as sphingolipids. For example, a cultured cell paradigm in which basal 
(Chapter 3) and increased (Chapter 4) quantities of sphingolipids were observed has 
been confirmed to be the results of increased de novo sphingolipid biosynthesis, rather 
than increased catabolism of pre-existing sphingolipids. 
 Specifically, the over-expression of SPT, the first enzyme of de novo sphingolipid 
biosynthesis, in HEK293 cells resulted in increased quantities of sphingolipids, and a 
greater accumulation of [M + 16] and [M + 32] sphingolipids after treatment with [U-13C]-
palmitate (Chapter 4). In addition, the induction of SPT mRNA expression in RAW264.7 
cells by Kdo2-Lipid A treatment resulted in increased quantities of sphingolipids, and a 
greater accumulation of [M + 16] and [M + 32] sphingolipids after treatment with [U-13C]-
palmitate (Chapter 4). The ability to quantitate [M + 0] and [M + 16] palmitoyl-CoA 
showed that in both paradigms the isotopic enrichment of palmitoyl-CoA was not the 
source of observed differences in isotopically labeled sphingolipids. 
 Furthermore, the quantitation of the isotopic enrichment of palmitoyl-CoA allowed 
the true quantity of de novo biosynthesized sphingolipids to be estimated, if one 
assumes that a single, well-mixed pool of palmitoyl-CoA is available for serine 
palmitoyltransferase. Comparison of the observed quantity of unlabeled ceramide to the 
quantity that was calculated to have been de novo biosynthesized implied that all of the 
observed unlabeled quantity could be accounted for by de novo biosynthesis in HEK293, 
SPT1/2, and control RAW264.7 cells, but not in Kdo2-Lipid A-treated RAW264.7 cells 
(Chapters 3 and 4). Therefore, quantitation of the isotopic enrichment of palmitoyl-CoA 
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provided data that significantly changed the interpretation of sphingolipid quantitation in 
these experiments. 
 The wealth of data for isotopic labeling of sphingolipids (Chapter 3) suggested 
the application of previously described approaches for the analysis of metabolic labeling, 
one such approach (88) led to calculating enrichment for fatty acyl-CoAs and 
sphingolipids and the observation that some species clearly reached isotopic 
equilibrium. Modeling this isotopic enrichment and measurement of metabolite quantities 
with LC-ESI-MS/MS allowed the estimation of the rate of appearance of unlabeled 
metabolite, which quantitated the increase in de novo sphingolipid caused by over-
expression of serine palmitoyltransferase in HEK293 cells (Chapter 4). 
 Although informative, an alternative to metabolic labeling of de novo sphingolipid 
biosynthesis with [U-13C]-palmitate was also used: labeling of de novo biosynthesized 
palmitate via treatment of cultured cells with [1-13C]-acetate (Chapter 5). Two previously 
described mathematical approaches based on multinomial distribution (14, 15) were 
taken for the analysis of the [1-13C]-acetate labeling data; both approaches reached 
similar conclusions about the isotopic enrichment of the biosynthetic precursor acetate 
(6 to 10%) and the fraction of newly biosynthesized palmitoyl-CoA (~ 60%) after 6 hr of 
treating RAW264.7 cells with 1.0 mM [1-13C]-acetate. 
 In summary, the quantitation of fatty acyl-CoAs, and particularly quantitation of 
their isotopic enrichment during stable isotope-labeling studies of lipid metabolism, can 
provide data that significantly change the interpretation of analyte quantitation, as 
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